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ABSTRACT 
(a) A modified H-phosphonate strategy, which involves coupling at -40°C 
effected by bis(2-chlorophenyl) phosphorochloridate followed by a sulphur 
transfer step, was applied in the assembly of an antisense oligonucleotide 
phosphorothioate 21-mer, ISIS 2922. Also a four-component H-phosphonate 
approach was developed. By using diphenyl phosphorochloridate as coupling 
agent and succinimide derivatives as sulphur-transfer agents, side reactions 
associated with H-phosphonate chemistry can be reduced, especially when the 
preparation is carried out on a large scale. Pivaloyl chloride was found to be 
an efficient coupling reagent in the H-phosphonate approach at 0°C. By using 
a combined strategy of these two approaches, ISIS 2922 was prepared on a 
relatively large scale (2.0 mmol). The product and the intermediates were 
unblocked and characterised by reverse-phase HPLC, ion-exchange LC, 1H 
NMR, 31P NMR, capillary gel electrophoresis and MALDI-TOF mass 
spectroscopy. Also a procedure to convert protected S-(2- 
cyanoethyl) phosphorothioate triesters to phosphate diesters was investigated. 
By alkylation of phosphorothioate diesters with bromoacetonitrile, S- 
(cyanomethyl) phosphorothioate triesters can be obtained, which upon 2- 
nitrobenzaldoximate treatment gave phosphate diesters as the only products. 
This approach was applied in the conversion of a series of fully-protected 
oligonucleotide phosphorothioate triesters to phosphate diesters, which were 
characterised by NMR spectroscopy and enzymatic digestion. 
(b) A group of new achiral protecting groups for 1,2-diol systems was developed. 
2', 3'-O-[Di-p-(anisyl)methylene]uridine, 2', 3'-O-(xanthen-9-ylidene)uridine 
and 2', 3'-O-(2,7-dimethylxanthen-9-ylidene)uridine were prepared and the 
rates of hydrolysis of these compounds were compared with that of 2', 3'-O- 
isopropylideneuridine in trifluoroacetic acid-water-methanol. All of these 
new protecting groups were found to be more labile than the commonly used 
isopropylidene protecting group under these conditions. The racemic form and 
the (1 - and (5} enantiomers of 1,2-0-(xanthen-9-ylidene)glycerol and 1,2-0- 
(2,7-dimethylxanthen-9-ylidene)glycerol were prepared. The stearoyl esters of 
racemic 1,2-0-(xanthen-9-ylidene)glycerol and 1,2-0-(2,7-dimethylxanthen- 
9-ylidene)glycerol, (I-- and (S}1,2-0-(xanthen-9-ylidene)glycerol were 
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prepared. The xanthen-9-ylidene protecting groups were unblocked under 
very mild conditions (pyrrole-dichloroacetic acid). 
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AcOH acetic acid 
Ade adenine 
B base residue 
C cytidine 
CDC13 deuterated chloroform 
CMV cytomegalovirus 
CPG controlled pore glass 








DMSO-d6 deuterated dimethylsulphoxide 
DMTr 4,4'-dimethoxytrityl 
DNA 2'-deoxyribonucleic acid 




HPLC high performance liquid chromatography 
IMS industrial methylated spirit 
IR infrared spectrometry 
m multiplet 
M molar concentration 





mp melting point 




RNA ribonucleic acid 
Rt retention time 
SVPD snake venom phosphodiesterase 
t triplet 
T thymidine 
TEAA triethylammonium acetate 
THE tetrahydrofuran 
Thy thymine 
TLC thin layer chromatography 
TMG tetramethylguanidine 
TMS trimethylsilyl 
TOF time of flight 
Tr trityl (triphenylmethyl) 
Ura uracil 
UV ultraviolet spectrometry 
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Introduction to Nucleic Acid Chemistry 
1.1 Nucleic Acids 
The chemical study of the nucleic acids dates back to 1868 when Friedrich Miescher 
first isolated a phosphorus-containing compound from the nuclei of pus cells which 
he obtained in abundant supply from surgical bandages. He named the substance 
`nuclein' and carried out a precise elemental analysis giving a phosphorus content of 
9.59%. ' In fact nuclein was nucleoprotein and it fell subsequently to Richard Altmann 
in 1889 to obtain the first protein-free material, to which he gave the name `nucleic 
acid'. Between 1877 and 1907 the pyrimidine and purine bases were isolated and 
characterised by Kossel and co-workers and by Fischer. The first generally accepted 
direct evidence that deoxyribonucleic acid (DNA) was the genetic material was 
reported by Hershey and Chase2 in 1952, using radioactively labelled phosphorus in 
the DNA of bacteriophage T2. Later, the regularity in the concentration of pyrimidine 
and purine bases was found by Chargaff3 and others by analysing the composition of 
DNA from various organisms. In 1955, by comparison of the first chemically 
synthesised dinucleotide with naturally occurring DNA, Michelson and Todd4 
confirmed the postulated primary structure of DNA. 
Naturally, there exist two forms of nucleic acids, ribonucleic acid (RNA) and 
deoxyribonucleic acid (DNA). They are both constructed from three components: 
nitrogen heterocyclic bases, pentose sugars, and phosphate residues. When a 
heterocyclic base is joined with a pentose sugar, a nucleoside is formed. The 
phosphate ester of a nucleoside is referred to as a nucleotide. 
The primary structures of nucleic acids, i. e. the order in which the components are 
linked together, are shown in Figure 1.1. DNA and RNA are poly-dialkyl phosphate 
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esters in which the 3'-hydroxy group of one nucleoside unit is covalently linked with 
the 5'-hydroxy group of another through an internucleotide phosphodiester linkage. 
The nucleoside units in ribonucleic acid (RNA, 101a) and deoxyribonucleic acid 
(DNA, 101b) are ß-D-ribofuranosides 102a and ß-D-deoxyribofuranosides 102b 
respectively, of pyrimidine 103 and purine 106 bases. In ribonucleic acids, the four 
principal base residues are uracil-1-yl 104a, cytosin-l-yl 105, adenin-9-yl 107 and 
guanin-9-yl 108; in deoxyribonucleic acids, three of the four base residues, cytosin-l- 
yl, adenin-9-yl and guanin-9-yl, are the same as those in ribonucleic acids, but the 
other principal base residue is thymin-1-yl 104b instead of uracil-1-yl 104a. 
-0ýý4 
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Figure 1.1 DNA, RNA, nucleosides and nucleobases. 
In 1953, Watson and Crick5 proposed the double helical structure of DNA based on 
the X-ray crystallographic data obtained by Franklin and Wilkins6'7 and further 
postulated a mechanism of DNA replication. The double helix or Watson-Crick 
structure is referred to as the secondary structure of DNA (Figure 1.2). The purine and 
12 
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pyrimidine bases are on the inside of the helix, and the phosphate and sugar moieties 
are on the outside. The planes of the bases are perpendicular to the helix and the 
planes of the sugar molecules are nearly at right angles to those of the bases. The two 
chains are anti-parallel, i. e. they run in opposite directions. The two strands have 
different sequences, but one sequence specifies the other because of the rigid rule of 
complementary base pairing. Adenine always pairs with thymine (A: T) and guanine 






Figure 1.2 DNA double helix (Source: www. accessexcellence. or, /AB/GG/dna molecule. html). 
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R= deoxyribose linkage to DNA 
A: T base pair G: C base pair 
Figure 1.3 Complementary hydrogen bonded base-pairs as proposed by Watson and Crick. 
This isomorphism of purine : pyrimidine base pairing ensures that there is no major 
distortion of the phosphodiester backbone of a double helix. Hydrogen bonding 
interactions between purines and/or pyrimidines other than A: T or G: C are possible, 
but the distortion of the backbone introduces an energy penalty that leads to rejection 
of such interactions in a perfect double helix. However under certain circumstances 
some such base pairing can be accommodated within a double helix. Furthermore, a 
third oligonucleotide chain can also hybridise with a double helix to form a triplex in 
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T"A: T base triplet C+"G: C base triplet 
Figure 1.4 Hoogsteen hydrogen-bonding motif for pyrimidines bound in the major groove to the 
Watson-Crick bonded A: T and G: C pairs. 
The characterisation of the semi-conservative mechanism of DNA biosynthesis 
followed in 1960.8 The use of novel enzymatic and chemical tools for manipulating, 
sequencing and synthesising oligonucleotides9 facilitated the subsequent explosion in 
14 
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molecular biology. The potential use of synthetic oligonucleotides as specific 
inhibitors of transcription (antigene oligonucleotides) or inhibitors of translation 
(antisense oligonucleotides) has prompted organic chemists to undertake the synthesis 
of a variety of oligodeoxyribo-/oligoribo- nucleotide analogues, especially those 
analogues in which the sugar residues or internucleotide linkages are modified. 
Recently, the development of DNA chips and their analytical and diagnostic 
applications have invited a plethora of studies. 1° 1 
1.2 The Chemical Synthesis of Oligonucleotides 
The first chemical synthesis of a nucleoside was accomplished by Michelson and 
Todd4 in 1955. Methods of phosphorylation were developed and a dinucleotide 
[d(TpT)] 109 was synthesised which was identical to naturally occurring DNA. Over 
the past four decades, several methods for the synthesis of oligonucleotides, both in 
solution and on solid supports, have been established. However, additional studies are 
required for the large-scale synthesis of oligonucleotides and their analogues as the 











1.2.1 Overall Strategy 
Nucleic acids are highly sensitive to a wide range of chemical reactions and thus only 
mild reaction conditions can apply in the assembly of oligonucleotide chains. The 
phosphodiester backbone is vulnerable to hydrolysis, and the heterocyclic bases are 
prone to alkylation, oxidation and reduction. Hence, the chemical reactions in 
oligonucleotide synthesis are limited to (1) mild alkaline hydrolysis; (2) mild acidic 
15 
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hydrolysis; (3) mild nucleophilic displacement; (4) base-catalysed elimination; and 
(5) certain mild redox reactions. 
The key step in the synthesis of oligonucleotides is the specific formation of 
internucleoside 3' --> 5' phosphodiester linkages which is known as a coupling (or 
condensing) reaction. In the formation of the linkage, functional groups, except those 
involved in the reaction, must be suitably protected during the reaction and 
subsequent purification. In the example of joining a 5'-protected-dT unit 110 to a 3'- 
protected-dC unit 111 (Scheme 1.1), one of the two units must be phosphorylated or 
phosphitylated and then condensed with the other nucleoside via a coupling reaction. 
Where R' and R2 are conventional protecting groups, the synthesis is described as 
solution-phase; if either R' or R2 is an insoluble or inorganic support, the process is 






OH + NHR3 
110 N 


















Scheme 1.1 Joining of a 5'-protected-dT to a 3'-protected-dC unit; R'-R5 = protecting groups. 
1.2.2 Ways of Making an Internucleotide Linkage 
The development of an efficient method for the formation of an internucleotide bond 
has been the most vital issue in oligonucleotide synthesis for many years. Over the 
16 
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past four decades, several methods have been successfully developed, which include 
the phosphodiester, phosphotriester, phosphite triester, phosphoramidite and H- 
phosphonate approaches. 
1.2.2a The Phosphodiester Approach 
In a communication to Chemistry & Industry in 1956, Khorana and co-workers12 
reported the preparation of dithymidinyl phosphate via the phosphodiester approach. 
With toluene-p-sulphonyl chloride 113a as activating agent, 5'-O-tritylthymidine 114 
and thymidine 5'-phosphate 115 were allowed to react in anhydrous pyridine to form 
the desired dinucleotide 116 in 45% yield (Scheme 1.2). In their later studies, the 3'- 
hydroxy function of 115 was blocked with an acetyl group, and 1,3- 
dicyclohexylcarbodiimide13'14 (DCC, 117) and other arylsulphonyl chlorides' 5 were 

























113 a; R1 = H, R2= Me 
b; R1 =R2=Me 
c; R1 = R2 = CH(CH3)2 
d; R' =R2=H 
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Over a decade after this method was proposed, the total syntheses of the genes 
encoding a tyrosine suppressor tRNA from E. coli16 and an alanine tRNA from yeast 
were achieved. 17 
The main drawback of this approach is that the phosphodiester functions of the 
growing oligonucleotide are nucleophilic and therefore vulnerable to attack in the 
subsequent phosphorylation steps to give a branched pyrophosphate by-product, 
which complicates subsequent purification and also lowers the yield. 
1.2.2b The Phosphotriester Approach 
In the mid-1950s, Michelson and Todd4 reported the first chemical synthesis of 
nucleotides via the phosphotriester approach. In their study, 5'-O-acetylthymidine-3'- 
O-benzyl-H-phosphonate 118 was activated by N-chlorosuccinimide 119 then 
coupled with 3'-O-acetylthymidine 121 to give a dinucleotide triester 122 (Scheme 
1.3), which upon removal of the protecting groups afforded natural dithymidine 
monophosphate 109. Compared with the phosphodiester approach, this approach has 
the advantage that phosphotriester intermediates (e. g. 122) are neutral species which 
can be purified by chromatography and which are not susceptible to phosphorylation 
of the internucleotide linkages. After the desired chain has been assembled, the benzyl 







































However, the benzyl protecting group was found not to be stable enough in pyridine. 
So the search for stable phosphate protecting groups, as well as for methods leading 
to their removal, was pursued intensively. 
The 2-cyanoethyl group (as in 123) was first examined as an alternative to the benzyl 
i protecting group by Letsinger and Oglvie. '819 UP to a tetramer triphosphate was 
prepared. However, the 2-cyanoethyl group is still very labile to bases, and if a 
comparatively long oligonucleotide is to be synthesised, loss of 2-cyanoethyl 
protecting groups during subsequent coupling, work-up and purification is bound to 
occur. 
Subsequently, Reese and Saffhi1120 proposed aryl groups (as in 124) as potential 
protecting groups even though their removal by alkaline hydrolysis led to significant 
cleavage of internucleotide linkages. The extent of this cleavage was controlled by 
incorporation of electron-withdrawing substituents in the phenyl group21-23 and 
replacement of the alkaline hydrolysis step by treatment with the conjugate base of 
either (E)-2-nitrobenzaldoxime 125 or (E)-pyridine-2-carboxaldoxime24 126. Typically, 
reaction of dinucleotide O-(2-chlorophenyl)phosphotriester with the 1,1,3,3- 
tetramethylguanidinium salt of E-2-nitrobenzaldoxime resulted in the complete 
removal of the 2-chlorophenyl phosphate protecting group within 30 min, while the 
cleavage of internucleotide linkages occurred to less than 0.1%. 24 As a result of these 
elegant studies, the 2-chlorophenyl group was established to be the phosphotriester 
protecting group of choice in the phosphotriester approach, and (E}2- 
19 
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124 a; R=H, R'= Cl 











It is noteworthy that in the course of these investigations, a stepwise chain elongation 
strategy was developed. In conjunction with the use of trityl (or MMTr, or DMTr) as 
5'-hydroxy protecting group, the ß-benzoylpropionyl group (as in 127) was used to 
mask the 3'-hydroxy function. Treatment of a 3'-O-(ß-benzoylpropionyl) 
phosphotriester with hydrazine hydrate in pyridine-acetic acid removed the 
benzoylpropionyl protecting group without internucleotide linkage cleavage. 25,26 On 
the other hand, the 5'-trityl protection can be removed by acidic treatment. Thus, 
chain assembly can be directed as required. This stepwise synthetic strategy was 
demonstrated by Letsinger and co-workers26 in the preparation of a tetrathymidinyl 
triphosphate (Scheme 1.4). 
20 




























Scheme 1.4 Reagents and conditions: i, NH2NH2, C5H5N-CH3COOH; ii, CH3COOH, H20. 
A critical step in the phosphotriester approach is the activation of the phosphodiester 
prior to chain extension. Arylsulphonyl chlorides (phenyl- 113d, p-tolyl- 113a, 2,4,6- 
trimethylphenyl- 113b, 2,4,6-triisopropylphenyl- 113c, and 8-quinolinyl- 131) have 
been examined for this purpose. ' 5,27 To minimize sulphonylation of the 5'-hydroxyl 
21 
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function, sterically hindered arylsulphonyl chlorides are preferred. Hindered 
arylsulphonyl azolides, which were found to have lower reactivity towards alcoholic 
functions, have been used more successfully than the chlorides. While various 
imidazolides, 28 triazolides, 29 and 4-nitroimidazolides 
30 have been found to be only 
marginally useful as coupling agents, 2,4,6-triisopropylbenzenesulphony] tetrazolide31 
132 and mesitylenesulphonyl 3-nitrotriazolide (MSNT)32'33 133 were found to be very 
efficient. Because MSNT is considerably more stable than 2,4,6- 
triisopropylbenzenesulphonyl tetrazolide, it was established as the coupling agent of 











1.2.2c The Phosphite Triester Approach 
The first investigation of the phosphite triester approach was reported in the mid- 
1970s by Letsinger and co-workers. 34'35 The basic aspects of this method are shown in 
Scheme 1.5.5'-O-Protected nucleoside 134 was allowed to react with the bifunctional 
phosphitylating agent (2,2,2-trichloroethyl)phosphorodichloridite 135 to generate a 
3'-O-phosphorochloridite intermediate 136 at low temperature (-78°C); 136 
underwent rapid coupling with a second nucleoside 137. The phosphite triester 138 
formed was oxidised in situ by aqueous iodine treatment to generate a phosphate 
triester 139. This approach was employed in solid phase synthesis using a silica 
support attached through a 3'-O-succinate linkage. By adding 1H-tetrazole 140 to the 
deoxynucleoside chlorophosphite 136, coupling rates and yields were increased 
significantly. A dodecanucleotide was prepared in an overall yield of 55%. 
36.37 
Despite the rapid coupling rate, this approach suffers from several drawbacks. The 
preparation of the nucleoside chlorophosphite 136 from the bifunctional 
phosphitylating agents such as 135 had to be performed at low temperature in the 
absence of moisture; and because of the sensitivity of the reagents to oxidation and 
hydrolysis, they have to be prepared immediately before use. A more serious problem 
22 
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with this approach is the formation of 3' -ý 3' and 5' -4 5' symmetrical isomers due 
to the use of the bifunctional phosphorodichloridite reagents. Efforts to improve this 




























1.2.2d The Phosphoramidite Approach 
N 
N- NH /N 
140 
In 1981, the preparation of a new class of reagent called nucleoside phosphoramidites 
was reported by Beaucage and Caruthers; 38 this led to a new strategy called the 
phosphoramidite approach. As a modification to the phosphite triester approach, the 
reactive chlorophosphite in the phosphite triester approach was replaced with a 
phosphoramidite, which is stable to hydrolysis and oxidation under normal laboratory 
23 
Chapter 1 Introduction to Nucleic Acid Chemistry 
conditions, but is readily activated to form an internucleotide linkage in virtually 
quantitative yield with very few side reactions. 
This approach consists of reacting the protected deoxynucleoside 141 with chloro- 
N, N-dimethylaminomethoxyphosphine 142 and N, N-diisopropylethylamine. The 
product 143, upon activation by N, N-dimethylaniline hydrochloride 144 affords the 
corresponding chlorophosphite 145 which couples rapidly with a second nucleoside 
with a free hydroxyl function 146 to give a phosphite triester 147. As in the phosphite 
triester approach, iodine oxidation of the phosphite triester 147 produces the 




[(CH3)2CH]2NCH2CH 1 144 142 N(CH3)2 












Scheme 1.6 The original phosphoramidite chemistry. 
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Tertiary amine hydrochlorides however are hygroscopic, which leads to unreliable 
and unreproducible results. 1H-Tetrazole 140, which is a non-hygroscopic weak acid, 
was then chosen as a suitable activating agent in the phosphoramidite approach. 38 3'- 
O-(Methoxy-N, N-dimethyl)phosphoramidites 143 were however found to be unstable 
in acetonitrile which is the solvent most commonly used in solid phase synthesis. 
Therefore, more detailed investigation was directed to the exploration of stable 
phosphoramidite derivatives. 
Several methyl N, N-dialkylaminophosphoramidites, for example methoxy- 
morpholinophosphine derivative 149 and (methyl NN-diisopropylphosphoramidite) 
derivative '40150 were later found to be stable in acetonitrile. After the chain assembly 
process is complete, the methyl protecting groups can be removed by treatment with 
thiophenol, which is rather unpleasant. To eliminate this thiolate treatment, more 
phosphoramidite derivatives were prepared. Among them, (2-cyanoethyl NN-diisopro- 
pylphosphoramidite) derivative 41 151 were found to be stable in acetonitrile and the 
cleavage of the cyanoethyl protecting groups from the oligonucleotides could be 
effected under basic conditions required for the removal of the nucleobase protecting 
groups, i. e. aqueous ammonia treatment. This proved to work extremely well and has 
since been widely used in standard phosphoramidite oligonucleotide synthesis. By 
using these phosphoramidites, relatively large oligonucleotides (up to 150-mer) were 
successfully synthesised by solid phase synthesis on nonporous silica microbeads42 
and rigid non-swelling polystyrene beads43 with stepwise coupling yields averaging 
from 98% to 99%. 
25 
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1.2.2e The H-Phosphonate Approach 
150 151 
Nucleoside H-phosphonates were first used in the synthesis of oligonucleotides by 
Todd and co-workers44 in the late 1950s. In their studies, 2', 3'-protected uridine 5'-H- 
phosphonate 152 was activated by diphenyl phosphorochloridate 153 and coupled 
with 2', 3'-protected adenosine 154, affording the corresponding dinucleotide H- 
phosphonate 155 in high yield. The H-phosphonate diester linkage was easily 
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This approach was applied to polymer-supported solid phase synthesis of short 
oligomers (di, tri, and tetramers) in the early 1970s but only gave poor to moderate 
yields (46-80%). 45 The H-phosphonate approach did not therefore receive intensive 
study until the mid-1980s. In 1985, Stawir ski and co-workers46 found that 5'-0- 
dimethoxytrityl thymidine 3'-H-phosphonate 157 reacted rapidly with 3'-0- 
benzoylthymidine 158 in the presence of diphenyl phosphorochloridate 153 and 1- 
methylimidazole to give the dithymidinyl H-phosphonate 159 in nearly quantitative 
yield. It was postulated that a reactive mixed-anhydride 160 was formed from the 
activation of the H-phosphonate with diphenyl phosphorochIoridate, which underwent 










1P, O pyridine 










It was also found that a trinucleoside metaphosphite 161 could be formed when the 
activated H-phosphonate (i. e. mixed-anhydride 160) was allowed to stand in pyridine 
for 5 min. 47 This metaphosphite could then be converted to phosphorodichloridite 162 
depending on the amount of diphenyl phosphorochloridate used. 48 
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Apart from diphenyl phosphorochloridate, other activating agents were also 
evaluated. Sterically hindered acyl chlorides, such as pivaloyl chloride49 163 and 
adamantanecarbonyl chloride50 164 were found to be very efficient coupling agents. 
These acyl chlorides activate the H-phosphonates 157 by the same mechanism as 
diphenyl phosphorochloridate does, and a mixed-anhydride intermediate 165 is 
generated as the reactive species51'52 (Scheme 1.9). In the presence of excess acyl 
chloride, the mixed-anhydride further reacts with the activating agent to form a bis- 
acylphosphite 166 or a more complicated by-product 167. 
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Scheme 1.9 Acyl chloride as activating agent. 
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A less reactive coupling agent, dipentafluorophenyl carbonate 168 was later 
demonstrated to minimise the side reactions discussed above. 53 
Although the H-phosphonate approach had shown great potential for the preparation 
of oligonucleotides, it was not until very recently that it emerged as an approach of 
choice in large-scale synthesis of oligonucleotides in solution. A couple of years ago, 
Reese and co-workers54'55 developed a modified H-phosphonate strategy involving 
the coupling of an H-phosphonate 169 with a nucleoside (or nucleotide) with a free 
hydroxyl function 170, followed by a sulphur-transfer step, to give a fully protected S- 
aryl or S-alkyl phosphorothioate triester 172. As soon as the coupling had gone to 
completion, the H-phosphonate diester 171 was converted in situ to a stable 
phosphorothioate triester 172 by reacting with a sulphur-transfer agent 173 or 174 in 
one pot (Scheme 1.10). 
DMTr 8 
% KO 
H 0169 couplir 
H 
170 171 
Scheme 1.10 A modified H-phosphonate approach. 
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173 a; R= CH2CH2CN 174 
b; R= Aryl 
172 a; R= CH2CH2CN 
b; R=Ar 
According to the choice of sulphur-transfer agent (S-(2-cyanoethyl) or S-aryl) and 
unblocking reagent (DBU or oximate), either a phosphorothioate diester 175a or 
phosphate diester 175b could be obtained (Scheme 1.11). It is therefore possible to 
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Scheme 1.11 Unblocking of the fully-protected phosphorothioate triesters. 
1.2.3 Solid Phase Synthesis of Oligonucleotides 
The idea of carrying out an organic synthesis on a solid support was proposed by 
Merrifield56 in relation to peptide synthesis. This strategy was afterwards adapted to 
oligonucleotide synthesis. 57 The attractive feature of this strategy is obvious: the 
separation of the growing oligomer products can be easily effected through simple 
filtration and further washing, which avoids time-consuming isolation and 
purification involved in solution synthesis. Therefore, tremendous work has since 
been directed towards this innovative field. 
As a result of intensive studies, several solid supports emerged to be suitable for the 
synthesis of oligonucleotides. HPLC grade silica36'37 and controlled-pore glass 
(CPG)58 have been used successfully in . solid phase oligonucleotide synthesis. 
Particularly, CPG has been used extensively in automated oligonucleotide synthesis. 
At the present time, the leader nucleoside is anchored covalently to the commercially 
available `long-chain alkylamine' CPG through a succinate linkage (Figure 1.5). 
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Figure 1.5 Immobilisation of a nucleoside on a solid support. 
Over the past four decades, all the approaches discussed above have been evaluated 
on solid supports for the preparation of oligonucleotides. However, solid phase 
synthesis of oligonucleotides using the phosphoramidite approach has so far been the 
most successful strategy and has been established as the standard methodology. The 
optimised solid phase cycle is shown in Scheme 1.12. Four basic steps are involved in 
this approach: detritylation, coupling, capping and oxidation. The cycle is repeated 
until the desired oligonucleotide has been assembled. After the desired chain has been 
assembled, it is then cleaved from the solid support by treatment with aqueous 
ammonia, which removes the exocyclic NH protecting groups on the nucleobases as 
well. 
Phosphoramidite-based solid phase synthesis offers great versatility in assembling 
oligonucleotides of moderate chain length and the time required for this process is 
very much shorter than for solution phase synthesis. But whether it can be scaled up 
to a manufacturing scale is yet to be investigated. 
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Scheme 1.12 A phosphoramidite solid phase synthesis cycle. 
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Antisense Oligonucleotides and Analogues 
In 1978, synthetic oligonucleotides were for the first time proposed by Zamecnik and 
Stephenson59 as a class of potential therapeutics to inhibit gene expression through an 
antisense mechanism. In the January 1990 issue of Scientific American, an 
introduction to the field of antisense nucleic acids was presented by Weintraub, 60 in 
which he defines the field as follows: 
Antisense RNA and DNA 
`Molecules that bind with specific messenger RNAs can selectively 
turn off genes. Eventually certain diseases may be treated with them. ' 
After this novel therapeutic strategy was conceived, a great deal of work was directed 
towards the elucidation of the mechanism of antisense inhibition, the development of 
new antisense oligonucleotides and studies on their pharmacokinetics. The intensive 
investigation of this strategy led to a clinical trial of the first drug of this kind in the 
mid-1990s. 
2.1 Mechanism of Antisense Inhibition 
It was established a few decades ago that the genetic information is encoded in 
double-stranded DNA and transcribed into single-stranded mRNA, which is then 
expressed as protein, the functioning biological species. Whereas traditional drug 
discovery targeted the protein or later stages of metabolism, it has been assumed that 
a drug which operates at the DNA or RNA level could be superior to traditional 
drugs. It is the progress in biological techniques which opens up the possibility of 
introducing normal, functioning genes to replace defective, non-functioning genes, 
and also that of selectively preventing the expression of unwanted genes. By such 
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means, it may be possible to develop highly effective antiviral agents which suppress 
viral genes without simultaneously affecting the expression of host cellular genes. 
Such selective inhibition is possible in theory due to the known complementary 
Watson-Crick base pairing rules. Oligonucleotides which bind with single-stranded 
RNA are named as antisense oligonucleotides, while those which interact with 
double-stranded DNA are called antigene oligonucleotides. 
The mechanism of action of an antisense oligonucleotide depends on the target 
sequence it seeks. Although the structural requirements to be met by an effective 
antisense oligonucleotide have not yet been clearly defined, there are concrete 
theories about the mechanism of its action. To understand the principles behind the 
design of antisense oligonucleotides, it is necessary to recall briefly the biosynthesis 
of protein. 
At the beginning of the process, DNA is transcribed. But in addition to the coding 
sequences which are called exons, the precursor mRNA also contains extra 
nucleotide sequences called introns. In the next step which is called splicing, introns 
are excised from the precursor mRNA and the exons are joined together to form the 
mature mRNA. The mature mRNA, which contains a 5'-cap region, an untranslated 
leader sequence, an AUG initiation codon which signals the ribosome to start protein 
synthesis, the coding regions, a terminating codon which signals the ribosome to stop 
protein synthesis, and a 3'-untranslated sequence with a polyadenylate tract, is then 
transported through the nuclear membrane to the cytoplasm, where protein synthesis 
takes place (Figure 2.1). 
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Figure 2.1 Biosynthesis of mRNA and Protein. (RBS = ribosome binding site. ) 
The mechanism of antisense therapy can be simply illustrated as in Figure 2.2. An 
antisense oligonucleotide binds specifically with a complementary area within an 
mRNA, according to Watson-Crick base pairing rules. Thus the biological synthesis 
of a protein is switched off. 
To view the process in more detail, several possible antisense mechanisms can be 
considered. 
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Figure 2.2 Brief mechanism of antisense therapy. 
2.1.1 Transcription Inhibition 
At the stage of transcription, RNA polymerase binds to DNA to form a closed 
complex. The closed complex is then converted into an open complex where the 
double-stranded DNA is unwound. When this open complex is attacked by an 
antisense oligonucleotide, transcription is inhibited (Figure 2.3). 
2.1.2 Inhibition of Splicing 
When an antisense oligonucleotide targets at an exon/intron junction, the 
complementary complex formed will block the access of the spliceosome to this 
junction, resulting in an improperly spliced mRNA which degrades in the nucleus. 
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Figure 2.3 Transcription inhibition. 
2.1.3 Non-Sequence-Specific Mechanism 
Although it is generally believed that antisense oligonucleotides work on the basis of 
specific binding of the oligos with mRNA, there is evidence which supports non- 
sequence-specific mechanisms. Inhibition of Rauscher leukaemia virus by 
homopolynucleotides61 and inhibition of HIV by phosphorothioates62 based on 
inhibition of reverse transcriptase have been shown to be possible. 
2.1.4 RNase H Mechanism 
In some circumstances, RNase H selectively cleaves the RNA strand at the antisense 
oligonucleotide-binding site. 63-65 The antisense oligonucleotide itself is not cleaved 
and therefore is free to bind to another RNA molecule. However, this action of 
RNase H entails the risk of a certain lack of specificity because even brief interaction 
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of only 5-6 base pairs may be recognised as a DNA : RNA substrate. 66'67 Especially 
at the site of injection, the transient high local concentration of oligos can bring 
about a non-specific mRNA breakdown. 68 
2.2 Requirements of Antisense Oligonucleotides 
For oligonucleotides to be useful as antisense therapeutic agents, they must meet the 
following requirements: 
1. The oligonucleotides must have good stability towards extra- and intra-cellular 
enzymes. Oligonucleotide phosphates, the natural nucleotides, are therefore not 
suitable for this purpose because they are degraded by nucleases quickly in vivo. 
2. The oligonucleotides must be able to penetrate through the cell membrane. 
3. The oligonucleotides must specifically bind to the targets to form duplexes. Non- 
sequence-specific interaction with other macromolecules should be avoided. 
4. For the antisense oligonucleotides to be useful in clinical therapy, they must be 
synthesised and scalable easily. Phosphoramidite based solid-phase chemistry has 
greatly eased synthesis and improved availability of oligonucleotides. Large-scale 
oligonucleotide synthesis is still pursued intensively. 
2.3 Deciding the Length of Antisense Oligonucleotides 
To achieve a high degree of selectivity of an antisense oligonucleotide in the 
interaction with its target, it should be capable of binding only to its target mRNA 
and not to other mRNAs. 
Statistically, a 17-mer oligonucleotide sequence occurs just once in the human 
genome. 69 Furthermore, at a particular point in time, only 10-20% of the genes in the 
cell are being transcribed into the corresponding mRNA. Also, if one takes into 
account the percentage of the genome which is actually expressed as mRNA (0.5%), 
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an oligonucleotide with 15-20 bases will be uniquely complementary to a single 
nucleotide sequence within the human genome, which contains approximately 4x 109 
base pairs. 70 
The affinity of the binding between an oligonucleotide and its target should also be 
taken into account in deciding the base-pair length of an antisense oligonucleotide. 
This affinity is characterised by the melting temperature (TR, ). Tm, which is the 
temperature at which 50% of the double strand has dissociated into its two single 
strands, is dependent on the concentration of the oligonucleotide and on the 
properties of the solvent. For an unmodified oligonucleotide with a length of ca. 12- 
20 bases, the rule of Wallace71 can be used to estimate its T, n at high salt 
concentr Lion: 
Tm =nx (2°C) +mx (4°C) 
where n is the number of dA"T base pairs and m is the number of dG"dC base pairs. 
Under physiological conditions (37°C, low salt concentration), at least 12 base pairs 
are required to achieve reasonably stable hybridisation of an oligonucleotide with its 
target sequence. In practice, a 20-mer oligonucleotide with average base pairing may 
72 be assumed to have a Tm of ca. 54°C (DNA duplex in 0.1 M NaCI). 
2.4 Modified Oligonucleotides 
In order to improve the properties of oligonucleotides such as nuclease stability, 
cellular penetration and potency, there has been an explosion of effort towards the 
synthesis of oligonucleotide analogues. These investigations have involved 
modifications of the phosphodiester backbone, the base, and the sugar ring. 
The development of modified oligonucleotides started with the replacement of the 
phosphodiester linkage, which was earlier identified as a necessary requirement for 
advancing antisense oligonucleotides, since unmodified oligonucleotides are rapidly 
degraded by nucleases that recognise the phosphodiester linkage. Virtually any 
modification to the phosphodiester backbone confers stability to nucleases. Anionic 
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201b-e, cationic 202 and neutral phosphate analogues 203a-g, 204 have been found 
to be resistant to nucleases. And these backbone modifications may also allow for 
enhanced affinity and increased cellular penetration of the oligos. Among these 
analogues, phosphorothioates 201b, morpholino derivatives 205,206 and peptide 
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Modification of the ribose portion has also been pursued. The ribose ring has been 
appended to and substituted, conformation ally restricted or replaced by hexose. The 
introduction of substituent groups at the 2' position is the most straightforward 
modification. 2'-O-Methyl'83 2'-fluoro-2'-deoxy, and 2'-O-(2-methoxyethyl)84 ribose 
derivatives 208a-c have been investigated. The trend is that nuclease stability 
increases, and binding affinity decreases, with increasing substituent size. The 
replacement of the ribose with a hexose scaffold confers significantly enhanced 




208 a; R= OMe 
b; R=F 
c; R= OCH2CH2OMe 
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Modifications of the aromatic base residues are also made to enhance affinity 
towards RNAs. A simple modification is to introduce a propynyl group on the 5- 
position of pyrimidines85 (209,210) or 7-position of 7-deazapurines86'87 (211,212). 







N NJ NNN H2 
211 212 
However, some of these modifications do not allow the oligonucleotides to mediate 
the destruction of the target mRNA by an RNase H mediated mechanism. RNase H 
requires an RNA/DNA hydrid molecule as a substrate. If the oligonucleotide is 
modified too much (e. g. by modification at the 2' position of the sugar ring), it is no 
longer recognised by RNase H. To get around this problem, oligonucleotides have 
been designed such that some of their bases are modified to allow for increased 
stability and affinity, while others are left unmodified to allow hybrids of the 
oligonucleotides with RNA to remain viable substrates for RNase H. 88-90 Another 
advantage of these chimeric oligonucleotides is that they have been found to have 
even fewer toxic side effects than oligonucleotide phosphorothioates. These 'second- 
generation' antisense oligonucleotides are beginning to make their way into clinical 
trial and may replace oligonucleotide phosphorothioates altogether in the near future. 
Two examples of the chimeric oligonucleotides are shown in Figure 2.491 (213,214). 
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Figure 2.4 Chimeric oligonucleotides. 
2.5 Oligonucleotide Phosphorothioates (PS-Oligos) 
In this context, our attention is drawn towards first generation oligonucleotide 
phosphorothioates. 
There are three constitutionally isomeric forms of intcrnucleotide phosphorothioate 
linkage. Replacement of either the 3'- or 5'-oxygen in a phosphodiester linkage, 215, 
results in the respective thiolo structures 216 or 217, whereas substitution of a non- 
bridging oxygen with sulphur gives a thiono (phosphorothioate) structure 218,219. 
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O00 
11 11 11 
(3'-O)-P= (5'-O) (3'-S)-P_ (5'-O) (3'-O)-P_ (5'-S) 
OOO 
215 216 217 
0 i- 1 
(3'-O)-P-(5'-O) '« : (3'-O)-P-(5'-O) 
SS 
218 219 
Compared with oxygen, sulphur has a larger atomic radius and lower 
electronegativity, and displays less multiple bonding. 
92 It is generally accepted that in 
the P=Z bonding type, charge transfer takes place, which is greater in P=O than in 
P=S, and therefore the former bond is always stronger; on the other hand, the P=S 
bond is more polarizable than the P=O bond. 
93 Therefore, the phosphorothioate 
linkage is better represented by the thio ion 218 than by the oxy ion 219. 
Oligonucleotide phosphorothioates possess the following physicochemical and 
biological properties: 
1. The substitution of oxygen with sulphur generates chirality at the phosphorus 
(Rp and Sp) centres and therefore the number of diastereoisomers is 2", where 
n is the number of phosphorothioate linkages. 
2. In comparison to that of unmodified oligonucleotide phosphates, the 
enzymatic resistance of phosphorothioates is greatly improved. This 
improved resistance was first observed by Eckstein94 and later it was found 
that snake venom phosphodiesterase (SVPD) only digests the Rp 
configuration phosphorothioates95 and nuclease P, only accepts the Sp 
configuration phosphorothioates. Studies on the digestion of oligonucleotide 
phosphorothioates by three nucleases (S1, P1 and SVPD) showed that96 the 
rates of digestion of oligonucleotide phosphorothioates with nuclease Si and 
P1 were ca. 10-100 times slower than those of unmodified oligonucleotide 
phosphates, and oligonucleotide phosphorothioates were digested some 102- 
103 times slower than unmodified phosphate oligonucleotides with SVPD. In 
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vivo studies showed that they are cleaved only slowly by metabolism, with 
elimination half lives of 48 hours or longer in all species studied. 
97 
3. The oligonucleotide phosphorothioates retain water solubility and chemical 
stability of charged phosphate analogues. 
4. The oligonucleotide phosphorothioates are capable of hybridising effectively 
with their complementary strands to form stable duplexes. However, in terms 
of Tn,, the duplexes formed between phosphorothioate oligonucleotides and 
their complementary strands are less stable than normal duplexes, with lower 
T,,, values. 96 
5. The duplexes formed between oligonucleotide phosphorothioates and their 
complementary strands remain as substrates for RNase H. 
98 
So far, oligonucleotide phosphorothioate analogues have received intensive studies 
and clinical trials of a few oligonucleotide phosphorothioates are under way (Table 
2.1). Among these analogues, the anti-human-cytomegalovirus (CMV) agent ISIS 
2922 (known as VitraveneTm commercially, 220) (Figure 2.5) has been licensed for 
therapeutic use. 99 
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Table 2.1 Some oligonucleotide phosphorothioates in clinical trials. 
Clinical 
Molecular Target Sequence (5'-0) Disease Target Status 
Viral diseases 
CMV GCG TTT 
GCT CTT CMV-induced retinitis Approved CTT CTT GCG 
CMV 
UGG GGC TTA CCT CMV-induccd retinitis Phase II TGC GAA CA 
HIV- I 
CTC TCG CAC CCA HIV-I-AIDS Withdrawn 
TCT CTC TCC TTC T 
HPV TTG 
CTT CCA TCT Genital warts Withdrawn TCC TCG TC 
Oncological and hematological diseases 
bcl-2 
TCT CCC AGC GTG Prostate; Phase UII 
CGC CAT non-Hodgkin's lymphoma 
CGC TGA AGG GCT 
bcr-abl TCT TCC TTA TTG CML, advanced phase Pilot 
AT 
CGC TGA AGG GCT 
bcr-abl TTT GAA CTG TGC CML, blast crisis Pilot 
TT 
CML, blast crisis, 
refractory leukaemia 
Phase I 
TAT OCT GTG CCG 




GCT AAC GTT GAG Restenosis Withdrawn 
GGG CAT 
TCC CGC CTG TGA Prostate, breast, ovarian, 
c-raf Phase II CAT GCA TT pancreas, colon, lung 
Ha-ras GGG ACT 
CCT CGC Solid tumors Phase I TAC TGC CT 
Crohn's disease, psoriasis, 
rheumatoid arthritis, 
ICAM-I GCC CAA GCT GGC ulcerative colitis, tissue Phase II ATC CGT CA 
rejection after organ 
transplantation 
_ AML-and myelodysplastic 
syndrome, refractory or Phase II CCC TGC TCC CCC 
p53 CTG GC CC relapsed T 
AML and myelodysplastic Pilot 
s ndrome 
PKA-RIa 
GCG UGC CTC CTC 
Solid tumors Phase II ACU GGC 
Ovarian, prostate, breast, 
PKC-a 
GTT CTC GCT GGT brain, lung, colon, Phase II GAG TTT CA 
melanoma 
Note: a. AML, acute myeloid leukemia; CML, chronic myeloid leukemia; CMV, cytomegalovirus; 
HPV, human papilloma virus; ICAM, intercellular adhesion molecule; PKA, protein kinase A; PKC, 
protein kinase C; RIa, regulatory subunit Ia. b. All the sequences contain phosphorothioate 
interlinkages; plain and bold letters indicate deoxy- and 2'-O-methyl-ribonucleosides, respectively. 
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2.6 Fomivirsen (ISIS 2922 sodium salt) 
Human cytomegalovirus (CMV), a ubiquitous herpes virus, is the most common 
cause of viral retinitis in immunocompromised individuals, including patients with 
HIV infection. 100 Cytomegalovirus retinitis is a sight-threatening disease, 
characterised by the progressive destruction of retinal cells, and is a major cause of 
morbidity in patients with AIDS. 101 
Fomivirsen (ISIS 2922) is an antisense oligonucleotide phosphorothioate with 21 base 
residues (Figure 2.5), which specifically inhibits replication of human 
cytomegalovirus and is the first antisense drug evaluated in the treatment of patients 
with AIDS-related CMV retinitis. 99 
The antiviral action of fomivirsen is based on a combination of antisense and non- 
antisense mechanisms. Immediate-early gene expression, which is essential for viral 
replication, is inhibited by fomivirsen via an antisense mechanism and the adsorption 
of cytomegalovirus to host cells can also be inhibited through a sequence-independent 
mechanism. 102,103 The administration of fomivirsen significantly delays progression of 
CMV in patients with AIDS in preliminary clinical trials. 104"05 The common adverse 
events with this drug reported in clinical trials include increased intraocular pressure 
and mild to moderate intraocular inflammation, which is generally transient or 
reversible with topical steroid treatment. 106.107 On July 22 1998, the Ophthalmic 
Subcommittee of the Dermatologic and Ophthalmic Drugs Advisory Committee of 
the FDA recommended approval of the new drug application for fomivirsen sodium 
(VitraveneTM) for the treatment of patients with cytomegalovirus-induced retinitis by 
intravitreal injection. 
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Figure 2.5 Fomivirsen (ISIS 2922) 220. 
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Synthesis of Oligonucleotide Phosphorothioates 
3.1 Chemical Synthesis of Oligonucleotide Phosphorothioates 
Oligonucleotide phosphorothioates can be and have been prepared by all the 
approaches used for unmodified oligonucleotides. Among these strategies, the 
phosphotriester, phosphoramidite and H-phosphonate approaches have proved to be 
effective for this application. So far, the phosphotriester approach has been mainly 
used in the preparation of oligonucleotide phosphorothioates in solution, whereas the 
phosphoramidite and H-phosphonate approaches have almost exclusively been used 
in solid phase synthesis. 
3.1.1 The Phosphodiester Approach 
The chemical synthesis of oligonucleotide phosphorothioates via the phosphodiester 
approach was first reported by Eckstein94,108 in 1967. By using 
triisopropylbenzenesulphonyl chloride (TPS-Cl, 113c) as condensing agent, 3'-O- 
acetylthymidine 5'-phosphorothioate 301 was coupled with 5'-O-tritylthymidine 114 
in pyridine. The desired dithymidine phosphorothioate 302 was obtained in 18% 
yield. Loss of sulphur, which generated dithymidine phosphate 303 in 33% yield, was 
also observed (Scheme 3.1). 
The low yield is not surprising. Firstly, one of the starting materials 301 itself is 
bifunctional and the product 302 is also open to further phosphorylation; secondly, 
TPS-Cl may not be a suitable condensing agent to activate the thio ion. It was actually 
observed that when DCC 11794 was used as coupling agent, complete loss of sulphur 
occurred and only fully-desulphurised product 303 was formed. 
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Scheme 3.1 Preparation of phosphorothioate via phosphodiester approach. 
3.1.2 The Phosphotriester Approach 
Perhaps the most straightforward remedy for the phosphodiester approach is to 
introduce a suitable protecting group (as in 304) on the phosphorus centre of the 
phosphorothioate monoester. By doing this, the side-reactions resulting from the 
bifunctionality of the starting material 301 and the vulnerability of the coupling 
product to further phosphorylation can be suppressed. Also, loss of sulphur due to the 





















Scheme 3.2 Preparation of phosphorothioate via phosphotriester approach. 
The S-(2-cyanoethyl) group was first used by Malkievicz and Smrt'09 in the 
preparation of dithymidine phosphorothioates. The 3'-O-acetylthymidine 5'- 
phosphorothioate S-(2-cyanoethyl) diester 304 was activated by TPS-Cl 113c and 
coupled with 5'-O-dimethoxytritylthymidine 305. The desired phosphorothioate 
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triester DMTr-Tp(s)T-Ac`, 306, was obtained in 80% yield (Scheme 3.2). Unblocking 
of this triester was carried out in two steps. After treatment with 90% acetic acid, 
methanolic ammonolysis of the material gave the fully-unblocked phosphorothioate 
diester Tp(s)T in quantitative yield. However 3'-U-acetylthymictine ZI'- 
phosphorothioate S-cyanoethyl diester 304 was difficult to prepare and the yield was 
poor. 
In the following decade, several other activating agents were investigated for this 
approach. Reese et al. 1 " and van Boom et al. 12 introduced 2,5-dichlorophenyl 
phosphorodichloridothioate 307 as a coupling agent. This is a very reactive activating 
agent but it is very sensitive to moisture. In addition, it is a bifunctional 
phosphorylating agent; therefore, some symmetrical (3'-+3')-phosphotriester 308 is 
formed along with the activated intermediate 309. Both 309 and 307 can condense 
with a nucleoside with free 5'-hydroxy function to produce the desired asymmetrical 
(3'-- 5')- and the respective symmetrical (5'- 5')-phosphotriester 310 and 311. The 
symmetrical products 308 and 311 are undesirable because they lower the yield of 
310 and also create purification problems 113 (Scheme 3.3). 
'A number of years ago, Reese and co-workers 10 introduced a system of 
abbreviations for protected oligonucleotides in which nucleoside residues and 
internucleotide linkages are italicised if they are protected in some defined way. In the 
present context, T, G and C represent thymidine protected on 0-4 with a phenyl 
group, 2'-deoxyguanosine protected on N-2 and 0-6 with isobutyryl and 2,5- 
dichlorophenyl groups, and cytidine protected on N-4 with a benzoyl group, 
respectively; and p(s) represents an S-(2-cyanoethyl)-protected phosphorothioate. 
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O-P-CI base Ar-O-P-OR 
+ Ar-O-P-OR + unreacted 307 
CI CI OR 
CI 307 309 308 
SSS R'OH 
Ar-O-P-OR + Ar-O-P-OR 1 Ar-O-P-OR' base OR OR' OR' 
308 310 311 
ROH = 3'-OH substrate; R'OH = 5'-OH substrate 
Scheme 3.3 2,5-Dichlorophenyl phosphorodichloridothioatc promoted coupling reaction. 
Van Boom' 12 also proposed the use of 1-hydroxybenzotriazole derivatives of 2,5- 
dichlorophenyl phosphorodichloridothioate, 312a, b as condensing agents. By using 
2,5-dichlorophenyl-O, O-bis(6-nitro-l-benzotriazolyl) phosphorothioate 312b as 
activating agent, hexadecamers were assembled, and the yields for 10-min synthesis 








312 a; R=H 
b; R= N02 
A facile preparation of nucleoside 3'-phosphorothioate S-(2-cyanoethyl) diesters was 
reported by Reese 114 (Scheme 3.4). Suitably protected nucleoside 313 was treated 
with phosphorus trichloride and 1H-1,2,4-triazole 314 to give H-phosphonate 
monoester 315 in good yield (98%). Then a sulphur transfer step was incorporated. H- 
Phosphonate monoester 315 was allowed to react with chlorotrimethylsilane and N- 
[(2-cyanoethyl)sulphanyl]phthalimide 173a to form 3'-phosphorothioate S-(2- 
cyanoethyl) ester 316 in quantitative yield. 
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Scheme 3.4 Reagents and conditions: i, (a) PC13,314, Et3N, THF, -35°C; (b) Et3N - water, room 
temp.; ii, 173a, Me3SiCI, 4-methylmorpholine, CH2CI2, room temp.; iii, aq. Et3NH+HCO3 . 
This methodology proved very effective and was later successfully applied to the 
preparation of an octamer Tp(s)Tp(s)Gp(s)Gp(s)Gp(s)Gp(s)Tp(s)T 317 using 
blockmer strategy' 15 (Figure 3.1). 
317 
Figure 3.1 
3.1.3 The Phosphite and Phosphoramidite Approaches 
In the late 1970s, Burgers and Eckstein 116 described the first synthesis of 
diribonucleoside phosphorothioates by oxidation of phosphite triesters with sulphur 
(Scheme 3.5). After diribonucleoside phosphite triester 318 was formed at -78°C, the 
sulphurisation was effected by treating phosphite triester 318 with aIM solution of 
S8 in pyridine and the reaction was complete in 16 hours at room temperature to give 
the corresponding diribonucleoside phosphorothioate triester 319. 
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This methodology was later extended to oligodeoxynucleotide synthesis on solid 
supports. By using controlled pore glass (CPG) as solid support, the standard 
phosphoramidite method was adapted for this application (Scheme 3.6). The 
sulphurisation reagents used by Eckstein"? and Zon118 were a 0.2 M solution of S8 in 
CS2-pyridine (1: 1 v/v) (30 minutes at room temperature) and a 0.4 M solution of S8 
in 2,6-lutidine (15 minutes at 60°C). But the poor solubility of elemental sulphur in 
these systems, and actually in most organic solvents, caused the reaction to be slow. 
In automated synthesis, this may also lead to blockage of the synthesizer. Therefore, 
for this strategy to work well, alternative sulphur-transfer reagents are required. 
For a compound to be suitable as a sulphur transfer agent, it should be prepared 
readily and handled easily under laboratory conditions; it should be stable and its 
solubility in various solvents should be compatible with automated oligonucleotide 
synthesis; and finally it must convert phosphite triesters to phosphorothioate triesters 
fast and quantitatively without modification of the nucleosides. 
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Scheme 3.6 
So far, various compounds have been examined. Among them several have been 
shown to be suitable for this application. Beaucage reagent, 
119,120 3H-1,2- 
benzodithiol-3-one 1,1-dioxide 323, van Boom's reagents, 12' di-(phenylacetyl) 
disulphide 324 and dibenzoyl disulphide 325, ABI's reagent" 22 tetraethylthiuram 
disulphide (TETD) 326, Reese's reagent, 123 dibenzoyltetrasulphide 327, Stec's 
reagent, 124 bis-(O, O-diisopropoxy phosphinothioyl)disulphide 328 and Cruachem's 
reagent, 125 benzyltriethylammonium tetrathiomolybdate 329 were found to be very 
promising. Among these, the Beaucage reagent 323 appeared most rapid and efficient, 
with average sulphurisation efficiency being 99.75% in a synthesis of S-d(TTG CTT 
CCA TCT TCC TCG TC) on a 10. tmol scale. '26 However, use of this reagent on an 
automated synthesizer requires some precautions or special treatment of the reagent 
bottle. 127 The reagent bottle has to be treated with dilute sulphuric acid followed by 
washing with water and methanol. Prior to use, the bottle has to be treated with 
Sigmacote or 2% dichlorodimethylsilane solution in carbon tetrachloride followed by 
methanol. The metal filter also has to be replaced with a Porex filter, and the solution 
should be covered with aluminium foil to minimize exposure to light. The ABI 
reagent 326 offers the advantages of being a relatively low-cost chemical commodity 
that is nonhazardous (used also as a pharmaceutical), and is both very soluble (0.5 M) 
and indefinitely stable in acetonitrile - the prevailing solvent for solid phase 
synthesis. By using the ABI reagent as sulphur transfer agent, an overall 
sulphurisation efficiency greater than 99% was achieved for the synthesis of S-d(TCA 
CAG TCT GAT CTC GAT) on a 0.1 mmol scale. 128 
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So far, phosphoramidite chemistry has been almost exclusively used in solid phase 
synthesis and it has several advantages over other approaches. The coupling is very 
fast and efficient; it is very flexible for assembly of oligonucleotides of short to 
medium length and the process can be easily automated. But whether it can be scaled 
up to meet the demand for clinical application of oligonucleotides may be another 
story. 
3.1.4 The H-Phosphonate Approach 
The H-phosphonate approach was first adapted by Hata'29 for the preparation of 
oligonucleotide phosphorothioates, by using elemental sulphur (S8) to convert H- 
phosphonate diester 330 into phosphorothioate diester 331 (Scheme 3.7). This 
methodology was shortly afterwards employed in solid phase synthesis of 
oligonucleotide phosphorothioates, 130 and oxidation was effected in a single-step 
sulphurisation at the end of chain assembly in virtually quantitative yield. 
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Scheme 3.7 
It is generally recognised that the advantages of this strategy are: 131 
i. Nucleoside H-phosphonates are very stable solids; they can be stored 
under argon for more than 3 years. In a pyridine-CH3CN solution, H- 
phosphonates are also very stable; when decomposition does take place, 
it is the slow loss of the acid labile 5'-dimethoxytrityl protecting 
group. '32 Nucleoside H-phosphonates are resistant to oxidation and 
hydrolysis, and are only oxidized by strong oxidants, such as Mn04 . 
133 
ii. Protection at the phosphorus centre is not required. 
iii. Oxidation can be performed either as one synthetic step after the 
assembly of an oligonucleotide chain is complete, or stepwise. 
iv. This approach offers easy access to oligonucleotide analogues by 
changes in the oxidation step. Therefore, combined backbone linkage 
oligonucleotides having PO, PS, and PN linkages can be prepared by this 
methodology. ' 34 
An efficient and rather general approach to the preparation of nucleoside H- 
phosphonates was based on phosphorus trichloride-base-imidazole46 or 1,2,4- 
triazole49 and the yields are normally greater than 75%. The preparation is outlined in 
Scheme 3.8. Generally, no detectable 5'-dimethoxytrityl nucleoside 141 was observed 
during aqueous work-up of the intermediate 332, but the PX3 derivatives are very 
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sensitive to moisture, so the solvent must be extremely dry and this reagent must only 
be generated in situ prior to synthesis. 
DMTr B DMTr B DMTr B 
PX3 aa. work-up, 
OH X. P. 
O O\ ýO 








Another method for the preparation of H-phosphonate monoesters was suggested by 
van Boom and co-workers, ' 35 where PX3 was replaced with 2-chloro-4H-1,3,2-benzo- 
dioxaphosphorin-4-one 334. The reaction was rapid and virtually quantitative with 
formation of very little of the 3'-3'-symmetrical dimer. However, hydrolysis of the 
intermediate phosphite leads to ca. 5% of starting material and the salicyclic acid 






Another phosphite-based preparation of H-phosphonate monoesters involves the use 
of tris-(1,1,1,3,3,3-hexafluoro-2-propyl) phosphite136 335. This reagent was used in 
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Several other methods have also been developed for the synthesis of nucleoside H- 
phosphonates. Phosphonic acid 337, when used in conjunction with triphosgene 338, 
offers an alternative way to prepare H-phosphonate monoesters137 (Scheme 3.9). 
However, only moderate yields were achieved (58-75%). 
DMT DMTr 
OO OO 
+ HO-P-OH + C13C0 liý OCCI3 b 
OH 
H0 
141 337 338 Hý o- 
333 
Scheme 3.9 
A better method based on a P(V) starting material was described by Stawinski and co- 
workers. 138,139 When suitably protected nucleosides were mixed with diphenyl H- 
phosphonate 339 in pyridine, phenyl H-phosphonate diester 340 was generated. Upon 
aqueous work-up, H-phosphonate monoester 333 was formed in good yields (>80%) 
(Scheme 3.10). Compared with the methods described earlier in this context, this 
methodology is simple and the reaction goes to completion in only 15 min. The 
formation of symmetrical dimers can also be suppressed to a minimal amount (1.5%) 



















A common feature for the above procedures is that the phosphorus-donating agents 
are all multifunctional, so formation of symmetrical products is bound to occur to 
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some extent. A convenient and effective procedure for the preparation of H- 
phosphonate monoesters from a monofunctional starting material was developed by 
Reese and co-workers. 140 In this approach, ammonium aryl H-phosphonates 342a-d, 
which were prepared from phenols and phosphorus trichloride (Scheme 3.11), were 
used as starting materials. 
ArOH i, ii, iii 
Arm O+ 
341 a-d HO NH4 342a-d 
C)-ý 
b; Ar = KII5: i:. 
ý 
c; Ar = Me 
ý d; Ar = CI 
j 
Scheme 3.11 Reagents and conditions: i, PCl3,160°C, 3 h; ii, tert-butanol, 100°C, 30 min; iii, conc. 
aq. NH3,0°C. 
Treatment of reagent 343a-d with suitably protected nucleoside 141 in the presence 
of pivaloyl chloride 163 generates aryl H-phosphonate diester 344 which breaks down 
upon aqueous work-up to give the desired nucleoside H-phosphonate monoester 333 
(Scheme 3.12). After purification by chromatography, virtually quantitative yields 
were achieved on all four deoxynucleosides. This methodology, in our view, is 
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c; Ar = Me 
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_+ 141 H OAr HO NHEt3 
333 
344 
Scheme 3.12 Reagents and conditions: i, Et3N, pyridine; ii, 343, Me3000Cl, -35°C, 30 min; iii, (a) 
H20, pyridine, room temperature, I h; (b) pH 7.0 triethylammonium phosphate buffer. 
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In the earlier studies on the H-phosphonate approach, oxidation of H-phosphonate 
diesters was generally accomplished as one synthetic step after the assembly of an 
oligonucleotide chain was complete. The obvious disadvantage, as has been reported 
elsewhere, 141 is that H-phosphonate diesters are not stable to long-term exposure to 
the coupling conditions. An interesting and indeed novel modification was proposed 
by Reese and Song54,55 a couple of years ago which incorporated an in situ sulphur 
transfer step after the coupling was complete (Scheme 1.10, Scheme 1.11 and Scheme 
3.13). This offers a flexible methodology for preparation of phosphate and 
phosphorothioate diester, or chimeric sequences. More advantages include virtually 
quantitative coupling and the possibility of scaling up. 
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172 a; R= CNCH2CH2 
b; R= Ar 
Scheme 3.13 Reagents and conditions: i, 347, pyridine, CHZCI2, -40°C, 5-10 min; ii, 173 or 174, 
pyridine, CH2CI2,15 min; iii, 125, TMG, MeCN, room temperature, 12 h; iv, conc. aq. NH3,55°C, 15 
h; v, DBU, TMS-C1, CHZCI2, room temp., 30 min; vi, DBU, 125, MeCN, room temp., 12 h; vii, 
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3.2 Stereocontrolled Synthesis of Oligonucleotide Phosphorothioates 
As was described in the last chapter, incorporation of sulphur into the internucleotide 
linkage generates chirality at the phosphorus centre, therefore there exist 2" possible 
diastereoisomers of a given sequence having n centres of such chirality. The R and S 
phosphorothioate configurations are shown in Figure 3.2. 
Figure 3.2 
It appears that the configuration of the phosphorothioate linkage affects the stability 
of the duplex formed between oligonucleotide phosphorothioates and complementary 
single-stranded nucleic acids. In a self-complementary oligodeoxyribonucleotide 
containing a single phosphorothioate linkage, the Rp isomer melted approximately 
2°C lower than the oligomer with normal phosphodiester linkage. 142 So far, 
separation of diastereoisomers has been achieved by means of chromatographic 
techniques, but effectiveness of the separation depends on the number of 
phosphorothioate linkages within the oligonucleotide chain and is practically limited 
ton=1,2.143 
The preparation of diastereoisomerically pure (or enriched) oligonucleotide 
phosphorothioates in cases with only one, two or three phosphorothioate linkages has 
been reported. ' 18,144 
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An example was shown by Lesnikowski144,145 in the preparation of [SpSP]- and [RßRp]- 
isomers of triuridine phosphorothioate by using 5'-O-monomethoxytrityluridine-3'- 
O-[S-(2-nitrobenzyl)-O-(4-nitrophenyl)phosphorothioate] 348 as substrate. 
MM1 
02N 
348 (B = uracil-1-yl) 
Despite little hope of practical application to assemble oligonucleotide chains of 
antisense length, a strategy for the preparation of oligonucleotide phosphorothioates 
of pre-determined stereochemistry was described by Stec and co-workers. '46 This 
method involves preparation and chromatographic separation of diastereoisomerically 
pure 5'-O-dimethoxytrityl nucleoside 3'-O-(2-thio-1,3,2-oxathiaphospholanes) 349 
for stereospecific (99%) coupling with support-bound 5'-hydroxy functions under 


















Preparation of the diastereoisomerically pure starting material 349 was achieved by 
treatment of protected nucleoside 141 with 2-N, N-diisopropylamino-1,3,2- 
oxathiaphospholane 350 in the presence of IH-tetrazole 140 followed by in situ 
treatment with elemental sulphur (Scheme 3.14). A mixture of diastereoisomers (in 
55: 45 ratio) was formed and the two isomers were separated by chromatography. By 
using these diastereoisomerically pure starting materials, up to eight contiguous 
phosphorothioate linkages of predetermined stereochemistry were obtained on solid 
support with an average of 95% effectiveness for a single coupling step (Scheme 
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3.15). The purity of the material, as indicated by polyacrylamide gel electrophoresis 
and HPLC, was comparable with that of the sample prepared by phosphoramidite- 
stepwise sulphurisation or H-phosphonate-tandem sulphurisation methods. 147 
DMT 
DMTrO B 














Although further studies on this methodology are in progress, one has to realise that 
as high as 99% stereospecificity of a single step of synthesis does not yield a 
diastereoisomerically pure oligonucleotide. Using this protocol, the chemical 
synthesis of a 27-mer oligonucleotide phosphorothioate leads to material of at best 
75% diastereoisomeric purity. It is worthwhile to mention here that by using ring- 
restricted diastereoisomerically pure oxazaphospholidine phosphoramidites 353,354, 
larger oligonucleotide phosphorothioates (up to 20-mers) containing stereo-enriched 
all [RP] or all [Se] linkages have been synthesized. 148 Also, oligonucleotide 
phosphorothioates containing a central [RP] segment and [Sr] segments on either side 
or vice versa were prepared using the appropriate phosphoramidite. 
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Another phosphoramidite-chemistry-based procedure was suggested by Beaucage and 
co-workers149 recently. By using stereoisomerically pure cyclic N- 
acylphosphoramidites 355,356 as starting materials, stereo-controlled syntheses of 















Oligonucleotide phosphorothioates prepared via a polymerase-based process utilizing 
2'-deoxynucleotide 5'-O-(1-thiotriphosphate) (dNTPaS) substrates are believed to be 
100% [all RP] diastereoisomerically pure. '50, "51 The pivotal limitation of enzymatic 
synthesis is caused, however, by the fact that oligonucleotide phosphorothioates of 
only all-RP configuration are easily obtainable, although it was later announcedl52 that 
when 2'-deoxynucleotide 5'-O-(pyrophosphoryl methylphosphonate) [d(NTPaCH3)] 
was used as substrate, all-Sp oligonucleotide phosphorothioates could be obtained as 
well. 
In a recent study on a 15-mer, LR-3280 (5'-AAC GTT GAG GGG CAT-3'), both the 
all-RP and all-SP versions of this sequence were obtained by using 3'-O-(2-thio-1,3,2- 
oxaselenaphospholanes) 357 (X = Se) as building blocks. 153 The relative melting 
temperatures for the LR-3280 duplexes with complementary RNA were found to be 
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in the following order: all-RP (Tm = 55.2°C) > stereorandom (Tm = 50.7°C) > all-Sr 
(Tm = 48.3°C). The activities of these compounds in in vivo studies show the same 
trend: all-RP > stereorandom > all-SP (Figure 3.3). 
co-, x 














Figure 3.3 Growth inhibition in human smooth muscle cells by RP, stereorandom and S, LR-3280. 
Although the all-RP phosphorothioate oligonucleotides show consistent and 
reproducible biological effects, the current opinion is that their use in clinical settings 
is unwarranted due to their high cost and much lower accessibility. '54 
3.3 Preparation of ISIS 2922 21-Mer by the Modified H-Phosphonate Approach 
The aim of the present work is to carry out synthesis of a specific oligonucleotide 
phosphorothioate to evaluate the modified H-phosphonate methodology as shown in 
Scheme 3.13. ISIS 2922 (220) with sequence GCG TTT GCT CTT CTT CTT GCG 
was selected as the target. 
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3.3.1 Protection of 5'-Hydroxy Function 
The protection of 5'-hydroxy functions of nucleosides can be categorized into three 
systems according to the unblocking method: 155 (i) acid conditions, (ii) alkaline or 
ammoniacal conditions, or (iii) selective unblocking reagents applied essentially in 
the absence of acid or base. Whichever method is chosen must be integrated into an 
orthogonal protection system for the synthesis of nucleotides. So far, a number of 5'- 
hydroxy protecting groups have been developed, which include: triarylmethyl (trityl) 
derivatives 14,156 358, pixyl derivatives' 57 359, acyl protecting groups158,159 360, 







b; R=R'=H, R"=OCHS 
c; R=H, R'=R"=OCHS 
359 a; R=H 
b; R=CI 






The dimethoxytrityl 358c and pixyl 359a derivatives are so far most widely used for 
masking of the 5'-hydroxy function. They can both be removed in very mild acid 
conditions. Since 4,4'-dimethoxytrityl protected nucleosides are commercially 
available, this group was chosen as protecting group for the 5'-hydroxy function in 
our current studies. Removal of this group was effected with a solution of hydrogen 
chloride in dioxane at -50°C (Scheme 3.16). No depurination was observed under 
these conditions. 
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The levulinyl (Lev) group162 364 was chosen as the protecting group for the 3'- 
hydroxy function. The introduction of the Lev group is facile. For suitably protected 
T, dC, and dA, treatment of the nucleoside with levulinic anhydride in the presence of 
N, N-dimethylaminopyridine (DMAP) and triethylamine gives the corresponding 3'- 
levulinyl derivatives. However, when protected dG was treated under these 
conditions, base modification occurred; thus milder conditions have to be used. It was 
found that acylation went to completion when suitably protected dG was treated with 
a solution of levulinic anhydride in dry pyridine over a period of 12 h. 
The unblocking of the levulinyl group was effected under nearly neutral conditions, 
i. e. treatment with hydrazine hydrate in glacial acetic acid-pyridine (1: 4 v/v)163 
(Scheme 3.17). No internucleotide linkage cleavage was observed. 
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Scheme 3.17 Reagents and conditions: i, hydrazine hydrate, glacial acetic acid-pyridine (1: 4 v/v), 
0°C, 10 min; ii, 2,4-pentanedione, 15 min. 
3.3.3 Protection of Base Residues 
The choice of nucleobase protecting groups and unblocking protocols is of paramount 
importance in oligonucleotide synthesis. The protecting groups should meet several 
criteria: 22 
i. they should be able to be introduced using a stable reagent that is readily 
obtainable; 
ii. they should be achiral; 
iii. they should be readily introduced on the nucleoside; 
iv. they should enhance the solubility of the nucleoside in organic solvents; 
v. they should be stable to the conditions used in assembling the chain; 
vi. they should not cause other structural changes in the nucleoside during their 
introduction or removal, or during oligonucleotide assembly. 
The exocyclic amino group at the 2-position of guanine residues is susceptible to 
electrophilic attack and is therefore protected with the isobutyryl group. 164 2'-Deoxy- 
5'-O-(4,4'-dimethoxytrityl)-2-N-isobutyrylguanosine 368 is currently commercially 
available from several suppliers. At the end of the chain assembly, this protecting 
group can be removed by ammonolysis at 55°C. '65,166 
71 
Chapter 3 Synthesis of Oligonucleotide Phosphorothioates 
O 






It was found167'168 that base modification may also occur at the 4-0-position of 
thymine and 6-0-position of guanosine; protecting groups are required not only to 
prevent possible side reactions but also to improve lipophilicity and solubility in 














Scheme 3.18 Reagents and conditions: i, MeCN, N-methylpyrrolidine, TMS-Cl, room temp., 1 h; ii, 
POCl3,0°C, 20 min; iii, phenol, 0°C, 3 h; iv, water, room temp., overnight. 
The phenyl group was found to be suitable for the protection of the 4-0-position of 
thymine. The introduction of this group is illustrated in Scheme 3.18. At the 
beginning of the synthesis, the 3'-hydroxy function of 5'-O-dimethoxytrityl thymidine 
305 was temporarily blocked with a trimethylsilyl (TMS) group. Then N- 
methylpyrrolidine and phosphoryl chloride were added to generate an activated 
quaternary salt 370 which was allowed to react with phenol at 0°C. After the silyl 
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protecting group was removed by aqueous work-up, the desired 5'-O-dimethoxytrityl- 
4-O-phenylthymidine 371 was obtained in good yield (>80%). 
Similarly, the 6-0-position of 2'-deoxyguanosine is protected with phenol 
derivatives. 2,5-Dichlorophenyl is a good candidate in this case. The introduction of 
this protecting group was accomplished in a similar way to that of the thymidine 

















Unblocking of the O-aryl protection was effected by treatment with the 1,1,3,3- 
tetramethylguanidinium salt of 2-nitrobenzaldoxime in acetonitrile. The unblocking 
proceeds by a two-step mechanism (Figure 3.4). In the case of O-phenylthymidine, 
the O-phenyl protecting group is firstly displaced with oximate; the intermediate 
formed then undergoes elimination in the presence of a strong base to regenerate 
thymidine in virtually quantitative yield. The complete displacement of the O-aryl 
protecting groups on thymine and guanine residues with oximate is essential in the 
unblocking of a fully-protected oligonucleotide sequence. Treatment of partially 0- 
aryl-protected compound with concentrated ammonia generates a modified base 
(Scheme 3.19). In the case of a 4-0-phenylthymine residue 372, a 5-methylcytosine 
residue 373 could be generated. 
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The exocyclic 4-NH2 group of 2'-deoxycytidine was protected with a benzoyl group. 
Three strategies can be used (Scheme 3.20). Firstly, the trimethylsilyl group is used as 
temporary protecting groups for the 3'- and 5'- hydroxy functions of 2'-deoxycytidine 
374. The resulting compound is treated with excess of benzoyl chloride in pyridine to 
give 375. Upon ammonia treatment at ambient temperature, the TMS groups and one 
of the benzoyl groups are removed to give N-benzoyl-2'-deoxycytidine 376 (Route 1). 
Alternatively, 2'-deoxycytidine 374 can be perbenzoylated to yield 378, which is then 
treated with sodium hydroxide to give N-benzoyl-2'-deoxycytidine 376 (Route II). 
The benzoyl protecting group can also be directly incorporated on the exocyclic 
amino group by using benzoic anhydride or its activated esters (Route III). The 3'- 
hydroxy function of N-benzoyl-2'-deoxycytidine 376 is then masked with a DMTr- 
protecting group. 
Unblocking of the exocyclic amino protecting groups is performed by treatment of the 
substrate with concentrated aqueous ammonia at 55°C over a period of 15 hours. No 
concomitant internucleotide linkage cleavage has been observed. 
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i, TMSCI; ii, BzCI OTMS 


















3.4 Synthetic Strategy for Chain Elongation 
One advantage of the modified H-phosphonate approach is that an oligonucleotide 
chain can be assembled by adding one nucleoside unit or a blockmer per coupling 
cycle. If the target sequence is dissected as indicated in Figure 3.5, only four trimers 
(GCT, CTT, TTT, GCG) are required for assembly of the chain. The advantage of 
adding a blockmer each time is that the purification of the product may turn out to be 
easier than by adding one nucleoside unit each time, due to the bigger difference in 
physical properties between the by-products and the desired product. For example, if 
a3+3 -ý 6 coupling does not go completion, it is likely to be possible to remove the 
truncated sequence (trimer) from the desired hexamer by means of chromatography, 
whereas in the case of 1+5 -a 6, the chance for the separation of the desired hexamer 
and truncated pentamer would be very small. 
The drawback of this strategy is that valuable trimer H-phosphonates have to be used. 
Because an excess of H-phosphonate is always required to ensure successful 
coupling, the cost may add up. But if a method is in place to recover the excess of H- 
phosphonate, this problem can then be minimized. 
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In practical terms, it is not recommended to use a blockmer H-phosphonate larger 
than a trimer because the elution of such big blockmer H-phosphonates from silica gel 
columns proved to be rather difficult. In our preparation of the target 21-mer, 




It is conceivable that with the increase of molecular weight, the rate of coupling 
drops; so it is crucial to increase the amount of H-phosphonate as the molecule gets 
larger. Starting off with 20% excess of H-phosphonate for aI+1 -ý 2 and I+2 -> 3 
coupling, an increase of 5% in the excess of H-phosphonate is applied, i. e. 25% 
excess for 3+3 -4 6,30% excess for 6+6 -3 12 coupling and so on. It is also 
recommended in practice to increase the amount of the coupling agent and the amount 
of pyridine used in the coupling reactions with the increase of molecular weight. 
3.5 Preparation of Dimer Building Blocks 
The preparation of dimer building blocks is outlined in Scheme 3.21. Suitably 
protected 5'-O-dimethoxytrityl nucleoside 141 was allowed to react with p- 
methylphenyl H-phosphonate 343c at low temperature (-35°C) to give the 
corresponding 5'-O-dimethoxytrityl nucleoside H-phosphonate 333. The yields were 
well above 90% (Table 3.1). 
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Scheme 3.21 Reagents and conditions: i, 343c, pivaloyl chloride, pyridine, -35°C, 1 h; ii, (a) levulinic 
anhydride, N, N-dimethylaminopyridine, NEt3, CHZC12, room temp., 30 min (in the case of G, levulinic 
anhydride, pyridine, room temp., overnight); (b) CIZCHCOOH, pyrrole, CH2CI2,0°C, 10 min; iii, (a) 
347, pyridine, -40°C, 5-10 min; (b) 174, pyridine, -40°C, 10 min; (c) HCI in dioxane, CH2CI2, -50°C, 
10 min. 
The suitably protected 3'-O-levulinyl nucleosides 146 were prepared by treating the 
appropriate 5'-O-dimethoxytrityl nucleoside 141 with levulinic anhydride in the 
presence of N, N-dimethylaminopyridine and triethylamine. An exception is the 
preparation of the 2'-deoxyguanosine derivative, where 2'-deoxy-5'-O- 
dimethoxytrityl-6-O-(2,5-dichlorophenyl)-2-N-isobutyryl guanosine 380 was allowed 
to react with levulinic anhydride in pyridine to avoid possible side reactions. The 
resulting 5'-O-dimethoxytrityl 3'-O-Ievulinyl nucleoside was then treated with 
dichloroacetic acid and pyrrole in dichloromethane to give the corresponding 




















Formation of the dinucleoside internucleotide linkages was carried out at low 
temperature (-40°C) to minimise possible side-reactions. The suitably protected 
nucleoside H-phosphonate 333 was coupled with a 3'-O-levulinyl-5'-hydroxyl 
nucleoside 146 by using bis(2-chlorophenyl) phosphorochloridate 347 as activating 
agent. The reaction was very fast and went to completion within 5 min with virtually 
no by-products as indicated by TLC. The dinucleoside H-phosphonate diester formed 
was then treated in situ with 4-[(2-cyanoethyl)sulphanyl]morpholine-3,5-dione 174 to 
give the corresponding S-(2-cyanoethyl)dinucleoside phosphorothioate triester. The 
5'-O-dimethoxytrityl group was then removed by hydrogen chloride in dioxane at low 
temperature (-50°C). Under these conditions, no depurination was observed even for 
the most sensitive N-benzoyl-2'-deoxyadenosine derivative (not involved in this 
synthesis). The desired dinucleoside phosphorothioate triester 379 was obtained by 
chromatography as a colourless glass in high yield and in very good quality (Table 
3.1). 
Table 3.1 Yields for the preparation of monomer and dimer building blocks. 
Compound Yield (%) 
DMTr-Cp(H) 381 95.5 
DMTr-Tp(H) 382 95.4 
DMTr-Gp(H) 383 92.8 
HO-G-Lev 384 90.6 
HO-T-Lev 385 82.1 
HO-Cp(s)G-Lev 386 99.8 
HO-Tp(s)T-Lev 387 93.5 
HO-Cp(s)T-Lev 388 94.0 
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The 5'-hydroxy dinucleoside phosphorothioate triesters were characterised by HPLC, 
'H (plus D20 exchange) and 31P NMR spectroscopy. As expected, two lines were 
recorded in the 31P NMRs which represent the two diastereoisomers. An example is 
shown in Figure 3.6. 
Figure 3.6 31P NMR (DMSO-d6) and HPLC profile of HO-Tp(s)T-Lev 387. 
3.6 Preparation of Trimer Building Blocks 
Four trimer building blocks were used in the preparation of the ISIS 2922 21-mer, 
GCG, TTT, GCT and CTT. However, GCG and CTT have to be prepared in both 5'- 
hydroxyl and 3'-hydroxyl terminating forms (Scheme 3.22). 
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i, ii 
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Scheme 3.22 Reagents and conditions: i, (a) 347, pyridine, -40°C, 5-10 min; (b) 174, pyridine, 
-40°C, 10 min; ii, HCI in dioxane, CH2CI2, -50°C, 10 min; iii, (a) NH2NH2"H20, AcOH, pyridine, 
0°C, 10 min; (b) 2,4-pentanedione, 0°C - room temp., 15 min; iv, 343c, pivaloyl chloride, pyridine, 
-35°C, 1 h. 
It was found that 20% excess of H-phosphonate was sufficient for a1+2 --> 3 
coupling. For the preparation of the 5'-hydroxyl terminating trimer 389, detritylation 
was carried out after the coupling and sulphur-transfer steps were complete, without 
purification. The detritylated trimer 389 was isolated by chromatography as a 
colourless glass in high yield (Table 3.2). 
Fully protected trimers (e. g. 390) were prepared under the same coupling conditions 
and were isolated as colourless glasses by chromatography, in high yields. The 
products obtained were then treated with hydrazine hydrate in a mixture of acetic acid 
and pyridine to remove the 3'-O-levulinyl protecting group. The reaction went to 
completion in 10 min. Purification was effected by precipitation from diethyl ether 
after workup and evaporation to give 5'-O-dimethoxytrityl-3'-hydroxy trimers (e. g. 
391) in virtually quantitative yields (Table 3.2). 
5'-O-Dimethoxytrityl-3'-hydroxy trimers (e. g. 391) were then converted to the 
corresponding 3'-H-phosphonates (e. g. 392) by a similar procedure to that used for 
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the preparation of monomer H-phosphonates. Because of their higher molecular 
weight, the products could only be eluted off the column by eluents with high 
percentages of methanol (15-20%). As a result, it was found that upon evaporation of 
the appropriate fractions, the triethylammonium moiety was lost (as recorded by 'H 
NMR). An attempt to use this material directly as starting material for the next 
coupling reaction lead to a failed condensation. Our initial effort to resolve this 
problem was to replace triethylammonium with a more stable cation. DBU cation is 
more stable and easier to prepare, but modifications had to be made to our existing 
strategy. We found later that by washing with triethylammonium phosphate buffer 
(0.5 M, pH 7.0), the H-phosphonates 393, in which triethylammonium moiety was 
lost, were converted to the desired H-phosphonate triethylammonium salts 394 
(Scheme 3.23). 
triethylammonium 
,o 0. ýo 
HýýOH phosphate buffer HýýO NHEt3 
393 394 
Scheme 3.23 
The trimer building blocks were characterised by HPLC, 'H (plus D20 exchange) and 
3'P NMR spectroscopy. Up to eight lines could be recorded in the 31P NMR. For the 
trimer H-phosphonates, extra lines were expected at ca. 0 ppm, which integrate for 
one phosphorus centre. Figure 3.7 shows an example of the 31P NMR spectra and 
HPLC profiles of the trimer H-phosphonates. The inset NMR shows the undecoupled 
phosphorus NMR spectrum, where a P-H coupling constant of 593.85 Hz was 
observed. 
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Figure 3.7 31P NMR (DMSO-d6) and HPLC profile of DMTr-Cp(s)Tp(s)Tp(H) 398. 
Table 3.2 Yields for the preparation of the trimer blocks. 
Compound Yield (%) 
HO-Gp(s)Cp(s)G-Lev 389 91.0 
HO-Cp(s)Tp(s)T-Lev 395 92.3 
DMTr-Cp(s)Tp(s)T-Lev 396 95.0 
DMTr-Cp(s)Tp(s)T-OH 397 95.7 
DMTr-Cp(s)Tp(s)Tp(H) 398 92.3 
DMTr-Gp(s)Cp(s)T-Lev 399 95.7 
DMTr-Gp(s)Cp(s)T-OH 3100 91.6 
DMTr-Gp(s)Cp(s)Tp(H) 3101 89.2 
DMTr-Tp(s)Tp(s)T-Lev 3102 91.6 
DMTr-Tp(s)Tp(s)T-OH 3103 95.1 
DMTr-Tp(s)Tp(s)Tp(H) 3104 90.7 
DMTr-Gp(s)Cp(s)G-Lev 390 94.3 
DMTr-Gp(s)Cp(s)G-OH 391 95.0 
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3.7 Preparation of Hexamer Building Blocks 
Two hexamer building blocks were required in the preparation of ISIS 2922 under the 
current synthetic strategy, i. e. CTT CTT and CTT GCG. The preparation is outlined 
in Scheme 3.24. 
DMTr-Cp(s)Tp(s)Tp(H) + HO-Cp(s)Tp(s)T-LevºDMTr-Cp(s) Tp(s)Tp(s)Cp(s)Tp(s)T-Lev 
398 395 3105 
1 DMTr-Cp(s) Tp(s)Tp(s)Cp(s)Tp(s)Tp(H) DMTr-Cp(s)Tp(s)Tp(s)Cp(s)Tp(s)T-OH 
3107 3106 
DMTr-Cp(s)Tp(s)Tp(H) + HO-Gp(s)Cp(s)G-Lev - HO-Cp(s)Tp(s)Tp(s)Gp(s)Cp(s)G-Lev 
398 389 3108 
Scheme 3.24 
The fully-protected hexamer 3105 was prepared by coupling of DMTr- 
Cp(s)Tp(s)Tp(H) 398 with HO-Cp(s)Tp(s)T-Lev 395 under the similar conditions 
used for the trimer blocks. After treatment with hydrazine hydrate in pyridine-acetic 
acid, the corresponding 5'-O-dimethoxytrityl3'-hydroxyl hexamer 3106 was obtained 
in high yield. It was then converted to H-phosphonate 3107 in the same way as 
described for the preparation of trimer H-phosphonates. A triethylammonium 
phosphate buffer washing was also essential at the end of column chromatography to 
recover triethylammonium salt, which allows the next successful coupling. 
The other hexamer, the 5'-hydroxyl hexamer 3108, was prepared by assembling H- 
phosphonate 398 with 389 using the same coupling and detritylation procedures 
described above. The product was obtained by short column chromatography in good 
yield (Table 3.3). 
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Table 3.3 Yields for the preparation of hexamers. 
Compound Yield (%) 
DMTr-Cp(s) Tp(s)Tp(s)Cp(s)Tp(s)T-Lev 3105 90.8 
DMTr-Cp(s) Tp(s)Tp(s)Cp(s)Tp(s)T-OH 3106 92.0 
DMTr-Cp(s)Tp(s)Tp(s)Cp(s)Tp(s)Tp(H) 3107 90.4 
HO-Cp(s)Tp(s)Tp(s)Gp(s)Cp(s)G-Lev 3108 89.0 
The hexamers were characterised by 'H (plus D20 exchange) and 31P NMR 
spectroscopy. For the hexamer H-phosphonate 3107, a bunch of lines at around 0 ppm 
was also recorded which corresponds to the phosphorus centre on the H-phosphonate 
moiety. The undecoupled 31P revealed a P-H coupling constant of 575.87 Hz (Figure 
3.8). 
Figure 3.8 31P NMRs of DMTr-Cp(s)Tp(s)Tp(s)Cp(s)Tp(s)Tp(H) 3107 in DMSO-d6. 
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3.8 Preparation of Dodecamer, Pentadecamer and Octadecamer Building 
Blocks 
The preparation of the dodecamer 3109 was conducted by joining two hexamer 
building blocks 3107 and 3108 and removing the 5'-terminal dimethoxytrityl group. 
The pentadecamer 3110 and octadecamer 3111 were prepared by adding a trimer each 
coupling cycle (Scheme 3.25). The yield fell below 90% (83.6,88.2,86.1 %) because 
the high molecular weight made the recovery from column chromatography more 
difficult. 
D MTr- Cp(s) Tp(s) Tp(s) Cp(s) Tp(s) Tp (H) HO- Cp(s) Tp(s) Tp(s) Gp(s) Cp(s) G-Lev 











3.9 Preparation of the 21-Mer 
The final step in the assembly of the target 21-mer was to join a GCG trimer building 
block 392 with the octadecamer 3111. After detritylation, the 5'-hydroxy 21-mer 
3112 was obtained in 85.2% yield by column chromatography as a colourless glass. 
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HO - Gp(s) Cp(s) Gp (s) Tp(s) Tp(s) Tp(s) Gp(s) Cp(s) Tp (s)[Cp(s) Tp(s) Tp (s)]3Gp(s) Cp(s) G-Lev 
3112 
3.10 Application of 1H NMR in the Characterisation of the Oligonucleotide 
Phosphorothioate Triesters 
Nucleosides have relatively simple 'H NMR spectra. The aromatic protons of 
pyrimidines and purines resonate at low field (S 7.6 to 6 8.3 with C5-H close to 6 5.9). 
The anomeric proton is a doublet for ribonucleosides and a double-doublet for 2'- 
deoxynucleosides at 6 5.8-6.4. The pentoses provide a multi-spin system which 
generally moves from low to high field in the series: H-3', H-4', H-5' and H-5" (2'- 
deoxynucleosides). Lastly, 2'-deoxynucleosides have H-2' and H-2" as an ABMX 
system near S 2.5. An example, the proton NMR spectrum for cytidine, is shown in 
Figure 3.9. 










Figure 3.9 Proton NMR spectrum for cytidine (D20 at 400 MHz). 169 
However, for a large oligonucleotide, especially when it is fully protected on the base 
residues, 3'-hydroxy, 5'-hydroxy and internucleotide linkages, the proton NMR 
becomes very complex. In the case of phosphorothioate triesters, the existence of 
diastereoisomers makes the complete analysis of the spectra very difficult. However, 
in our studies, 'H NMR spectroscopy proved to be a useful tool in indicating the 
nucleoside ratios and the purities of oligonucleotides. 
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The first useful feature of the 'H NMRs of phosphorothioate triesters is the 
integration of the aromatic protons. Although accurate integrals are difficult to 
achieve, it is possible to show the purity of the oligonucleotide qualitatively. 
The nucleoside ratios (T + C) /T can be determined by measuring the integrals of the 
anomeric protons, of which T and C normally superimpose together. It is usually 
feasible to determine the percentage of thymidine in the oligonucleotide by measuring 
the integral of the 5-methyl group. The methyl groups of the isobutyryl protecting 
group of 2'-deoxyguanosine also provide a means for the calculation of the G- 
content. 
Table 3.4 presents the analysis of the 1H NMRs of some of the building blocks in our 
studies. 
Table 3.4 Analysis of the proton NMRs of oligonucleotide phosphorothioate trimesters. 
Compound 
12-mer 3109 15-mer 3110 18-mer 3111 21 -mer 3112 Entries 
Aromatic Calculated 72 89 107 122 
protons Observed 74 89 106 123 
Calculated 5.00 4.00 5.00 3.20 
(C + T) /G Observed 5.40 3.98 5.38 3.66 
Number of T Calculated 6.00 7.00 10.00 10.00 
indicated by 
5-Me group Observed 6.60 6.67 10.03 10.98 
Number of G Calculated 2.00 3.00 3.00 5.00 
indicated by 
the methyl Observed 2.10 3.10 3.05 4.66 
groups on 'Bu 
3.11 Removal of S-(2-Cyanoethyl) Group 
The 2-cyanoethyl group has been used to protect the phosphate triester linkage for a 
long time and its removal is normally effected under basic conditions. The alkaline 
unblocking takes place via /elimination (Figure 3.10). Various procedures have 
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been investigated so far. Among amines, it was found that primary amines are the 
most effective in achieving rapid cleavage. The following times for complete 
cleavage of the cyanoethyl group from phosphate were obtained: triethylamine, 180 
min; diisopropylethylamine, 60 min; diethylamine, 30 min; sec-butylamine, 20 min; 
tert-butylamine, 10 min; n-propylamine, 2 min. Further study showed that tert- 
butylamine was the most suitable reagent because it did not react with protected 
nucleobases. Methylamine and ammonia were also fast (5 min) and effective 
reagents for deprotection. 170 
(B 
HN 




Figure 3.10 Unblocking of cyanoethyl group under basic conditions. 
Other bases, including aqueous ammonia in dioxane171 and 1,8- 
diazabicyclo[5.4.0]undec-7-ene (DBU, 3113)172 were also investigated. Fluoride ion 
(Bu4N'F")173 was also found to show selective cleavage of the 2-cyanoethyl group. 
N 
3113 
Although primary amines offer fast unblocking of the protecting group, there is a 
potential danger of primary amines attacking the 6-0-position of guanine base 
residues. DBU has proved superior to these primary amines because it offers fast 
removal of the protecting group and no danger of modification to the base residues 
has been observed. 
Treatment of fully protected phosphorothioate triesters 172a with DBU in 
dichloromethane converts the triesters to the corresponding phosphorothioate diesters 
346 within 30 min. However, this reaction is very sensitive to moisture. The presence 
of very small amounts of moisture could lead to loss of sulphur, which produces 
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small amounts of phosphate 345 (Scheme 3.26). A simple solution is to add a few 
percent of chlorotrimethylsilane (TMS-Cl) which uses up moisture in the first 
instance. 55 The other advantage of including TMS-Cl in the reaction is that the attack 
on base residues by acrylonitrile produced in the course of removal of 2-cyanoethyl 
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Scheme 3.26 Reagents and conditions: i, DBU, TMS-CI, CH2CI2, room temp., 30 min. 
3.12 Unblocking of the Fully-Protected 21-Mer 
The protocols for the unblocking of the 5'-hydroxy 21-mer 3112 are indicated in 
outline in Scheme 3.27. The material was first acetylated (step i), and the resulting 
fully-protected 21-mer was then unblocked by a three-step procedure. First, the 
internucleotide linkages were unblocked. By treatment with DBU in extremely dry 
dichloromethane, the S-(2-cyanoethyl) protecting groups were removed (step ii). 
Secondly, the 6-0-(2,5-dichlorophenyl) and 4-O-phenyl protecting groups were 
removed from the guanine and thymine residues respectively by oximate treatment 
(step iii). Finally, all the acyl protecting groups were removed by treatment with a 
mixture of 2-mercaptoethanol and concentrated aqueous ammonia at 55°C (step iv). 
The presence of 2-mercaptoethanol174 suppressed the loss of sulphur during ammonia 
treatment. 175,176 The material obtained was then passed through an ion exchange 
column to replace the counterions with sodium ion (step v). The product was 
characterised by 'H, 31P NMR and reverse phase HPLC. No loss of sulphur was 
observed as indicated by the 31P NMR spectrum (Figure 3.1 1). 
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Iii, iii, iv, v d[Gp(s)Cp(s)Gp(s)Tp(s)Tp(s)Tp(s)Gp(s)Cp(s)Tp(s)[Cp(s)Tp(s)Tp(s)]3Gp(s)Cp(s)G] 
220 
Scheme 3.27 Reagents and conditions: i, acetic anhydride, pyridine, room temp., overnight; ii, DBU, 
TMS-Cl, CH2CI2, room temp., 30 min; iii, DBU, E-2-nitrobenzaldoxime, CH3CN, room temp., 15 h; 
iv, 2-mercaptoethanol, conc. ay. ammonia, 55°C, 15 h; v, Amberlite (IR120, Na* form) ion exchange 
column. 
Figure 3.11 31P spectrum of the fully unblocked 21-mer 220 in D2O. 
To conclude this chapter, we have evaluated the modified H-phosphonate approach in 
the preparation of oligonucleotide phosphorothioates. By carrying out the coupling 
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reaction at -40°C with bis(2-chlorophenyl) phosphorochloridate 347 as activating 
agent, followed by in situ sulphur transfer, ISIS 2922 21-mer was prepared in good 
yield. We believe that this strategy is very effective in the preparation of both 
oligonucleotide phosphorothioates and phosphates of short to moderate chain length. 
However, it would be more attractive if this approach could be adapted for use at 









Large-scale Synthesis of Oligonucleotide Phosphorothioates in 
Solution 
The solution phase synthesis of oligonucleotide phosphorothioates via the -40°C H- 
phosphonate approach described in the previous chapter was primarily developed to 
meet the anticipated demand for multikilogram quantities of oligonucleotides and 
their analogues for therapeutic purposes. The question of whether or not it is feasible 
for the process to be scaled up is a matter of great importance. It seemed likely that 
the chance of developing an efficient large-scale synthesis would be much greater if it 
were possible for both the coupling and the sulphur-transfer reactions to be carried 
out at room temperature or, in any case, not below 0°C. As H-phosphonate diesters 
401 are sensitive intermediates, it seemed reasonable to assume that the best way to 
avoid undesirable side-reactions at higher temperatures would be to ensure that the 
sulphur-transfer reaction took place as soon as possible after coupling had occurred 
(Scheme 4.1). The resulting phosphorothioate triesters 402 would be expected to be 





4.1 Possible Side-Reactions in the H-Phosphonate Approach 
Although H-phosphonates 403 and their esters 405 have been widely believed to exist 
in equilibrium between phosphite (404 and 406) and phosphonate (403 and 405) 
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forms'77 (Figure 4.1), the amount of phosphite is believed to be below a level 
observable by any spectroscopic methods used. Therefore, these compounds are 
represented by their phosphonate forms in this context. 
O 








4.1.1 Activation of H-Phosphonate Monoesters 
Condensation of H-phosphonate monoesters with a hydroxylic component in the 
presence of an activating agent is a multi-step reaction which involves formation of 
activated H-phosphonate or phosphite intermediates, followed by their reactions with 
a hydroxylic component. By using 31P NMR spectroscopy, it was found that the first 
reaction (the activating step) is rate-determining for all studied activating 
agents 52,178,179 
When a limited amount of a condensing agent is added to a solution of an H- 
phosphonate monoester 407 in pyridine, various intermediates can be recorded by 31P 
NMR. 52 In the case of pivaloyl chloride, three intermediates are generated: the mixed 
acyl phosphonic anhydride 408, the corresponding H-pyrophosphonate 409, and the 
bisacyl phosphite 410. When these intermediates are allowed to react with an alcohol, 
the corresponding H-phosphonate diester 411, a mixture of H-phosphonate diester 
and monoester, and a phosphite triester 412 are formed respectively. The formation 
of 408 and 409 proceeds at a much faster rate than that of 410. In the presence of 
excess of acyl chloride, however, only bisacyl phosphite 410 is formed initially. 
Upon prolonged reaction, formation of the acylphosphonate 413 is observed. 
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Scheme 4.2 Activating pathways of H-phosphonate by pivaloyl chloride in pyridine. 
The activating pathways of other coupling agents are similar to that of acyl chloride. 
Those of diaryl phosphorochloridates47 414, arylsulphonyl chlorides178 113 and 
carbonate derivatives53 415 have been investigated in detail. 
000 
if 11 11 
ArO-P-OAr Ar-S-Cl RO-C-OR 
CI 0 
414 113 415 
Exposure of H-phosphonate monoesters to excess of activating agents over a long 
period of time can lead to another side-reaction. We observed that by mixing H- 
phosphonate with various coupling agents (pivaloyl chloride, adamantanecarbonyl 
chloride, diphenyl phosphorochloridate), symmetrical products were recorded by 
31P 
NMR spectroscopy. Thus, on mixing 5'-O-dimethoxytritylthymidine 3'-H- 
phosphonate 157 with 5 molar equivalents of pivaloyl chloride in pyridine overnight, 
followed by addition of sulphur transfer reagent 174 (Scheme 4.3), a 3' -3 3' 
symmetrical dithymidine phosphorothioate triester 416 was detected by 
31P NMR 
spectroscopy, which was confirmed by independent preparation. The same is true for 
other activating agents, and the order of rates of this reaction effected by various 
activating agents was observed to be: diphenyl phosphorochloridate > pivaloyl 
chloride > adamantanecarbonyl chloride. 
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4.1.2 Stability of H-Phosphonate Diesters 
Dialkyl H-phosphonate diesters are generally resistant to air oxidation, but they 
undergo slow hydrolysis in the presence of moisture. When stronger oxidants are 
present, e. g. aqueous iodine and sulphur, they are readily oxidized. Under the 
coupling conditions, they can react with excess of activating agents and form various 
by-products. 
Non sterically hindered acyl chlorides can react with H-phosphonate diesters to give 
acylated phosphonates. Thus, H-phosphonate diester 411 reacts with excess of 
pivaloyl chloride to form pivaloylphosphonate 417180 (Scheme 4.4). 
O0 
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This kind of reaction does not occur readily when diaryl phosphorochloridates are 
used as coupling agent. '8' 
4.2 The Aim of This Part of the Work 
As one can see from the previous material, the modified H-phosphonate approach, 
i. e. coupling, which is effected by bis(2-chlorophenyl) phosphorochloridate at -40°C, 
followed by sulphur transfer reaction, has shown several advantages over other H- 
phosphonate approaches. However, when this approach is carried out at higher 
temperature, which is favoured for large-scale synthesis, various side-reactions occur. 
Thus, it would be advantageous if this strategy could be adapted such that fast and 
quantitative coupling could be achieved at higher temperature or, in any case, not 
below 0°C. 
4.3 The Four-Component Solution Phase Synthesis 
It occurred to us that the best way of ensuring that the sulphur-transfer reaction would 
follow as soon as possible after coupling would be by carrying out a four-component 
reaction. This would involve adding a mixture of the coupling and sulphur transfer 
agents to a solution of a mixture of the H-phosphonate monoester and the component 
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Scheme 4.5 Reagents and conditions: i, 174, CSDSN, room temp., ii, 174,347, pyridine - CH202 
(98: 2 v/v), 0°C. 
O N-S O-P-O b CI 
174 347 
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In such a reaction mode, the coupling agent and sulphur transfer agent, which are 
both electrophilic, would not be expected to react with each other. Our observation is 
that no change can be detected if these two agents are mixed in anhydrous pyridine 
over a period of 72 hours. However, there is a potential problem (Scheme 4.5) in that 
the H-phosphonate monoester building block 157 can react with the sulphur transfer 
agent to give the corresponding phosphorothioate diester 418 before the coupling 
process is complete. This could clearly result in a diminished yield of the desired 
product. 
The reaction between triethylammonium 5'-O-dimethoxytritylthymidine 3'-H- 
phosphonate 157 and 4-[(2-cyanoethyl)sulphanyl]morpholine-3,5-dione 174 to give 
the corresponding 3'-(2-cyanoethyl)phosphorothioate diester 418 is extremely slow. 
Thus when a 0.1 M solution of the H-phosphonate monoester 157 in d5-pyridine 
solution was allowed to react with a 1.5 fold excess of the sulphur transfer agent 174 
at room temperature (Scheme 4.5, step i), the estimated percentage conversion to 
phosphorothioate diester 418 after 47.5 hours was only 13.3. On the other hand, when 
the H-phosphonate 157 was allowed to react with a 2.5 fold excess each of bis(2- 
chlorophenyl) phosphorochloridate 347 and the morpholine-3,5-dione reagent 174 in 
pyridine - dichloromethane (98: 2 v/v) solution at 0°C (Scheme 4.5, step 
ii), the 
sulphur transfer reaction was very much faster and the estimated percentage 
conversion to phosphorothioate diester 418 after 1 hour was ca. 85. This vast 
difference is obviously due to the fact that the sulphur transfer reaction of the 
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Nevertheless, as the coupling reaction effected by bis(2-chlorophenyl) 
phosphorochloridate appears to go to completion within 10 min at -40°C, it is likely 
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to be fast enough at room temperature for it to go to completion well before the 
excess (usually 20%) of H-phosphonate has been consumed by the sulphur transfer 
agent. It therefore seemed likely that four-component oligonucleotide synthesis in 
solution would prove to be a feasible proposition. The issue here is then to find the 
best match between coupling and sulphur transfer agents. 
To ensure the excess H-phosphonate is not consumed by the sulphur transfer agent in 
either way described in Scheme 4.5 before the coupling is complete, a very reactive 
coupling agent is required. It is believed that among the commonly used activating 
agents, the reactivity follows the order: diaryl phosphorochloridate > pivaloyl 
chloride > adamantanecarbonyl chloride. Bis(2-chlorophenyl) phosphorochloridate 
347 and diphenyl phosphorochloridate 153 show similar activating properties, but the 
latter is commercially available and economically cheaper, therefore it is the 
preferred coupling agent among diaryl phosphorochloridates. Arylsulphonyl 
chlorides are not suitable for this application because of their more complex 
activating pathways and therefore more possible side-reactions. 
As far as the sulphur transfer agent is concerned, it has to be reasonably soluble in the 
reaction medium, and more importantly the rate of sulphur transfer must match the 
rate of coupling. N-[(2-Cyanoethyl)sulphanyl]morpholine-3,5-dione 174 is only 
moderately soluble in pyridine, which is the solvent for both coupling and sulphur 
transfer reactions, and it reacts fairly rapidly with H-phosphonate monoesters in the 
presence of coupling agent. This agent is therefore not suitable for the four 
component reactions because its use leads to the consumption of the excess of H- 
phosphonates before the coupling goes to completion. Therefore, an alternative 
sulphur transfer agent which is both more soluble in pyridine and less reactive was 
sought. N-[(2-Cyanoethyl)sulphanyl]succinimide 420a proved to be more soluble in 
pyridine than N-[(2-cyanoethyl)sulphanyl]morpholine-3,5-dione 174, and is less 
reactive. As a comparison, when this agent was allowed to react with a 0.1 M solution 
of 5'-O-dimethoxytritylthymidine 3'-H-phosphonate 157 in d5-pyridine at room 
temperature, the estimated percentage conversion to phosphorothioate diester 418 
after 47.5 hours was ca. 1.1 compared with 13.3 for N-[(2- 
cyanoethyl)sulphanyl]morpholine-3,5-dione 174. Thus the succinimide reagent 420a 
appears to react with the H-phosphonate monomer 157 more than an order of 
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magnitude more slowly than the morpholine-3,5-dione 174. For this reason, the 
succinimide derivatives 420 (a, N-[(2-cyanoethyl)sulphanyl]succinimide; b, N- 
(phenylsulphanyl)succinimide) were selected as the sulphur transfer agents in the 
present four-component synthetic studies. 
0 
N-SR 420 a; R= NCCH2CH2 
b; R=Ph 
0 
The four-component reactions were carried out according to Scheme 4.6. To a 
solution of H-phosphonate monoester 333 and a component with free 5'-hydroxy 
function 146, a solution of coupling agent, i. e. diphenyl phosphorochloridate 153, and 
sulphur transfer agent 420a (or b) in pyridine was added at room temperature. After 
10 to 30 min, the reaction was quenched by addition of water. A 2.5-fold excess of 
both the coupling and sulphur transfer agents was found to be sufficient for 


















421 a; R= NCCH2CH2 
b; R=Ph 
Scheme 4.6 Reagents and conditions: i, a solution of 420 and 153 in pyridinc, room temp., 10-30 
min. 
In the preparation of dimers, a 1.2-fold excess of H-phosphonate monomer was found 
to be sufficient. However, when a1+2 -3 3 coupling was examined, incomplete 
coupling was observed, which we believe was due to a relatively slower coupling 
reaction. Thus, a 1.4-fold excess of H-phosphonate monomer was used in the 
preparation of trimers. For this reason, it is conceivable that if a block larger than a 
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trimer were to be prepared in this way, more H-phosphonate monoester would be 
required. So far, our studies on four-component reactions have been limited to dimers 
and trimers. 
In the four-component reactions, two by-products were recorded by 31P NMR 
spectroscopy. On the basis of reverse phase HPLC and 
31P NMR spectroscopy data, 
they were identified as symmetrical 3' - 3' 422 and 5'- 5' 423 dimers. This has 
been confirmed by independent preparation (Scheme 4.7). It seems likely that the 
formation of these symmetrical products was due to the H-phosphonate monomers 
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Scheme 4.7 Reagents and conditions: i, 347, -40°C, 10 min; ii, 174,10 min; iii, pyridine, room temp., 
1.5 h; iv, 174,10 min. 
Two possible reasons may account for the occurrence of the unphosphonylated 
precursor 141. Firstly, after the H-phosphonate monoester was eluted off the silica 
gel column, dephosphonylation might have occured during the concentration 
procedure, to give unphosphonylated precursors 141 and phosphonic acid 337. 
Secondly, dephosphonylation could happen during the course of activating in the 
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presence of activating agent, which would result in the formation of the 
unphosphonylated precursors 141 and phosphonic acid 337 as well (Scheme 4.8). It 
seems though that the latter is more likely to be the case because no signal of 
phosphonic acid or its salt can be identified in the 31P NMR spectrum of the H- 
phosphonate monoesters obtained after concentration of eluents from 
chromatography. Further evidence is that when the reaction mixture was left for a 
longer period of time, greater quantities of the symmetrical products were formed 
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The formation of these symmetrical products can be compensated for by stepwise 
chromatography. Indeed, if purification is carried out after `detritylation', the `doubly 
de-tritylated' contaminants from 422 can be removed much more easily, at least at 
dimer or trimer stage. On the other hand, when the detritylated dimer 424 which is 
contaminated with the 5' -a 5' contaminants 423 couples with a second H- 
phosphonate monoester 425 to give a trimer block 426 (Scheme 4.9, step i), followed 
by `delevulination' (Scheme 4.9, step ii) and conversion to trimer H-phosphonate 428 
(Scheme 4.9, step iii), the 5' -> 5' symmetrical dimer 423 undergoes the 
corresponding reactions (Scheme 4.9, steps iv, v) and ends up as a bis H-phosphonate 
430 whose polarity is very much different from that of the desired trimer H- 
phosphonate 428 and therefore can be removed by chromatography quite easily. 
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If the four-component approach is applied to solid phase oligonucleotide synthesis, 
only the 3'-*3' symmetrical by-products could be formed, which could be removed 
completely by acetonitrile washing after each chain assembly cycle. 
4.4 Sequential H-Phosphonate Coupling Reaction 
As has been argued in section 4.3, if the four-component reaction is to be used in the 
preparation of building blocks beyond trimers, a much larger excess of H- 
phosphonate would be required. To avoid usage of a large excess of H-phosphonate, 
an alternative approach was examined. 
The -40°C sequential H-phosphonate approach has been demonstrated to be effective 
in our preparation of the ISIS 21-mer. It would be reasonable to argue that if a 
suitable coupling agent is selected, it may be possible to carry out coupling and 
sulphur transfer reactions in a sequential way at higher temperature. So, in this 
section we set out to investigate the efficacy of various activating agents. 
For a compound to be suitable as an activating agent, it must (i), be sterically 
hindered to avoid reaction with the 5'-hydroxyl component; (ii), be very active in 
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activating the H-phosphonate monoester, and do so selectively; and (iii), be readily 
accessible and economically feasible. 
Four categories of compounds were investigated in detail in the early studies of the 
H-phosphonate approach. They are acid chlorides 431, diary] phosphorochloridates 
414, arylsulphonyl chlorides 113 and carbonates 415. 
O00 
11 11 11 
R-Cý ArO-P-OAr Ar-S-Cl RO-C-OR 
Cl CI 0 
431 414 113 415 
In our studies, DMTr-Tp(s)T-Lev 433 was selected as the model molecule because 
good separation of this compound from the uncoupled 5'-hydroxyl component, i. e. 
HO-T-Lev 432 (Scheme 4.10) can be easily achieved by HPTLC, so the progress of 
the reaction can be monitored easily. 
DMTrO 114--i hy 
O1- O 









Scheme 4.10 Reagents and conditions: i, activating agent, pyridine, room temperature or 0°C; ii, 






Various activating agents were evaluated (Figure 4.2). The amount of by-products 
was recorded by 31P NMR spectroscopy of the crude reaction mixture. Among the 
acid chlorides, 2,4,6-trichloro- 438,2,4,6-tribromo- 439,2,4,6-triiodo- 440,2- 
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methoxy- 441,2-ethoxy- 442, and 2-acetoxy- 443 benzoyl chlorides behaved 
similarly and gave approximately 2% of 3' -4 3' and 0.5% of 5' --> 5' symmetrical 
products. Pivaloyl chloride 163, adamantanecarbonyl chloride 164,2,2- 
dimethylbutyryl chloride 434, and 2-acetoxy-2,2-dimethylacetyl chloride 435 proved 
to be better activating agents, and smaller quantities of symmetrical products were 
formed. Adamantanecarbonyl chloride is particularly good, and the amount of by- 
products was negligible when the coupling was carried out at 0°C. 
The dialkyl and diaryl phosphorochloridate series are generally too reactive to give 
clean couplings at temperatures above 0°C and considerable amounts of by-products 
could be detected by TLC and 31P NMR spectroscopy. Bis(2,4,6-tribromophenyl) 
phosphorochloridate 447a, however, gave improved results which was comparable to 
adamantanecarbonyl chloride. However, it proved difficult to prepare this reagent and 
its solubility in pyridine is poor. 
Carbonate derivatives have been used in H-phosphonate chemistry. The use of 
dipentafluorophenyl carbonate 168 was demonstrated by Efimov53 in solid phase 
synthesis of oligonucleotides. However, when this reagent was applied to our solution 
phase reactions, an undesirable by-product, which was unstable and was not 
identified, was observed. The percentage of by-product amounted to ca. 30%. 
Although this by-product may not pose a problem in the solid phase reaction as it 
may well be washed away, it is a serious problem in solution phase synthesis. The 
chloroformate derivatives 448,449, which are chemically similar to carbonates, were 
found to behave similarly to this reagent and therefore are not suitable for the current 
application. 
We believe that pivaloyl chloride, adamantanecarbonyl chloride, 2,2-dimethylbutyryl 
chloride and 2-acetoxy-2,2-dimethylacetyl chloride were suitable for the high 
temperature (not below 0°C) H-phosphonate coupling as fast and virtually 
quantitative coupling reactions were produced. In economic terms, however, pivaloyl 
chloride is superior because it is commercially available, and cheaper. Therefore in 
this part of the work, pivaloyl chloride was selected for the large-scale preparation of 
the target compound. 
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In conclusion to this section, we believe that we have developed a four-component 
oligonucleotide synthesis in solution. This approach is very efficient for the 
preparation of small oligonucleotides (dimers and trimers). In conjunction with the 
use of a 0°C H-phosphonate coupling reaction effected by pivaloyl chloride or 
adamantanecarbonyl chloride followed by a sulphur transfer reaction, we believe that 
this protocol is suitable for the preparation of oligonucleotides of moderate chain 
length on a large scale. Table 4.1 and Table 4.2 show results for the preparation of 
some dimer and trimer building blocks using these two approaches. 
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4.5 Detritylation 
In the preparation of the ISIS 21-mer by the -40°C approach described in Chapter 3, 
HCl in dioxane was used to remove the 5'-O-dimethoxytrityl protecting group at very 
low temperature (-50°C). In conjunction with our current high temperature 
preparation of oligonucleotides, a method of detritylation at high temperature is 
required. 
A couple of decades ago, Reese and co-workers' 82 introduced pyrrole as scavenger in 
the removal of the pixyl group. It was believed that when 9-phenylxanthen-9-yl 
protected oligonucleotide 456 was treated with acid in the presence of pyrrole, the 9- 
phenylxanthen-9-yl residue was quantitatively and irreversibly transferred to pyrrole 
to form 2-(9-phenylxanthen-9-yl)pyrrole 457 (Scheme 4.11). 
Ph 




This procedure has since been successfully employed in the synthesis of oligodeoxy- 
and oligo-ribonucleotides. 183-188 
Prompted by these results, we used very mild conditions, i. e. dichloroacetic acid and 
pyrrole in dichloromethane, to remove the 5'-O-dimethoxytrityl protecting group in 
the current studies. 
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4.6 The Application of the Four-Component and Sequential Coupling Reactions 
in the Assembly of ISIS 2922 21-Mer 
In order to evaluate the four-component and the sequential high temperature coupling 
approaches, the ISIS 2922 21-mer was chosen as the target sequence. In our current 
protocol, the four-component approach was used in the preparation of dimer and 
trimer blocks, and the pivaloyl chloride effected 0°C coupling was used in the 
assembly of the larger oligomers using the trimer blocks. The synthetic strategy is 
outlined in Figure 4.3. 
GCGTTTGCTCTTCTTCTTGCG 
Figure 4.3 
4.7 Preparation of the Dimer and Trimer Building Blocks 
Preparation of the dimers was performed in the four-component mode by using a 
20% excess of H-phosphonate monoester. Detritylation was carried out after the 
dimer assembly was complete without purification of the fully-protected dimers 
(Scheme 4.12). After removal of the 5'-O-dimethoxytrityl group, the material was 
purified by chromatography. The amount of impurities was below 1%, and it proved 
easy to remove the `doubly-detritylated' symmetrical dimers by chromatography. 
Trimer blocks were prepared in the same way, except for the use of a 40% excess of 
H-phosphonate due to relatively slower coupling reactions. Apart from the 3'- 
terminal trimer GCG, purification was carried out after each coupling to give fully 
protected trimers. 
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Scheme 4.12 Reagents and conditions: i, a solution of 153 and 420a in pyridine, room temp., 10-30 








The results of the preparation of the dimer and trimer building blocks by the four- 
component mode are presented in Table 4.3 
Table 4.3 Preparation of the dimers and trimers. 
Compound Yield (%) 
HO-Cp(s)G-Lev 386 94.4 
HO-Tp(s)T-Lev 387 92.5 
HO-Cp(s)T-Lev 388 97.0 
HO-Gp(s)Cp(s)G-Lev 389 95.2 
DMTr-Cp(s)Tp(s)T-Lev 396 92.5 
DMTr-Gp(s)Cp(s)T-Lev 399 93.2 
DMTr-Tp(s)Tp(s)T-Lev 3102 98.9 
DMTr-Gp(s)Cp(s)G-Lev 390 93.2 
The unblocking of the 3'-levulinyl protecting group and the conversion of the 5'-O- 
dimethoxytrityl-3'-hydroxy trimer building blocks to their corresponding H- 
phosphonates were performed in the same way as described in the previous chapter. 
The results are listed in Table 4.4. 
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Table 4.4 Removal of levulinyl protecting group and conversion of 3'-hydroxy components to 
corresponding H-phosphonates. 
Compound Yields (%) 
DMTr-Cp(s)Tp(s)T-OH 397 96.4 
DMTr-Cp(s)Tp(s)Tp(H) 398 91.9 
DMTr-Gp(s)Cp(s)T-OH 3100 95.1 
DMTr-Gp(s)Cp(s)Tp(H) 3101 92.8 
DMTr-Tp(s)Tp(s)T-OH 3103 95.1 
DMTr-Tp(s)Tp(s)Tp(H) 3104 93.2 
DMTr-Gp(s)Cp(s)G-OH 391 96.7 
DMTr-Gp(s)Cp(s)Gp(H) 392 93.5 
4.8 Coupling of Trimer Building Blocks with Oligonucleotides 
Trimers prepared in the four-component mode were used to assemble larger 
oligomers by the pivaloyl chloride effected approach at 0°C (Scheme 4.13). In order 
to ensure complete coupling as the chain length grew, a larger excess of trimer H- 
phosphonate was used. It is also necessary to increase the amount of pyridine to keep 
reactants in solution, and to increase the amount of pivaloyl chloride as the chain 
length gets longer. Table 4.5 indicated the results of the blockmer coupling reactions. 
DMTr-Cp(s)Tp(s)Tp(H) 





HO-[Cp(s)Tp(s)Tp(s)]3Gp(s)Cp(s)G-Lev . HO-[Cp(s)Tp(s)Tp(s)I2Gp(s)Cp(s)G-Lev 458 
398 
3109 
I DMTr-Gp(s)Cp(s)Tp(H) 3101 HO-Gp(s)Cp(s)Tp(sxCp(s))Tp(s)Tp(s)]3Gp(s)Cp(s)G-Lev 3110 
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Table 4.5 Blockmer synthesis. 
Reaction 







3+3 1.20 10mI/mmol 2.52 96.4 
3+6 1.25 11 MI / mmol 2.52 95.6 
3+9 1.30 14.5 m1/mmol 2.81 91.0 
3+12 1.35 20 ml / mmol 3.03 90.2 
3+15 1.35 25 ml / mmol 3.12 90.0 
3+18 1.45 30 ml / mmol 3.41 90.1 
Note: a, equivalents relative to 5'-OH component. 
4.9 Unblocking of the Partially Protected Blockmers (9-, 12-, 15-, 18-, and 21- 
mers) 
The unblocking protocol as indicated in Scheme 3.27 was applied here to the 
unblocking of the blockmers. The 5'-hydroxy oligonucleotides were first acylated 
and then unblocked by the three-step procedure (DBU treatment, oximate treatment, 
ammonolysis). Caution was exercised in generating the extremely dry reaction 
mixture during the DBU treatment to avoid loss of sulphur. 2-Mercaptoethanol was 
also used in the ammonolysis to prevent loss of sulphur. The fully unblocked 
oligonucleotide phosphorothioates were characterised by polyacrylamide gel 
electrophoresis (PAGE), 'H and 31P NMR spectroscopy, reverse phase HPLC, ion 
exchange chromatography, MALDI-TOF mass spectroscopy and capillary gel 
electrophoresis. 
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Channel 1: 21-Mer 
Channel 2: 18-Mer 
Channel 3: 15-Mer 
Channel 4: 12-Mer 
Channel 5: 9-Mer 
Channel 
ttttt 
1 234 5 
Figure 4.4 Polyacrylamide gel electrophoretogram of the fully unblocked 9-mer 459,12-mer 460,15- 
mer 461,18-mer 462 and 21-mer 220 phosphorothioates. 
The polyacrylamide gel electrophoretogram (PAGE) of the fully unblocked 9-mer, 
12-mer, 15-mer, 18-mer and 21-mer phosphorothioates (Figure 4.4) showed 
significant difference in mobility as expected. 
Table 4.6 Analysis of the 'H NMR spectra of the fully unblocked oligonucleotides. 
Compound 9-mer 12-mer 15-mer 18-mer 21-mer 
Entries 459 460 461 462 220 
Aromatic Calculated 9.0 12.0 15.0 18.0 21.0 
protons Observed 9.0 12.0 15.0 18.0 21.0 
Anomeric Calculated 12.0 16.0 20.0 23.0 27.0 
protons 
plus 
cytidine H- Observed 11.9 17.0 19.58 23.1 27.1 
5 protons 
H2'+3-Me of Calculated 30.0 42.0 51.0 66.0 72.0 
th idi e ym n 
Observed 31.1 46 0 54 6 68.3 72.1 
protons . . 
*Note: except H-5 proton of cytidine. 
The 'H NMR spectra of the fully unblocked oligonucleotide phosphorothioates 
showed very good superimposition, and the integrals observed have good consistency 
with the required values (Table 4.6). The amounts of loss of sulphur in the fully 
unblocked phosphorothioate blockmers were negligible (below 0.5% in all cases) as 
indicated by 31P NMR spectroscopy (Figure 4.5). 
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i 11 II A-7. 
Figure 4.5 'H and 31P NMR spectra of the fully unblocked oligonucicotide phosphorothioatcs in D20: 
a, 9-mer 459 'H NMR spectrum; b, 9-mer 459 31P NMR spectrum; c, 12-mer 460 'H NMR spectrum; 
d, 12-mer 460 31P NMR spectrum; e, 15-mer 461 'H NMR spectrum; f, 15-mer 461 31P NMR 
spectrum; g, 18-mer 462 'H NMR spectrum; h, 18-mer 462 "P NMR spectrum; i, 21-mer 220 'H 
NMR spectrum; j, 21-mer 220 31P NMR spectrum. 
The exact masses of the fully unblocked oligonucleotide phosphorothioates were 
measured by MALDI-TOF mass spectrometer (Figure 4.6). For all the blocks, the 
errors are very low and the observed masses are consistent with the expected values 
(Table 4.7). The isotopic patterns observed are also consistent with the theoretical 
modes (Figure 4.7). 
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Figure 4.6 MALDI-TOF mass spectroscopy of the fully unblocked oligonucleotides: a, 21-mer 220; 
b, 18-mer 462; c, 15-mer 461; d, 12-mer 460; e, 9-mer 459. 
Table 4.7 MALDI-TOF results for the fully unblocked oligonucleotide phosphorothioates. 
Compound Measured Mass (MH') Theoretical Mass Error % 
9-Mer 459 2807.6 2807.3 0.011 
12-Mer 460 3753.0 3752.4 0.016 
15-Mer 461 4721.7 4722.4 -0.015 
18-Mer 462 5683.7 5682.5 0.021 
21-Mer 220 6677.9 6677.6 0.004 
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Figure 4.7 The observed and theoretical isotope patterns of the fully unblocked oligonucleotides: a, 9- 
mer 459, observed mode; b, 9-mer 459, theoretical mode; c, 12-mer 460, theoretical mode; d, 12-mcr 
460, observed mode; e, 15-mer 461, observed mode; f, 15-mer 461, theoretical mode. 
The fully unblocked oligonucleotide phosphorothioates were also analysed by ion 
exchange chromatography (Figure 4.8). The 21-mer was compared with the authentic 
material prepared by solid phase synthesis followed by post-synthetic purification. 
Both materials eluted at the same retention time within experimental error (32.278 
and 31.952 minutes respectively). The percentage of the main peaks in the fully 
unblocked oligonucleotide phosphorothioates were determined and are shown in 
Table 4.8. The 18-mer showed significantly lower purity, which may well suggest an 
incomplete coupling. 
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Figure 4.8 Ion exchange chromatography profiles of the fully unblockcd oligonucleotide 
phosphorothioatcs: a, 21-mcr 220; b, 21-mer 220 prepared by solid phase synthesis; c, 18-mcr 462; d, 
15-mer 461; c, 12-mer 460; f, 9-mcr 459. 
Table 4.8 The percentage of the main peaks in the fully unblocked oligonuclcotide phosphorothioatcs 
as indicated by the ion exchange chromatography. 
Compound Integral of the main peak (%) 
9-mer 459 86.79 
12-mer 460 91.80 
15-mer 461 83.71 
18-mer 462 56.89 
21-mer 220 76.64 
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Finally, capillary gel electrophoresis analysis was carried out (Figure 4.9) and the 
results are shown in Table 4.9. The 21-mer was compared against the material 
prepared by solid phase synthesis. The materials both migrated at 21.5-22.1 minutes 
under the same conditions. The 18-mer showed the lowest purity, which corresponds 
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Figure 4.9 Capillary gel clectrophoretograms of the fully unblocked oligonucleotide 
phosphorothioatcs: a, 21-mer 220; b, 21-mer 220 prepared by solid phase synthesis; c, 18-mcr 462; d, 
15-mer 461; e, 12-mcr 460; f, 9-mer 459. 
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Table 4.9 The percentages of the main peaks in the capillary gel clectrophoretograms of the fully 
unblocked oligonucleotide phosphorothioates. 
Compound Integral of the main peak (%) 
9-mer 459 98.57 
12-mer 460 95.69 
15-mer 461 81.56 
18-mer 462 70.89 
21-mer 220 82.81 
In conclusion, the analysis above confirmed the authenticity of the fully unblocked 
oligonucleotide phosphorothioates. The purities of these materials vary in different 
analyses. However, if purification had been carried out after the unblocking 
procedure, much better material would have been obtained. The long retention time 
impurities in the ion exchange chromatograms, which correspond to the impurities of 
longer migration time in the capillary gel electrophoretograms, are believed to be 
symmetrical products of various chain-lengths. In practical terms, it is advantageous 
to carry out the unblocking procedure with the dimethoxytrityl group on. It would 
then be easier to separate the desired oligonucleotide phosphorothioates from the 
truncated sequences by ion exchange chromatography. 
4.10 Conclusion 
To conclude this chapter, we believe that we have demonstrated a protocol which is 
suitable for the preparation of oligonucleotide phosphorothioates on a large scale at a 
temperature not below 0°C. However, more work needs to be done to improve this 
strategy. In our view, several aspects should be looked into in more detail: 
1. The course of the formation of the symmetrical products and the way to 
suppress them need to be investigated; 
2. To ensure the stoichiometry to be as required, it would be advantageous to 
produce both the H-phosphonate and the 5'-hydroxyl components in a solid 
state instead of glass; 
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3. More selective coupling agents need to be evaluated in order to minimise the 
amount of by-products; 
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Conversion of Fully-Protected Phosphorothioate Triesters to 
Phosphate Diesters 
5.1 Introduction 
While oligonucleotide phosphorothioates have shown great potential in therapeutic 
applications, with improved stability towards nucleases, an analytical problem arises 
with their resistance to nucleases. This prevents the effective use of standard 
enzymatic digestion and sequence analysis methods, complicating the characterisation 
of these oligonucleotides. Although mass spectrometric sequencing of small 
oligonucleotides and their analogues appears a promising technique, only up to about 
30-50 nucleotides can be routinely sequenced using MALDI or ESI mass 
spectrometry. 189 
So far, a few papers have been published on the oxidative desulphurisation of a range 
of phosphorothioate diesters. In 1979, Burgers and Eckstein'90 reported the first 
desulphurisation of a dinucleotide phosphorothioate with an excess of ethanolic 
iodine at 0°C. In their study, a dimer (Up(s)A) was treated with iodine in aqueous 
ethanol (15%) containing 0.5% NaHCO3 at 0°C for 10 min. After the excess of iodine 
had been removed by repeated extraction with ether, the aqueous solution was 
digested with snake venom phosphodiesterase (SVPD) and alkaline phosphatase and 
analysed by HPLC to give a U: A nucleoside ratio which was close to unity. In later 
studies, solutions of iodine in pyridinel17,191 and iodine in 2,6-lutidine19' were also 
used for the desulphurisation of oligomers with phosphorothioate internuclcotide 
linkages. 
An effective procedure suitable for the desulphurisation of a phosphorodithioate 
diester 501 was later proposed by Porritt and Reese. 192 This led to the complete 
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desulphurisation of phophorodithioate dimers and trimers. A solution of iodine in 
THF-H20-1-methylimidazole was used as the reagent and the reactions went to 
completion in 90 min (Scheme 5.1). The resulting phosphates 502 were purified by 
reverse phase HPLC and characterised by enzymatic digestion. 
HO Ade H Ade 
OO 
(Ctmp)O O-, ýS 




OH OH OH OH 
501 502 
Scheme 5.1 
The iodine-promoted desulphurisation was later automated by Wyrzykiewicz and 
Cole. '93 In their study, oligomers which were still attached to solid supports 
(LCAA/CPG) were subjected to iodine oxidation followed by cleavage from the solid 
support. 2-Cyanoethyl protected phosphorothioate triesters, which were prepared by 
phosphoramidite chemistry, were first treated with tert-butylamine in pyridine (1: 9 
v/v) to remove the 2-cyanoethyl groups, under which conditions the succinoyl ester 
linkage to the solid support was shown to be stable. Then desulphurisation was 
effected with a 0.24 M solution of iodine in THF-water-l-methylimidazole, followed 
by cleavage of the succinoyl ester linkage from the solid support by standard 
ammonia treatment. The conversion yields were found to be 96.0% with a small 
amount of internucleotide linkage cleavage (ca. 2.5%) and ca. 2.5% undesulphurised 
phosphorothioate internucleotide linkages as indicated by 31P NMR spectroscopy. 
The desulphurised material was then purified by polyacrylamide gel electrophoresis 
(PAGE). A general cycle is demonstrated in Table 5.1. 
This solid support based desulphurisation offers a facile and fast approach to the 
conversion of phosphorothioate triesters to phosphate diesters. However, extensive 
post-synthetic purification had to be conducted to remove the truncated sequences 
formed during the solid phase synthesis, and the retention of phosphorothioate 
diesters cannot be completely avoided. 
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Table 5.1 Automated desulphurisation cycle. 
Function Reagent Time (min) 
Wash Acetonitrile (1 ml) 
Removal of cyanoethyl 10% solution of tert-butylamine in pyridine 
protecting groups (10 washes, 0.8 ml each) 110 
Wash Acetonitrile (1 ml) 
0.24 Msolution of iodine in THF-water-1- 
Desulphurisation methylimidazole (13 portions of the 
130 
oxidising solution) (0.77 ml each) 
Wash Acetonitrile (1 ml) 
An alternative approach involves the replacement of sulphur by oxygen at the 
phosphorothioate triester stage. Iodine oxidation was found to be ineffective in this 
approach. In a paper published by Michalski and co-workers, 194 a procedure involving 
trifluoroacetic anhydride (TFAA) and pyridine was proposed. Almost quantitative 
conversion was observed in a dinucleoside phosphorothioate model (Scheme 5.2). By 
means of diastereoisomeric cyclic phosphorothioates, it was established that this 
TFAA-promoted desulphurisation proceeds in a stereospecific manner with retention 
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Although the iodine-promoted desulphurisation procedure has been proved to be 
effective for phosphorothioate diesters, it is unlikely that pure products can be 
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obtained by this approach. Indeed, when a hexamer [Ac- 
Cp(s)Tp(s)Tp(s)Gp(s)Cp(s)G-Lev] (prepared by treating Ac-Cp(s)Tp(s)Tp(s)Gp(s) 
Cp(s)G-Lev with DBU) was treated with iodine in THF-1-methylimidazole-water, 
numerous impurities were observed by 1H NMR spectroscopy and reverse-phase 
HPLC. We believed that it should be possible to devise an approach involving 
oximate treatment of a fully-protected S-(2-cyanoethyl) oligonuclcotide 
phosphorothioate triester to give the corresponding unmodified oligonucleotide, with 
solely phosphodiester internucleotide linkages, as the only product. 
5.2 Oximate Treatment of Phosphate and Phosphorothioate Triesters 
Prior to the late 1970s, unblocking of the phosphotriester group was effected by 
alkaline hydrolysis. Under these conditions, ca. 3% internucleotide cleavage per 
phosphotriester group occurred. ' 13 A solution to this problem was suggested by Reese 
and co-workers, 32 which involved treatment of the phosphotriester group with the 
conjugate bases of various oximes. It was shown that treatment of a fully-protected 
tetranucleotide triphosphate triester 505 with the conjugate base (i. e. 1,1,3,3- 
tetramethylguanidinium salt) of (E)2-nitrobenzaldoxime 125 (2-NBO), 04- 
nitrobenzaldoxime 506 (4-NBO) or (E}pyridine-2-carboxaldoxime 126 gave the 
desired linkage-unprotected tetranucleoside triphosphate diester in high yield, with 
less than ca. 0.5-1% internucleotide cleavage per phosphotriester group. (E-2- 
Nitrobenzaldoxime 125 was found to be particularly fast (with a t1n of 20 min 23 in 
dioxane-water at 20°C) and effective, leading to not more than 0.1 % internucleotide 
cleavage23 per phosphotriester group. This method was thereafter widely used for 
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It was established'98 that the unblocking of the phosphotriester group by oximate ions 
proceeds by a two-step mechanism (Scheme 5.3), and oximes with pK values (Table 
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E-2-Nitrobenzaldoxime 125 10.28200 
E-2,4-Dinitrobenzaldoxime 507 9.64 201 
E-Pyridine-2-carboxaldoxime 126 199 10.05 
Butan-2,3-dione monoxime 508 9.30 
202 
2-Oxopropanal-l-oxime 509 8.30 202- 
5.3 Development of a New Approach for Conversion of S-(2-Cyanoethyl) 
Phosphorothioate Triesters to Phosphate Diesters 
On the basis of these observations, we believed that if conditions were optimised, 
oximate treatment of S-(2-cyanoethyl) phosphorothioates could yield phosphate 
diesters exclusively. 
Our initial attempt was to unblock the S-(2-cyanoethyl) phosphorothioate tricstcrs 
with different oximes and bases, using DMTr-Tp(s)T-Lev 451 as a model compound. 
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E-2-Nitrobenzaldoxime 125 TMG 510 ca. 100 -- 
E-2-Nitrobenzaldoxime 125 DIPEAa ca. 100 -- 
Butan-2,3-dione monoxime 508 TMG 510 62 38 
2-Oxopropanal 1-oxime 509 DIPEA 58 42 
Note: a, N, N-diisopropylethylamine. 
The above results indicated that the more acidic the oxime is, the more phosphate is 
formed by oximate treatment. But it seems unlikely that a very acidic oxime could be 
used for this purpose because its anion would be expected to be weakly nuclcophilic 
thereby resulting in a very long reaction time. 
This being the case, our attention was drawn towards a second approach, which 
involved replacement of the S-(2-cyanoethyl) group by a second protecting group 
before the oximate treatment was carried out. This approach is indicated in outline in 
Scheme 5.4. This approach was based on the fact that oximate treatment of S-aryl 
phosphorothioate triesters produces phosphate diesters virtually quantitatively. 
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A fully-protected S-(2-cyanoethyl) phosphorothioate triester 172a is treated with 
DBU to give a phosphorothioate diester 175a, which is then alkylated to form another 
phosphorothioate triester 511. Oximate treatment is then carried out. 
For an S-protecting group to be suitable for this purpose, (i), it must be easy to 
introduce; (ii), the oximate ion should attack exclusively on phosphorus. 
2,4-Dinitrofluorobenzene 512 is a very powerful elcctrophile and the S-(2,4- 
dinitrophenyl) group would be expected to behave as an S-aryl group as far as 
oximate treatment is concerned. But 2,4-dinitrofluorobenzcne did not react with the 









512 513 a; R, = H, R2 = N02 
b; R1 = R2 = N02 
Substituted benzyl groups 513 have been used' 4 as S-protecting groups and can be 
removed by nucleophilic attack by thiolate ions (e. g., the conjugate bases of 
thiophenol and p-thiocresol) on the benzylic CH2 groups (Figure 5.1). However, 
concomitant nucleophilic attack175'203 occurring on the C-5' carbon atoms adjacent to 
the internucleotide linkages can lead to internucleotide cleavage. 204 We found that the 
installation of a 4-nitrobenzyl group (as in 514a) on the phosphorothioate diester 
175a is facile, but treatment of the corresponding product 514a with the conjugate 
base of butan-2,3-dione monoxime 508, which is rather acidic, results in a mixture of 
phosphorothioate (27%) and phosphate (72%) diesters. By using the conjugate base 
of an even more acidic oxime, i. e. 2-oxopropanal 1-oxime 509, the formation of 
phosphorothioate can be suppressed at the expense of the rate of reaction. It was 
found that treatment of S-(p-nitrobenzyl) phosphorothioate triester 515 with 2- 
oxopropanal 1-oxime 509 and diisopropylethylamine resulted in the exclusive 
conversion of ca. 18% of 515 into the corresponding phosphate in 4 hours. This 
would not be practically useful because it would be too slow if a larger sequence were 
involved. 
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514 a; R1 = H, R2 = N02 515 
b; R1 = R2 = N02 
Figure 5.1 
OLev 
It occurred to us that the cyano group is such a strong electron-withdrawing group 
that if an S-cyanomethyl group were attached to a phosphorothioate internucleotide 
linkage, the chance for the nucleophilic attack of oximate on the -CH2 adjacent to the 
cyano group would be very small. Conjugate bases of various oximcs 509,516, 
517a-c were evaluated for the unblocking of S-cyanomethyl phosphorothioate 
triesters. In anhydrous solution, only a negligible amount (less than 2%) of 











517 a; R, = R2 =H 
b; R, = Cl, R2 =H 
c; R1=R2=CI 
Of the oximes examined, 2-oxopropanal-l-oxime 509 gave the best result. Treatment 
of an S-cyanomethyl phosphorothioate hexamer triester with 509 and 
diisopropylethylamine in acetonitrile led to full conversion to phosphate. However, 
this rather acidic oxime is not effective in unblocking the 0-aryl protecting groups of 
guanine and thymine residues. Ammonia treatment of resulting partially unblocked 
oligonucleotides would lead to undesirable side reactions. 
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Again, (E}2-nitrobenzaldoxime 125 was evaluated and satisfactory results were 
obtained. Thus, treatment of S-cyanomethyl phosphorothioate triester with 2- 
nitrobenzaldoxime 125 and TMG in acetonitrile unblocked the S-cyanomethyl groups 
overnight to give phosphodiester exclusively, and the carbonyl protecting groups on 
the base residues were also removed completely. 
Having established a suitable protecting group and oxime, a serious problem 
associated with the introduction of the cyanomethyl group onto the sulphur centre 
was identified. 
The problem is outlined in Scheme 5.5. A fully-protected dimer (Ac-Gp(s)C-Lcv, 
518) was treated first with DBU in dry dichloromethane to give the corresponding 
diester 519. The reaction mixture was precipitated from diethyl ether to remove the 
excess of DBU and then bromoacetonitrile and diisopropylethylaminc were added. 
Alkylation on sulphur was found to be very fast and complete in 1.5 h, but undesired 
alkylation on the cytosine base residue also occurred and the base-modified dimer 
(possibly 520) was isolated in 75% yield. Upon the subsequent oximate treatment and 
ammonolysis of the product, uncharacterised mixtures were obtained. This was also 
true when N-benzoyladenine was involved. 
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Scheme 5.5 Reagents and conditions: i, DBU, TMS-CI, CH3CN, room temp., 30 min.; ii, 
bromoacetonitrile, diisopropylethylamine, CH_C12, room temp., 1.5 h. 
We believed that the base alkylation must be due to the ionisation of the exocyclic 
NH- of the base residue (i. e. 6-N-benzoyladenine or 4-N-benzoylcytosine), and this 
was supported by several observations. 
1. Treatment of DMTr-C-Ac 521 and DMTr-A-Ac 522 with bromoacetonitrile in 
acetonitrile did not produce any product; 
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2. Treatment of DMTr-C-Ac 521 and DMTr-A-Ac 522 with bromoacetonitrile in 
the presence of N, N-diethylaniline (pKa ca. 6.6205) in acetonitrile did not 
produce any product; 
3. Treatment of DMTr-C-Ac 521 and DMTr-A-Ac 522 with bromoacctonitrile in 
the presence of diisopropylethylamine (pK, 11.5 '206 10.1207) 
in acetonitrile 
resulted in a higher Rf product; 
4. Treatment of DMTr-C-Ac 521 and DMTr-A-Ac 522 with bromoacetonitrile in 








Because 4-N-benzoyl-2'-deoxycytidine and 6-N-benzoyl-2'-deoxyadenosine probably 
have pK, of ca. 10-11 (this estimate is based on the pKa values of 4-N- 
benzoylcytidine and 6-N-benzoyladenosine208,209), a base of pK, greater than 11 may 
well remove the exocyclic NH-proton, and the resulting conjugate base may then 
undergo alkylation by bromoacetonitrile. 
A possible solution would be to avoid the use of strong base in the unblocking of the 
S-(2-cyanoethyl) protecting group. A weak base, such as an NN-dialkyl derivative of 
aniline, would be expected to be suitable in the alkylation step but not in the removal 
of the S-(2-cyanoethyl) protecting groups. To find an alternative for the DBU in the 
unblocking step was, however, problematic. 
We then thought. that if the ionised protected adenine and cytosine base residues 
could be temporarily protected prior to alkylation with bromoacetonitrile, base 
modification could probably be suppressed. 
136 
Chapter 5 Conversion of Fully-Protected Phosphorothioate Triesters to Phosphate Diesters 
CI 




If seemed probable that if diester 519 was treated with chlorotrimethylsilane (TMS- 
Cl) in the presence of N, N-dimethylaniline, the N3- (or N''-) position of cytosine (or 
N'- or the N6- position of adenine in corresponding compounds containing N- 
benzoyladenine residues) would be blocked by a TMS group. The phosphorothioatc 
diester would probably also be protected on sulphur to give 523 (Scheme 5.6). In this 
way, base modification could be suppressed. However, alkylation with 
bromoacetonitrile becomes sluggish (Scheme 5.7). Under these conditions, 
conversion of 523 to 524 takes over 48 hours. This is undesirable and in the case of 
larger blockmers, exposure of the substrates to bromoacetonitrile over a long period 
of time is likely to lead to a small amount of base cyanomethylation. 
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A better approach would be to neutralise the excess of base used in the unblocking of 
the S-(2-cyanoethyl) groups. This proved to work well. Thus, if 10 equivalents of 
DBU per internucleotide linkage were used in the unblocking of the S-(2-cyanocthyl) 
groups, and 9 equivalents of trifluoroacetic acid were added to the reaction mixture 
after the unblocking was complete, subsequent alkylation on the sulphur ion was fast 
and clean. Under these conditions, alkylation of a 21-mer only took overnight and 
base modification was not observed. 
Thus, we believe that we have established a protocol for the conversion of an S-(2- 
cyanoethyl) phosphorothioate triester to phosphate diester (Scheme 5.8). 
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Scheme 5.8 Reagents and conditions: i, DBU (10 eq. per internucleotide linkage), CH2CI2, room 
temp., 30 min; ii, (a) TFA (9 eq. per internucleotide linkage), 10 min; (b) BrCHZCN (3 eq. per 
linkage), N, N-dimethylaniline (3 eq. per internucleotide linkage), CH3CN, room temp., overnight; iii, 
E-2-nitrobenzaldoxime 125 (5 eq. per reaction function), TMG (4 eq. per reaction function), CH3CN, 
room temp., 15 h; iv, (a) conc. aq. NH3,55°C, 15 h; (b) Amberlite resin (Na; form). 
To start with, when a 5'-O-acetylated S-(2-cyanoethyl) phosphorothioate triester 172a 
was treated with DBU (10 equivalents per internucleotide linkage) in 
dichloromethane, the reaction went to completion in 30 min and then 9 equivalents of 
trifluoroacetic acid were added to neutralise the excess of DBU. After the 
oligonucleotide 175a had been precipitated, it was collected by centrifugation. It was 
then treated with bromoacetonitrile (3 equivalents per internucleotide linkage) in the 
presence of N, N-dimethylaniline in acetonitrile. The alkylation was assumed to finish 
after standing overnight. No base modified material was observed. The product 525 
was isolated by column chromatography and was then treated with 
(E}2- 
nitrobenzaldoxime 125 and TMG in acetonitrile. After ammonolysis, the crude 
material was passed through an Amberlite ion exchange column to give the sodium 
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desulphurised material was carried out by treatment with Crotalus adamanteus snake 
venom phosphodiesterase followed by E. coli alkaline phosphatase. 
This protocol was found to work well with a 21-mer phosphorothioate 
oligonucleotide (ISIS 2922) to give a product containing only 0.2% of 
phosphorothioate internucleotide linkages (as estimated by 31P NMR spectroscopy). 
This percentage of contamination is acceptable, as it may be estimated that, if the 
phosphodiester analogue of ISIS 2922 were contaminated with 1% of 
phosphorothioate diester internucleotide linkages, the nucleoside ratio as determined 
by enzymatic digestion would still be very close to theory. This estimate depends on 
the assumption that the remaining phosphorothioate diester linkages are randomly 
distributed in the sequence and are not cleaved by enzymes. 
5.4 Desulphurisation of Dimer and Trimer Blocks 
Using the protocol described above, some fully-protected dimer (Cp(s)G, Gp(s)A) and 
trimer (Gp(s)Cp(s)G, Cp(s)Tp(s)T, Ap(s)Tp(s)T) phosphorothioate tricsters were 
converted to their corresponding phosphate diesters. Very satisfactory NMR ('H and 
31P) spectra were recorded and no phosphorothioate diester contamination was 
observed. Enzymatic digestion of these blocks gave satisfactory nucleoside ratios 
(e. g. A: T = 1.04: 2.00 for 1.00: 2.00). The 'H and 31P NMR spectra and reverse 
phase HPLC traces of the desulphurised trimer derived from Ac-Ap(s)Tp(s)T-Lev are 
illustrated in Figure 5.2. 
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11 
Figure 5.2 Analysis of desulphurised trimer d(ATT) 526: a, 'H NMR spectrum (in D, O) of d(A'1T); 
b, 31P NMR spectrum (in D20) of d(ATT); c, reverse-phase HPLC profile of d(ATT); d, reverse-phase 
HPLC profile of the digest of d(ATT). 
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dA T dC dG 
d(CG) Calculated -- -- 1.00 1.00 
527 Observed -- -- 1.00 1.00 
d(GA) Calculated 1.00 -- -- 1.00 
528 Observed 1.05 -- -- 1.00 
d(GCG) Calculated -- 1.00 2.00 
529 Observed -- -- 1.00 1.94 
d(CTT) Calculated -- 2.00 1.00 -- 
530 Observed -- 1.94 1.00 -- 
5.5 Desulphurisation of Larger Blocks (6-, 12-, and 21-mers) 
The same protocol was also applied to the conversion of larger S-(2-cyanoethyl) 
phosphorothioate triester sequences to the corresponding phosphates. No 
modification of the procedure was needed compared with the dimer and trimer 
blocks, and the results were satisfactory. As an example, the ISIS 2922 21-mer was 
treated according to the conditions described in Scheme 5.8. Only approximately 
0.2% of phosphorothioate contamination was recorded by 31P NMR spectroscopy. 
The nucleoside ratio as determined by enzymatic digestion was found to be C: G: T = 
6.00: 5.53: 11.23 for 6: 5: 10. 
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Figure 5.3 Analysis of the desulphurised ISIS 2922 21-mer 531: a, 'H NMR spectrum (in D20); h, 31P 
NMR spectrum (in D20); c, reverse-phase HPLC profile; d, reverse-phase HPLC profile of enzymatic 
digest. 
The desulphurised 21-mer was compared with the material prepared by standard 
phosphoramidite solid-phase synthesis. They both eluted at the same retention time 
on reverse-phase HPLC and co-injection resulted in a single peak. 
Two other building blocks (CTT GCG, a hexamer and CTT CTT CTT GCG, a 
dodecamer) were also converted to their corresponding phosphate diesters using this 
approach. Satisfactory results were obtained. Nucleoside ratios as determined by 
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6-mer Calculated 2.00 2.00 2.00 
532 Observed 2.03 2.00 2.03 
12-mer Calculated 6.00 4.00 2.00 
533 Observed 5.95 4.00 1.92 
In conclusion, we believe that we have demonstrated a protocol for conversion of S- 




Development of Novel Protecting Groups for vic-Diols 
vic-Diols are very important species in synthetic and natural products. A large 
number of diol-protecting groups of varying stability to a substantial array of reagents 
have been made available over the past few decades. Among them, 1,3-dioxolanes 
and 1,3-dioxanes are the most commonly used protecting groups. 
In the 1960s, in connection with studies210 on the solution phase synthesis of 
oligonucleotides, a protecting group for the 2', 3'-cis-diol system of a ribonuclcoside 
that was considerably more acid-labile than the conventional isopropylidene group 
(as in 601) was required. Despite the fact that it is chiral, the methoxymethylene 
group211 (as in 602), which is some two orders of magnitude more labile to acidic 
hydrolysis than the isopropylidene group, was used. Much more recently, in 
connection with work on the synthesis of phosphatidylinositol-3,4,5-trisphosphate 
[PtdIns(3,4,5)P3] 603,212 Reese and Gaffney2t3'214 prepared 1-O-stearoyl-sn-glycerol 
((S)- I -O-stearoylglycerol) 604 from its 2,3-O-isopropylidene derivative 605. As the 
acidic conditions required for the removal of the isopropylidene group were relatively 
drastic, it would have been desirable to have used a more acid-labile protecting group 
and thereby to have ensured that absolutely no concomitant acyl migration and hence 
racemisation could have occurred. In this and no doubt in a number of other studies, a 
chiral protecting group such as methoxymethylene would not have been suitable as its 
use would almost certainly have led to an undesirable mixture of diastereoisomers. 
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6.1 vic-Diol Protecting Groups 
6.1.1 Acetals 
Acetals exhibit almost complete stability to basic conditions but they are labile 
towards acid. This property stems from participation of a lone pair on the adjacent 
oxygen atom in the cleavage of a protonated intermediate. Thus, they are unaffected 
by the basic conditions required for alkylation and acylation; they are also stable to 
oxidation by Cr03-pyridine, periodate, Pb(OAc)4, Ag2O, alkaline permanganate and 
under Oppenauer conditions. Also they are stable towards reduction by NaBH4, 
LiAIH4, Na-Hg and, with the exception of benzylidene acetals, to catalytic 
hydrogenolysis. 
The most commonly used protecting groups of this type are isopropylidenc acetals215 
and benzylidene acetals. Methylene and ethylidene acetals have also been used 
frequently. 
Isopropylidene acetals (also known as acetonides) have been used more frequently 
than any other protecting group for the protection of 1,2-diols. These acetals are 
easily prepared and they are stable to most reaction conditions except protic and 
Lewis acids. 
Benzylidene acetals are frequently used in carbohydrate chemistry. They are stable to 
most strong bases, mild oxidants and metal hydrides (in the absence of Lewis acids) 
but they are readily attacked by N-bromosuccinimide and ozone -a fact that can be 
usefully exploited. Benzylidene acetals are not stable to some strong bases such as 
alkyllithium reagents and they are hydrogenolysed in the presence of Pd or Pt 
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catalysts. Lewis acids can also decompose them. A further useful feature is that they 
can be reductively cleaved to give an alcohol and benzyl ether. 
The chemistry of cyclohexylidene acetals is very similar to that of isopropylidene 
acetals but the cyclic derivatives have two advantages over their acyclic counterparts. 
Firstly, they reduce the water solubility of low molecular weight fragments and 
therefore facilitate their isolation. Secondly, they also show a greater preference for 
the formation of 1,3-dioxolanes over 1,3-dioxanes. 
6.1.2 Cyclic Ortho Esters 
A variety of cyclic ortho esters, including cyclic orthoformates, have been developed 
to protect cis-1,2-diols. Cyclic ortho esters are more readily cleaved by acidic 
hydrolysis216 (e. g. by acidic phosphate buffer or by 0.005-0.05 M HCl) than are 
acetonides. Careful hydrolysis or reduction can be used to prepare selectively 
monoprotected diol derivatives. 
Cyclic orthoformates are stable in alkaline media, but undergo acid-catalysed 
hydrolysis under very mild conditions. Thus the half-time of hydrolysis of 2', 3'-O- 
methoxymethyleneuridine (602; B= uracil-l-yl) was found to be ca. 10 min in 0.01 N 
hydrochloric acid at 200C. 217 The use of methoxy- and ethoxy-methylene protecting 
groups has so far been restricted mainly to oligoribonucleotide synthesis. 
6.2 Mechanism of Acetal Hydrolysis 
The hydrolysis of acetals (Scheme 6.1) has been found to be a specifically acid- 
catalysed reaction with the accepted mechanism involving a fast pre-equilibrium 
protonation of the acetal followed by a rate-determining decomposition of the 
protonated intermediate to an alcohol and a resonance-stabilised carbocation. 218 
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Scheme 6.1 Mechanism of acetal hydrolysis. 
This mechanism has been confirmed with the aid of evidence such as the lack of 
racemisation at the alcohol carbon atom, 219 the proportionality between the logarithm 
of the rate constant and the Hammett acidity function, 22° H°, and the much faster rate 
of hydrolysis in D20 than in water (kD2o/kH2o = 2.0-3.0). 222 222 
Substituent and steric effects were studied to determine their impact on acetal 
hydrolysis. Fife and Jao223 studied the hydrolysis of a series of substituted 





606a; Y=H, X=OCH3 
b; Y=H, X=CH3 
c; Y=X=H 
d; Y=H, X=CI 
e; Y=H, X=N02 
f; Y=OCH3, X=H 
g; Y=CH3, X=H 








e; X= NO2 
The rates of hydrolysis were measured in 50% dioxanc-water (v/v) or 50% dioxane- 
acetate or formate buffer (v/v) with HC1 as proton donor. Results are presented in 
Table 6.1. 
148 
Chapter 6 Development of Novel Protecting Groups for vic-Diols 
Table 6.1 Rates of hydrolysis of substituted benzaldehyde diethyl acctals and 2-(p-substituted phcnyl)- 
1,3-dioxolanes in 50% dioxanc-water or 50% dioxane-D20. 




606d 181.3 541.1 





607b 119.2 335.9 
607c 25.4 70.1 
607d 6.19 17.8 
607e 0.0541 0.177 
a Acetate buffer; b Formate buffer. 
It is noticeable that the rates of hydrolysis drop drastically with the increase of the 
electron withdrawing effect of the substituents, which agrees with the established 
mechanism. With the introduction of an electron-withdrawing group, protonation 
whould be impeded which makes departure of the leaving group more difficult, and 
the carbocation intermediate is destabilised; therefore, the hydrolysis rate drops. 
Studies on steric effects in acetal hydrolysis were also carried out by Fife and 
Hagopian. 224 In this case, a series of diethyl acetals/ketals and 2,2-disubstituted 1,3- 
dioxolane derivatives 608 were studied. Results are listed in Table 6.2. 
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608 a; R1 = C6H5, R2: -- CH3 
b; R1 = C6H5, R2 = C2H5 
c; R1 =R2=C6H5 
d; RI = CH3, R2 = C2H5 
e; R1 = R2 = CH3 
f; R1 = CH3, R2 = CH(CH3)2 
g; R1 = CH3, R2 = C(CH3)3 
h; R1 = R2 = CH(CH3)2 
Table 6.2 Rates of hydrolysis of diethyl acetals/kctals and 1,3-dioxolane derivatives in 50% dioxanc- 
water or 50% dioxane-D20. 
Compound kH, 1-mole -'. min-' kD, I"mole '"min ' 
Benzaldehyde diethyl acetal 723.3 
Acetophenone diethyl ketala 24,200 
Propiophenone diethyl ketala 6,724 
Acetone diethyl ketalb 82,370 
2-Phenyl-1,3-dioxolane 25.4 70.1 
608a 5.00 14.76 







a Formate buffer; b Acetate buffer; '0.5 M HCI. 
Salomaa and Kankaanperä225 also found the relative rates for hydrolysis of methyl- 
substituted 1,3-dioxolanes, shown in Table 6.3. 
150 
Chapter 6 Development of Novel Protecting Groups for vic-Diols 
Table 6.3 Relative rates of hydrolysis of 1,3-dioxolanes in water at 25°C. 
Compound Relative hydrolysis rate 
1,3-Dioxolane 1.0 
2-Methyl-1,3-dioxolane 5,132 
2,2-Dimethyl- 1,3-dioxolane 54,339 
The fact that replacement of a hydrogen at the 2 position by one methyl group 
produced an increase in rate of over 5,000 times, quite similar to the difference in 
rates of hydrolysis of formaldehyde and acetaldehyde diethyl acetals, while 
substitution of the second methyl further increased the rate of hydrolysis by only a 
factor of 10 was interpreted as indicating that the presence of two substituents results 
in steric retardation of the rate so that the normal rate enhancement due to the 
inductive and/or hyperconjugative effects of the methyl groups is reduced. Since the 
rate increase due to substitution with the first methyl group was found to be so large, 
it was thought that steric hindrance was probably absent in the case of 
monosubstitution. In explaining these effects, it was assumed that the transition state 
has a great deal of oxo-carbocation character so that the bond between oxygen and the 
carbon at the 2-position has partial double-bond character (Figure 6.1). The groups 
bonded by these atoms would, therefore, approach coplanarity, resulting in steric 
interaction between one of the substituent groups and the ring. Presumably only the 
smaller of the two substituent groups would be turned towards the ring so that steric 








From the data presented in Table 6.2, it can be seen that replacement of the hydrogen 
atom at the 2-position in 2-phenyl-1,3-dioxolane by an alkyl group results in a large 
rate decrease. Thus, 2-phenyl-2-methyl-l, 3-dioxolane hydrolyses only one-fifth as 
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fast as 2-phenyl-1,3-dioxolane. However acetophenone diethyl ketal hydrolyses 
approximately 33 times faster than benzaldehyde diethyl acetal. It is apparent that the 
observed order of reactivity indicates the presence of a larger rate-retarding effect in 
the hydrolysis of the 2-phenyl-2-alkyl-1,3-dioxolanes than in the 2,2-dialkyl-1,3- 
dioxolane series. Of special interest is the very slow rate of hydrolysis of 2,2- 
diphenyl-l, 3-dioxolane. It might have been expected that this compound would 
hydrolyse more rapidly owing to the ability of the second phenyl group to stabilise a 
carbocation through a resonance effect. These results were explained as being due to 
either steric inhibition of resonance in the transition state or the transition state 
resembling the protonated substrate so that conjugation effects would be unimportant. 
609 a; R=R'=R"=H 
b; R=R'=H; R"=OCHS 
c; R=H; R'=R"=OCHS 
d; R=R'=R"=OCHS 
6.3 Development of New Acid-Labile Protecting Groups 
In the case of substituted 5'-O-trityluridine 609, it was found 226 that introduction of 
each p-methoxy group increased the rate of hydrolysis in 80% acetic acid at room 
temperature by a factor of approximately 10. Therefore, p-methoxy substituents 
would be expected to facilitate the acid-catalysed hydrolysis of 2,2-diphcnyl-1,3- 







O` ,O R" 
In the light of this observation, 2', 3'-O-[di-(p-anisyl)methylene]uridine 612 was 
prepared (Scheme 6.2) by reacting uridine 610 with di-(p-anisyl)-dimethoxymethane 
611 in the presence of a catalytic amount of (±)-camphor-10-sulphonic acid in 
acetonitrile solution. 
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Scheme 6.2 Reagents and conditions: i, (f)-camphor-10-sulphonic acid, CH3CN, room temp. 
The rate of hydrolysis of 2', 3'-O-[di-(p-anisyl)methylene]uridine 612 was evaluated 
against 2', 3'-O-isopropylideneuridine 613 in trifluoroacetic acid - water - methanol 
(1: 2: 7) and 2', 3'-O-[di-(p-anisyl)methylene]uridine 612 was found to be ca. two 






The increase in lability of 2', 3'-O-[di-(p-anisyl)methylene]uridine 612 to acids can 
probably be attributed to the mesomeric effect introduced by the para-methoxy 
groups. In the carbonium ion intermediate 614 in the hydrolysis of 2', 3'-O-[di-(p- 
anisyl)methylene]uridine 612, the positive charge delocalises over the ring and is 
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This effect can be further exploited if the two benzene rings are fused together 




615 a; R=H 
b; R =Me 
Indeed, it was found that 2', 3'-O-(xanthen-9-ylidene)uridine 616a and 2', 3'-O-(2,7- 
dimethylxanthen-9-ylidene)uridine 616b are both more labile to acids than 612, and it 
is particularly noteworthy that 2', 3'-O-(2,7-dimethylxanthen-9-ylidene)uridine 616b 
undergoes hydrolysis at a rate just over 20 times faster than that of 2', 3'-O- 
isopropylideneuridine 613 in trifluoroacetic acid - water - methanol (1: 2: 7), which is 
due to both the mesomeric effect and the hyperconjugation of the methyl groups with 
the aromatic rings (as in 617). Clearly, by an appropriate choice of substituents an 
even more labile xanthen-9-ylidene protecting group could be designed. The main 




Apart from the advantage that the xanthen-9-ylidene protecting groups are much 
more labile than the isopropylidene group, from the analytical point of view they 
have another advantage in that they absorb in the ultraviolet. This may not be of 
importance in nucleoside and nucleotide chemistry but it might well prove to be so in 
lipid and carbohydrate chemistry. 
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Table 6.4 Acidic hydrolysis of 2', 3'-protected uridine derivatives. 
Half-time (t1/2) min 
Substrate Trifluoroacetic acid - Trifluoroacetic acid - Trifluoroacetic acid-- 
water - methanol water - methanol water - methanol 
(1: 2: 7 v/v 30°C (1: 2: 7 v/v) 40°C (1: 1: 8 v/v) 40°C 
2', 3'-O-Isopropylidene 178.1 51.1 129.2 
uridine 613 
2', 3'-O-[Di-(p-anisyl) 56.9 22.7 52.5 
methyleneluridine 612 
2', 3'-O-(Xanthen-9- 31.7 10.1 22.8 
lidene)uridine 616a 
2' , 3'-O-(2,7-Dimethyl 
xanthen-9-ylidene) 8.6 2.5 
6.7 
uridine 616b 
To conclude this section, we have developed three new protecting groups, i. e. di-(p- 
anisyl)methylene, xanthen-9-ylidene and 2,7-dimethylxanthen-9-ylidenc groups (as in 
612,616a, and 616b respectively). The rates of hydrolysis of the corresponding 2', 3'- 
0-protected uridine derivatives were measured under three different sets of 
conditions. In each case, pseudo first order kinetics were observed and good straight 
lines were obtained by plotting logio(% remaining substrate) against time (see 6.6 
Appendix). The half times are presented in Table 6.4. 
6.4 Preparation of(ttý and(S)-1,2-O-Xanthen-9-ylideneglycerol 
Contemporary asymmetric synthesis is a widely used method for stereo-controlled 
reaction of C-C bonds in organic molecules. During recent years this approach to 
organic synthesis has greatly contributed to progress in the directed introduction of 
various functionalities, and in the highly controlled formation of new centres of 
chirality. These processes still remain the basic problems in the total synthesis of 
natural products. Preparation of the latter in an optically pure form by application of 
chiral starting materials is very advantageous, enabling precise planning and efficient 
realisation of synthetic pathways. Many monosaccharides and their readily available 
derivatives are versatile and relatively inexpensive substrates for the synthesis of 
optically active target molecules. 
D-Mannitol 618 and L-ascorbic acid 619, both of which are inexpensive polyhydroxy 
compounds, are widely used substrates for the synthesis of optically active target 
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molecules. The corresponding S- and R- enantiomers of glycerol acetonide (622 and 
626) can be prepared according to the outline in Scheme 6.3.228.229 
(a) 




19 HO OHTO_\ 
OH OH O OH HO', 
k,, O 
618 620 0 621 622 
(b) 
OH p 
0-7( -«O ý.., JOH 
pp %'O p OH O p--ý- 
_ 
-ý 
O-bo H -º HýO-ý HOý, O 
OH 
p HO OH HO OH COO 625 626 
619 623 624 
Scheme 6.3 
The key reagents required for the preparation of l, 2-O-(xanthen-9-ylidene) and 1,2- 
O-(2,7-dimethylxanthen-9-ylidene) derivatives are the 9,9-dichloroxanthenes 627a, b 
and corresponding 9,9-dimethoxyxanthenes 628a, b. Following a literature 
procedure, 230 9,9-dichloroxanthene 627a was prepared (Scheme 6.4, step i) in 
virtually quantitative yield by heating commercially available xanthcn-9-one 615a 
with thionyl chloride, under reflux, in the presence of a catalytic amount of DMF. 
Treatment of 9,9-dichloroxanthene 627a with sodium methoxide in methanol - THE 
(Scheme 6.4, step ii) gave 9,9-dimethoxyxanthene 628a in 94.5% overall yield for the 
two steps. In the same way, 9,9-dichloro-2,7-dimethylxanthene 627b and 9,9- 
dimethoxy-2,7-dimethylxanthene 628b were prepared from 2,7-dimethylxanthenc-9- 
one 615b. 
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0 CI CI MeO OMe 
R llzý RIRR ii R, I R to IN. 
615 a; R=H 627 a; R=H 628 a; R=H 
b; R =Me b; R= Me b; R= Me 
Scheme 6.4 Reagents and conditions: i, SOCl2, DMF, reflux; ii, NaOMe, MeOH, THF, 0°C to room 
temp. 
When glycerol 629 was allowed to react with 9,9-dimethoxyxanthenc 628a in the 
presence of a catalytic quantity of (±)-camphor-l0-sulphonic acid (CSA) in 
acetonitrile solution at room temperature (Scheme 6.5), racemic 1,2-0-(xanthen-9- 
ylidene)glycerol 630a was obtained and isolated as a crystalline solid in 81 % yield. In 
the same way, racemic 1,2-0-(2,7-dimethylxanthen-9-ylidene)glycerol 630b was 







OH Zýll / 
629 628 a; R=H 
b; R =Me 
630 a; R= H 
b; R=Me 
Scheme 6.5 Reagents and conditions: i, CSA, McCN, room temp., 4 h. 
Like (SS1,2-O-isopropylideneglycerol (as in Scheme 6.3a), 01,2-0-(xanthen-9- 
ylidene)glycerol 632a and (5)-1,2-0-(2,7-dimethylxanthen-9-ylidene)glycerol 632b 
may both be prepared from D-mannitol 618. Treatment of D-mannitol with 9,9- 
dichloroxanthene 627a in pyridine solution (Scheme 6.6a) gave 1,2: 5,6-di-O- 
(xanthen-9-ylidene)-D-mannitol 631a, which was isolated as a crystalline solid in 
84.5% yield. In the same way, D-mannitol 618 reacted with 9,9-dichloro-2,7- 
dimethylxanthene 627b to give its 1,2: 5,6-di-O-(2,7-dimcthylxanthen-9-ylidenc) 
derivative 631b in 81% isolated yield. Oxidative cleavage of 1,2: 5,6-di-O-(xanthen- 
9-ylidene)-D-mannitol 631a was effected either with lead (IV) acetate in ethyl acetate 
or with sodium metaperiodate in aqueous THE In both cases, the putative 
intermediate glyceraldehyde derivative was reduced with sodium borohydride 
157 
Chapter 6 Development of Novel Protecting Groups for vic-Diols 
(Scheme 6.6a, step iv) to give (S) -1,2-0-(xanthen-9-ylidene)glycerol 632a as a 
crystalline solid in 81 and 94% isolated yield, respectively, based on the D-mannitol 
derivative 631a. The 1,2: 5,6-di-O-(2,7-dimethylxanthen-9-ylidene) derivative 631b 
was similarly treated to produce(S) -1,2-0-(2,7-dimethylxanthen-9-ylidene)glycerol 






















632 a; R=H 
b; R= Me 
634 a; R=H 
b; R=Me 
Scheme 6.6 Reagents and conditions: i, CSHSN, 0°C to room temp.; ii, Pb(OAc)4, NaHCO3, EtOAc, 
room temp.; iii aq. Na104, NaHCO3, THF, H20, room temp., 4 h; iv, NaBH4, EtOH; v, CSA, McCN, 
reflux, 3 h; vi, (a) Li2CO3, (b) aq. H202,0°C to room temp., 16 h. 
(K}1,2-0-(Xanthen-9-ylidene)glycerol 634a and (1' -1,2-0-(2,7-dimethylxanthen-9- 
ylidene)glycerol 634b may both be prepared (Scheme 6.6b) from L-ascorbic acid 619. 
Thus L-ascorbic acid was first heated, under reflux, with a slight excess of 9,9- 
dimethoxyxanthene 628a in the presence of a catalytic quantity of CSA in dry 
acetonitrile (Scheme 6.6b, step v) to give its 5,6-0-(xanthen-9-ylidene) derivative 
633a. After the addition of an excess of lithium carbonate, the products were treated 
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first with aqueous hydrogen peroxide and then with lead (N) acetate (step vi and ii, 
respectively) to give the putative (S -2,3-0-(xanthen-9-ylidene)glyceraldehydes. 
Reduction with sodium borohydride (step iv) gave (R}1,2-0-(xanthen-9- 
ylidene)glycerol 634a, which was isolated as a crystalline solid in 41.5% overall 
yield. In the same way, (1 -1,2-0-(2,7-dimethylxanthen-9-ylidene)glycerol 634b was 
prepared in an overall yield of 32%. Compounds 634a and 634b are both levorotatory 
(Table 6.5). 
Table 6.5 Specific rotation ofUR* and* enantiomers of glycerol derivatives. 
Compound (a] ö *c c (ethanol) 
632a +15.7 1.5 
632b +18.2 1.5 
634a -15.3 1.5 
634b -18.2 1.5 
6.5 Preparation of(R} and(S}1-O-stearoylglycerol 
(5)-1-O-Stearoylglycerol 604 (1-O-stearoyl-sn-glycerol) is a very important building 
block in lipid and carbohydrate chemistry. In the preparation of phosphatidylinositol- 
3,4,5-trisphosphate [Ptdlns(3,4,5)P3] 603 carried out by Gaffney and Reese, 214 (S} 1-0- 







OO ý lol 
ü 
Ho job ý 
OH 
626 605; R= C17H35 604; R= C17H35 
Scheme 6.7 Reagents and conditions: i, DMAP, stearoyl chloride, Et3N, CH2C12,0°C to room temp.; 
ii, (EtO)3B, TFA, 2,2,2-trifluoroethanol, room temp., 5 h. 
It is noteworthy that in this preparation, rather drastic unblocking conditions were 
used and the product 604 was exposed to these conditions for a fairly long period of 
time (5 h). As a result, ca. 1% of concomitant acyl migration was observed. This is 
undesirable and alternative unblocking conditions were sought. 
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Racemic 1,2-0-(xanthen-9-ylidene)- and 1,2-0-(2,7-dimethylxanthen-9-ylidene)- 
glycerol 630a and 630b were both examined as potential starting materials for the 
preparation of racemic 1-O-stearoylglycerol 635. Treatment of the xanthen-9-ylidene 
derivative 630a with stearoyl chloride and 1-methylimidazole in dichloromethane 
solution (Scheme 6.8, step i) gave the putative stearate ester 636a as the sole product. 
It was found that the xanthen-9-ylidene protecting group could be removed under 
very mild conditions indeed. When a ca. 0.15 M solution of the intermediate stearate 
ester 636a in dichloromethane was treated with dichloroacetic acid (ca. 4 molar 
equivalents) and pyrrole (ca. 5 molar equivalents) at room temperature, rapid 
unblocking occurred and, following work-up of the product after 15 min, racemic 1- 
O-stearoylglycerol 635 was isolated as a pure crystalline solid in 80% overall yield. 
The other product was identified as 9,9-di-(pyrrole-2-yl)xanthene 647. It seemed 
desirable that the lipid product 635, which would be expected to undergo acyl 
migration under mildly basic conditions, should be isolated without recourse to 
column chromatography. This was achieved by treating a solution of the products (i. e. 
compounds 635 and 647) with an excess of iron (III) chloride in diethyl ether 
solution. In this way, the xanthene derivative 647 was quantitatively removed and a 
dark brown solid precipitate was obtained. Following the same procedure (Scheme 
6.8a) racemic 1,2-0-(2,7-dimethylxanthen-9-ylidene)glycerol 630b was also 
converted into racemic 1-O-stearoylglycerol 635, which was isolated in 85% overall 
yield. The xanthene by-product 648 was again removed by the iron (III) chloride 
precipitation method. 
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Scheme 6.8 Reagents and conditions: i, stearoyl chloride, 1-methylimidazole, CHZC12, room temp., 
1.5 h; ii, pyrrole, dichloroacetic acid, CH2C12, room temp., 15 min; iii, FeCI3, diethyl ether, room 
temperature, 30 min. 
It is noteworthy that the 2,7-dimethylxanthen-9-ylidene derivative 636b did not 
appear to undergo more rapid dichloroacetic acid-pyrrole promoted unblocking than 
the simple xanthen-9-ylidene derivative 636a. Therefore, if unblocking is to be 
effected in this way, there appears to be no obvious advantage in using the 2,7- 
dimethylxanthen-9-ylidene rather than the more easily accessible unsubstituted 
xanthen-9-ylidene protecting group. For this reason, the enantiomeric 0 and (1 -1-0- 
stearoylglycerol 604 and 639 were prepared from the corresponding (R} and (SJ-1,2-0- 
(xanthen-9-ylidene)glycerol 634a and 632a (Scheme 6.8b and 6.8c, respectively) by 
exactly the same procedure as was used for the preparation of the racemic material 
635 (Scheme 6.8a). (S-(+)-1-O-stearoylglycerol 604 and (R}(-)-1-O-stearoylglycerol 
639 were thereby prepared and isolated in 77 and 79% overall yields, respectively. 
The specific rotation data of the $J. and (I4-1-O-stearoylglycerol 604 and 639 are 
presented in Table 6.6. 
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Table 6.6 Rotation of the(S} and(% enantiomers of 1-O-stearoylglycerol 604,639. 
Substrate 
[a] ö 
20*C in CSHSN 
Measured Lit. 214 Lit. 231 
(S}1-O-stearoylglycerol 604 +3.64 (c 4.1) +3.66 (c 4) +3.55 (c 5.24) 
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645 646 
-RýOHý 
Scheme 6.9 Reagents: i, pyrrole, CIZCHCO2H, CH2CI2 
The procedure for the dichloroacetic acid-pyrrole promoted removal of the xanthen- 
9-ylidene protecting group is essentially the same as the procedure that was 
recommended some 15 years ago by Reese and co-workers182 for the removal of the 
9-phenylxanthen-9-yl and related (e. g. 4,4'-dimethoxytrityl) protecting groups from 
alcoholic hydroxy functions. Thus, when a 9-phenylxanthen-9-yl ether 640 (Scheme 
6.9a) is treated with dichloroacetic acid and pyrrole, the 9-phenylxanthen-9-yl cation 
641 is generated and then rapidly and irreversibly quenched by pyrrole to give 2-(9- 
phenylxanthen-9-yl)pyrrole 642. The suggested mechanism for the removal of the 
xanthen-9-ylidene protecting group, which is illustrated in Scheme 6.9b for an acyclic 
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perhaps be expected to be as stable as the 9-phenylxanthen-9-yl cation 641 inasmuch 
as the mesomeric effect of an alkoxy group (OR2) is generally unlikely to be smaller 
than that of a phenyl group. The monopyrrol-2-yl intermediate 645, formed by the 
reaction between cation 644 and pyrrole, would be expected to fragment very rapidly 
indeed under the reaction conditions to give cation 646. This intermediate 646, which 
is stabilized by the mesomeric effect of the pyrrol-2-yl residue, would be expected to 
be more stable than the 9-phenylxanthen-9-yl cation 641. Although we have not so 
far obtained any supporting experimental evidence, the inductive effect of the methyl 
substituents in the 2,7-dimethylxanthen-9-ylidene protecting group would be 






The two di-(pyrrol-2-yl) derivatives 647 and 648 were both obtained as pure 
crystalline compounds and were fully characterised. Racemic 1-O-stearoyl-2,3-0- 
(xanthen-9-ylidene)glycerol 636a was treated with an excess each of dichloroacetic 
acid and pyrrole in dichloromethane solution at room temperature. After the 
fractionation of the products, the di-(pyrrol-2-yl) derivative 647 was isolated as a 
colourless crystalline solid in 92% yield. The latter compound was also prepared from 
9,9-dimethoxyxanthene 628a and obtained in 74% isolated yield. In the same way, 
2,7-dimethyl-9,9-di-(pyrrol-2-yl)xanthene 648 was prepared both from racemic 1-0- 
stearoyl-2,3-0-(2,7-dimethylxanthen-9-ylidene)glycerol 636b and 9,9-dimethoxy- 
2,7-dimethylxanthene 628b and isolated in 82 and 64% yield, respectively. When a 
solution of each of these di-(pyrrol-2-yl) derivatives 647 and 648 was treated with a 
threefold excess of iron (III) chloride in dry diethyl ether solution, dark coloured solid 
precipitates were obtained and, in both cases, none of the starting material remained 
in the ethereal solution. No attempt has so far been made to characterise these 
precipitated solids. 
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To conclude, we believe that we have developed a series of new protecting groups 
which are more acid-labile than the conventionally used isopropylidene group. The 
appropriately protected enantiomeric isomers of glycerol derivatives were prepared. 
Their stearoyl esters were also prepared and unblocked under very mild conditions. 
6.6 Appendix - Hydrolysis Data of the 2', 3'-O-Protected Uridine Derivatives 
6.6.1 Hydrolysis of the Protected Uridine Derivatives 
Hydrolysis kinetics were examined under three sets of conditions. Using 3'-O- 
benzoylthymidine as internal standard, rates of disappearance of the substrates were 
calculated. Half-times of the substrates were calculated in the following way: 
So is defined as percentage absorbance of substrate at 260 nm at time zero; 
AO is defined as percentage absorbance of internal standard at 260 nm at time zero; 
S, is defined as percentage absorbance of substrate at 260 nm at time t; 
A, is defined as percentage absorbance of internal standard at 260 nm at time t; 
Then 100( 
Ao - S) is the percentage of substrate remaining at time t. A-So 
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6.6.2 Hydrolysis Charts of the Protected Uridine Derivatives 
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(b), 2', 3'-O-[Di-(p-anisyl)methylene]uridine in MeOH: H20: TFA = 8: 1: 1 at 40°C (ti, 2 
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(d), 2', 3'-O-(2,7-Dimethylxanthen-9-ylidenc)uridine in McOH: H20: TFA = 8: 1: 1 at 
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y= -0.01320x + 1.98544 
v. -0.04508x + 2.02859 
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(h), 2', 3' O-(2,7-Dimethylxanthen-9-ylidene)uridine in McOH: H20: TFA = 7: 2: 1 at 
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(k), 2', 3'-O-Isopropylideneuridine in McOH: H20: TFA=7: 2: 1 at 30°C (11/2 = 178.1 
min). 
y= -0.00169x + 1.99882 









(I), 2', 3'-O-(Xanthen-9-yl)uridine in McOH: H20: TFA=7: 2: 1 at 30°C (t112 = 31.7 min). 
y= -0.00947x + 1.99385 
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7.1 Instrumentation 
Melting points were measured with a Büchi melting pointing apparatus and are 
uncorrected. 'H NMR spectra were measured at 360 and 400 MHz with Bruker 
AM360, AM400 and AV400 spectrometers; tetramethylsilane was used as an internal 
standard; J values are given in Hz. 13C NMR spectra were measured at 90.6 and 100.6 
MHz with the same spectrometers. 31P NMR spectra were measured at 145.8 and 
161.9 MHz respectively with the same spectrometers, and were referenced to external 
85% H3PO4. Chemical shifts are given in ppm. Micro-analysis was carried out by the 
Analytical Services at the Department of Chemistry, University College London. 
Mass spectra were recorded on KRATOS MS890MS and JEOL JMS-AX505 mass 
spectrometers. MALDI Mass spectra were measured with a Micromas TofSpec 2E 
spectrometer. Capillary gel electrophoresis analysis and ion exchange 
chromatography were carried out at Avecia Pharmaceuticals. 
7.2 Chromatography 
Merck silica gel 60 F254 TLC plates (Art. 5715 and 5642) were developed in the 
following solvent systems: 
A [dich loromethane-methanol (95: 5 v/v)] 
B [dichloromethane-methanol (90: 10 v/v)] 
C [petroleum spirit (bp 60-80°C)-ethyl acetate (80: 20 v/v)] 
Merck silica gel 60H (Art. 7729 and 9385) was used for short-column 
chromatography. 
172 
Chapter 7 Experimental 
Reverse phase HPLC was carried out with the following programmes: 
A Hypersil 5µ ODS (250x4 mm) column which was eluted with acetonitrile-0.1 M 
aqueous triethylammonium acetate (TEAA): 
Programme I: linear gradient 10: 90 to 40: 60 v/v over 15 min then isocratic 
elution; 
Programme II: linear gradient 5: 95 to 15: 85 v/v over 10 min then isocratic 
elution; 
or acetonitrile-water: 
Programme III: linear gradient 30: 70 to 80: 20 v/v over 10 min then isocratic 
elution. 
7.3 Solvents 
Acetonitrile, 1-methylimidazole, 1-methylpyrrolidine, pyridine and triethylamine 
were dried by heating, under reflux, over calcium hydride and then distilled. Diethyl 
ether, tetrahydrofuran (THF) and toluene were refluxed over sodium and distilled. 
1,2-Dichloroethane and dichloromethane were dried by heating, under reflux, over 
phosphorus pentoxide and distilled. 1,8-Diazabicyclo[5.4.0]undec-7-ene (DBU), N, N- 
dimethylformamide (DMF), 2,6-lutidine and N', N', N3, N3-tetramethylguanidine 
(TMG) were dried by heating with calcium hydride at 60°C and then distilled under 
reduced pressure. 
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7.4 Experimental for Chapter 3 






2-Chlorophenol (207.2 ml, 2.00 mol), phosphorus oxychloride (93.2 ml, 1.00 mol) 
and 1-methylimidazole (1 ml) were heated at 180°C for 15 h. Then the reaction 
mixture was distilled under reduced pressure. The title compound was collected at 
172-175°C/1 mmHg as a colourless liquid (265.0 g, 78%). 




Ammonium 4-methylphenyl H-phosphonate (342c) 




p-Cresol (43.26 g, 0.40 mol) and phosphorus trichloride (17.44 ml, 0.20 mol) were 
heated together, first under gentle reflux, and then reacted at 160°C. After 3 h, tert- 
butanol (21 ml) was added with stirring and the reactants were kept at the same 
temperature for a further period of 30 min. The products were evaporated under 
reduced pressure. The residue was cooled to 0°C (ice-water bath) and poured into a 
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stirred, cooled (ice-water bath) solution of concentrated aqueous ammonia (33%, d 
0.88,125 ml, 2.13 mol) in water (200 ml). The mixture was allowed to warm up to 
room temperature over a period of 1h and evaporated under reduced pressure, 
followed by co-evaporation with absolute ethanol (2x100 ml). The residue was 
suspended in absolute ethanol (400 ml) and filtered through a bed of Celite (30 g) and 
the filter bed was washed with ethanol (100 ml). The filtrate and washings were 
combined and evaporated under reduced pressure to ca. half volume until crystals 
appeared. Then diethyl ether (400 ml) was added dropwise over a period of Ih and 
stirring was continued for a further 2 h. The title compound was collected by filtration 
and dried in vacuo as white crystals (32.95 g, 87%). 
SH[(CD3)2SO]: 2.22 (3 H, s), 6.81 (1 H, d), 6.95 (2 H, d, J 8.4), 7.04 (2 H, d, J 8.3), 
7.49 (4 H, br). 
6c[(CD3)2SO]: 20.1,120.2 (Jc, p 4.8), 129.4,131.1,150.4 (d, J c, p 6.5). 






Diglycolic acid (266.9 g, 0.20 mol) and ammonium carbonate (19.2 g, 0.20 mol) were 
powdered and thoroughly mixed together. The mixture, contained in a round- 
bottomed flask, was heated at 230°C in an atmosphere of argon. Water formed in the 
reaction was removed continuously. After 5 h, the homogeneous liquid was cooled to 
70°C, and water (200 ml) was added. The resulting solution was stirred with activated 
charcoal (1.0 g) for 10 min and then filtered. The residue was washed with hot water 
(20 ml). The filtrate and washings were combined and cooled to 0°C (ice-water bath) 
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to give morpholine-3,5-dione as colourless crystals (15.7 g, plus a second crop of 4.0 
g after concentrating the original mother liquor to ca. 20 ml; total yield 19.7 g, 85%). 
Recrystallisation of this material from ethanol gave colourless needles, mp 141- 
142°C. 
SH[(CD3)2SO]: 4.25 (4 H, s), 11.40 (1 H, br). 
Sc[(CD3)2SO]: 66.3 (CH2), 171.0 (C). 





Dichloromethane (400 ml), followed by sodium perborate tetrahydrate (44.1 g, 0.286 
mol) were added to a cooled (ice-water bath), stirred solution of S-(2- 
cyanoethyl)isothiouronium chloride (83.0 g, 0.50 mol) in water (500 ml). A solution 
of sodium hydroxide (30.0 g, 0.75 mol) in water (250 ml) was then added dropwise 
over a period of 30 min to the cooled, stirred reaction mixture. After a further period 
of 5 h, the two layers were separated and the aqueous layer was back-extracted with 
dichloromethane (3x50 ml). The combined organic layers were dried (MgSO4) and 
evaporated under reduced pressure. The residue was recrystallised from methanol to 
give the title compound as colourless needles (38.5 g, 89%), mp 47-48°C. 
SH[CDC13]: 2.91 (4 H, m), 3.02 (4 H, m). 
Sc[CDCIi]: 17.1 (CH2), 32.5 (CH2), 119.2 (C). 
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A solution of bromine (4.82 g, 1.55 ml, 30.2 mmol) in dichloromethane (20 ml) was 
added dropwise over 30 min to a stirred, cooled (ice-water bath) mixture of di-(2- 
cyanoethyl) disulphide (4.51 g, 26.2 mmol), morpholine-3,5-dione (5.75 g, 50.0 
mmol), 2,6-lutidine (17.4 ml, 0.15 mol) and dichloromethane (20 ml). The resulting 
reactants were stirred for a further period of 1.5 h. Ice-cold methanol (50 ml) was 
then added dropwise over 30 min. The solid obtained was collected by filtration to 
give the title compound as an off-white solid (8.23 g, 82%). Recrystallisation of this 
material from ethyl acetate gave colourless needles, mp 121-122°C. 
SH[(CD3)2SO]: 2.77 (2 H, t, J 6.9), 3.10 (2 H, t, J 6.9), 4.49 (4 H, s). 




1-Methylpyrrolidine (52.0 ml, 0.50 mol) and chlorotrimethylsilane (12.7 ml, 0.10 
mol) were added to a stirred suspension of 5'-O-(dimethoxytrityl)thymidine (21.78 g, 
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40.00 mmol) in dry acetonitrile (200 ml) at room temperature. After 1 h, the reactants 
were cooled to 0°C (ice-water bath), and stirred for 10 min. Phosphorus oxychloride 
(5.59 ml, 60 mmol) was added, followed after a further period of 20 min by phenol 
(22.59 g, 0.24 mol). After 3 h, water (10 ml) was added and the reactants were 
allowed to warm up to room temperature and stirred overnight. The products were 
evaporated under reduced pressure. The residue was dissolved in dichloromethane 
(200 ml) and washed with saturated aqueous sodium hydrogen carbonate (2x 150 ml). 
The aqueous layers were back-extracted with dichloromethane (2x30 ml). The 
combined dichloromethane layers were dried (MgSO4) and concentrated under 
reduced pressure. The residue was then purified by short column chromatography on 
silica gel. The appropriate fractions, which were eluted with dichloromethane- 
methanol (99: 1 v/v) were evaporated to give the title compound as a colourless glass 
(20.359 g, 82.0%). 
SH[(CD3)2SO]: 1.74 (3 H, s), 2.20 (1 H, m), 2.35 (1 H, m), 3.25 (2 H, m), 3.76 (6 H, 
s), 3.97 (1 H, d, J 3.3), 4.34 (1 H, d, J 4.7), 5.38 (1 H, d, J 4.6, cx), 6.15 (1 H, t, J 





Chlorotrimethylsilane (3.2 ml, 25.2 mmol) was added to a stirred solution of 2'- 
deoxy-5'-O-(4,4'-dimethoxytrityl)-2-N-isobutyrylguanosine (6.08 g, 9.50 mmol) in 
dry pyridine (15 ml) at room temperature. After 30 min, the resulting mixture was 
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concentrated under reduced pressure to ca. half volume and more dry pyridine (10 
ml) was added. 2-Mesitylenesulphonylchloride (3.28 g, 15.00 mmol) and 1-methyl 
pyrrolidine (10 ml, 96 mmol) were then added to the cooled (ice-water bath), stirred 
solution. After 15 min, 2,5-dichlorophenol (4.89 g, 30.00 mmol) was added and, after 
a further period of 3 h, triethylamine (5 ml, 35.87 mmol) and water (5 ml) were 
added. The stirring reactants were then left overnight and poured into saturated 
aqueous sodium hydrogen carbonate (200 ml). The resulting mixture was extracted 
with dichloromethane (3x100 ml). The combined organic layers were further washed 
with saturated aqueous sodium hydrogen carbonate (2x 100 ml). The aqueous layers 
were back extracted with dichloromethane (2x20 ml). The organic layers were dried 
(MgSO4) and evaporated under reduced pressure. The residue was fractionated by 
short column chromatography on silica gel. The appropriate fractions, which were 
eluted with dichloromethane-methanol (99: 1 v/v) were evaporated under reduced 
pressure to give 2'-deoxy-6-O-(2,5-dichlorophenyl)-5'-O-(4,4'-dimethoxytrityl)-2-N- 
isobutyrylguanosine as a colourless glass (7.06 g, 94.7%). 
5H[(CD3)2SOJ: 0.92 (6 H, t, J 6.4), 2.38 (1 H, m), 2.82 (1 H, m), 2.91 (1 H, m), 3.12 
(I H, dd, J 2.9 and 10.2), 3.72 (6 H, s), 4.00 (1 H, m), 4.57 (1 H, m), 5.33 (1 H, d, J 
4.6, ex), 6.42 (1 H, t, J 6.4), 6.74 (2 H, d, J 8.9), 6.79 (2 H, d, J 8.9), 7.19 (7 H, m), 
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A solution of 2'-deoxy-6-O-(2,5-dichlorophenyl)-5'-O-(4,4'-dimethoxytrityl)-2-N- 
isobutyrylguanosine (3.76 g, 4.79 mmol) and crude levulinic anhydride (2.14 g, 10.00 
mmol) in dry pyridine (15 ml) was stirred at room temperature. After 16 h, the 
products were concentrated under reduced pressure and the residue was partitioned 
between dichloromethane (50 ml) and saturated aqueous sodium hydrogen carbonate 
(50 ml). The organic layer was separated, washed with saturated aqueous sodium 
hydrogen carbonate (2x50 ml), dried (MgSO4) and evaporated under reduced 
pressure. The residue was co-evaporated with toluene (2x20 ml) and then dissolved in 
dichloromethane (150 ml). Pyrrole (5 ml, 72.07 mmol) and then a solution of 
dichloroacetic acid (4.14 ml, 50.18 mmol) in dichloromethane (50 ml) were added to 
the cooled (ice-water bath), stirred solution. After 10 min, the products were 
extracted with saturated aqueous sodium hydrogen carbonate (100 ml). The aqueous 
layer was back extracted with dichloromethane (3x50 ml). The combined organic 
layers were dried (MgSO4) and evaporated under reduced pressure. The residue was 
fractionated by short column chromatography on silica gel. The appropriate fractions, 
which were eluted with dichloromethane-methanol (98: 2, v/v) were evaporated under 
reduced pressure to give the title compound as a colourless glass (2.52 g, 90.6%). 
8H[(CD3)2SO]: 0.95 (6 H, d, J 6.7), 2.15 (3 H, s), 2.47-2.56 (3 H, m), 2.76-2.88 (3 H, 
m), 3.02-3.10 (1 H, m), 3.58-3.69 (2 H, m), 4.09 (1 H, m), 5.09 (1 H, ex), 5.38 (1 H, 
m), 6.38 (1 H, dd, J 5.9 and 8.6), 7.47 (1 H, dd, J 2.5 and 8.6), 7.68 (1 H, d, J 8.6), 
7.77 (1 H, d, J 2.5), 8.63 (1 H, s), 10.36 (1 H, s, ex). 






ýo + H' ýO HNEt3 
382 
180 
Chapter 7 Experimental 
Ammonium 4-methylphenyl H-phosphonate (5.64 g, 29.82 mmol) and triethylamine 
(8.36 ml, 59.98 mmol) were co-evaporated with pyridine (20 ml) under reduced 
pressure. 5'-O-Dimethoxytrityl-4-O-phenylthymidine (6.21 g, 10.00 mmol) was 
added to the residue and co-evaporated with dry pyridine (2x20 ml). The residue was 
redissolved in anhydrous pyridine (60 ml) and cooled to -20°C (IMS-dry ice bath). 
Pivaloyl chloride (3.67 ml, 29.80 mmol) was added dropwise to the stirred solution 
over a period of 5 min. The resulting reactants were stirred at the same temperature 
for 60 min. Water (15 ml) was added and the mixture was allowed to warm up to 
room temperature over a period of 1 h. Then it was partitioned between 
dichloromethane (300 ml) and saturated aqueous sodium hydrogen carbonate (200 
ml). The layers were separated and the aqueous layer was back extracted with 
dichloromethane (2x30 ml). The combined organic layers were washed with 
triethylammonium phosphate buffer (0.5 M, pH 7.0,2x100 ml). The aqueous layers 
were back extracted with dichloromethane (2x50 ml). The dried (MgSO4) combined 
organic layers were concentrated to a volume of ca. 40 ml. Toluene (50 ml) was 
added to the residue and the mixture was applied to a short silica gel column. 
Evaporation of the appropriate fractions, which were eluted with methanol- 
dichloromethane (5: 95 v/v), gave the title compound as a colourless glass (7.50 g, 
95.4%). 
SH[(CD3)2SO): 1.13 (9 H, t, J 7.3), 1.69 (3 H, s), 2.24-2.31 (1 11, m), 2.42-2.46 (1 H, 
m), 3.00 (6 H, m), 3.75 (6 H, s), 4.13 (1 H, d, J 3.4), 4.76 (1 H, br), 5.79 (0.5 H, s), 
6.13 (1 H, t, J 6.3), 6.92 (4 H, dd, J 1.9 and 8.9), 7.20 (4 H, d, J 1.1), 7.30-7.48 (10.5 
H, m), 8.00 (1 H, s), 10.76 (1 H, br, ex). 
5p[(CD3)2SO]: 1.17 (1JP_H 585.596). 
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Ammonium 4-methylphenyl H-phosphonate (8.47 g, 44.70 mmol) and triethylamine 
(12.54 ml, 89.97 mmol) were co-evaporated with dry pyridine (20 ml). 5'-O- 
Dimethoxytrityl-4-N-benzoyl-2'-deoxycytidine (9.51 g, 15.01 mmol) was added to 
the residue and co-evaporated with dry pyridine (2x20 ml). The residue was 
redissolved in dry pyridine (90 ml) and cooled to -20°C (IMS-dry ice bath). Pivaloyl 
chloride (5.51 ml, 44.74 mmol) was added to the solution over a period of 5 min and 
the reaction mixture was stirred at the same temperature for 60 min before it was 
quenched by addition of water (20 ml). The mixture was then allowed to warm up to 
room temperature over a period of 1 h. The resulting clear solution was partitioned 
between dichloromethane (450 ml) and saturated aqueous sodium hydrogen carbonate 
(300 ml). The layers were separated and the aqueous layer was back extracted with 
dichloromethane (2x40 ml). The combined organic layers were washed with 
triethylammonium phosphate buffer (0.5 M, pH 7.0,2x100 ml). The two layers were 
separated, and the aqueous layers were back extracted with dichloromethane (2x50 
ml). The combined organic layers were dried (MgSO4) and concentrated to a volume 
of ca. 80 ml. Toluene (100 ml) was added to the residue. The resulting mixture was 
then fractionated by short column chromatography on silica gel. Evaporation of the 
appropriate fractions, which were eluted with dichloromethane-methanol (95: 5 v/v) 
gave the title compound as a colourless glass (11.45 g, 95.5%). 
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5H[(CD3)2SO]: 1.13 (9 H, t), 2.25-2.32 (1 H, m), 2.90-2.96 (6 H, m), 3.75 (6 H, s), 
4.12-4.17 (1 H, m), 4.71-4.77 (1 H, m), 5.81 (0.5 H, s), 6.13 (1 H, t, J 5.8), 6.91 (4 
H, d, J 8.9), 7.18 (1 H, d, J 7.5), 7.23-7.44 (8.5 H, m), 7.52 (2 H, t, J 7.3), 7.63 (1 H, 
t, J 7.4), 8.01 (2 H, d, J 7.2), 8.22 (1 H, d, J 7.5), 11.30 (1 H, br, ex). 
Ep[(CD3)2SO]: 1.17 ('Jp_H 585.70). 
Triethylammonium 2'-deoxy-6-O-(2,5-dichlorophenyl)-5'-O-(4,4'-dimethoxy 




Ammonium 4-methylphenyl H-phosphonate (8.47 g, 44.78 mmol) and triethylaminc 
(12.5 ml, 89.97 mmol) were co-evaporated with dry pyridine (20 ml). 2'-Deoxy-6-O- 
(2,5-dichlorophenyl)-5'-O-(4,4'-dimethoxytrityl)-2-N-isobutyrylguanosine (11.770 g, 
15.00 mmol) was added to the residue and co-evaporated with dry pyridine (2x20 
ml). The residue was redissolved in dry pyridine (90 ml) and cooled to -20°C (IMS- 
dry ice bath). Pivaloyl chloride (5.51 ml, 44.75 mmol) was added to the solution over 
a period of 5 min and the reaction mixture was stirred at the same temperature for 60 
min before it was quenched with water (20 ml). The mixture was then allowed to 
warm up to room temperature over a period of I h. The resulting clear solution was 
partitioned between dichloromethane (450 ml) and saturated aqueous sodium 
hydrogen carbonate (300 ml). The layers were separated and the aqueous layer was 
back extracted with dichloromethane (2x40 ml). The combined organic layers were 
washed with triethylammonium phosphate buffer (0.5 M, pH 7.0,2x 100 ml). The 
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layers were separated, and the aqueous layer was back extracted with 
dichloromethane (2x50 ml). The combined organic layers were dried (MgSO4) and 
concentrated to a volume of ca. 100 ml. Toluene (100 ml) was added to the residue. 
The mixture was then subjected to short column chromatography on silica gel. 
Evaporation of the appropriate fractions, which were eluted with dichloromethane- 
methanol (95: 5 v/v) gave the title compound as a colourless glass (13.2 18 g, 92.8%). 
5p[(CD3)2SOJ: 1.07. 





Levulinic acid (11.60 g, 0.10 mol) and N, N'-dicyclohexylcarbodi-imide (10.30 g, 
0.05 mol) were stirred in dry diethyl ether (100 ml) for 1.5 h at room temperature. 
Then the reaction mixture was filtered and the residue was washed with diethyl ether 
(2x20 ml). The filtrate and washings were combined and concentrated under reduced 
pressure to give the title compound as a pale yellow oil (11.0 g, ca. 100%) which 
solidified upon storing at -4°C. 
SH[CDC13]: 2.71-2.79 (4 H, m), 2.63-2.68 (4 H, m), 2.13 (6 H, s). 
v,,,, x (Nujol) 1717,1747,1820 cm-1 
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To a solution of 5'-O-dimethoxytrityl-4-O-phenylthymidine (3.16 g, 5.09 mmol), 
triethylamine (1.75 ml, 12.56 mmol) and 4-dimethylaminopyridine (0.09 g, 0.74 
mmol) in anhydrous dichloromethane (25 ml) was added levulinic anhydride (2.14 g, 
10 mmol) and stirring was continued for 1h at room temperature. Then the reaction 
mixture was poured into saturated aqueous sodium hydrogen carbonate (30 ml). The 
layers were separated and the aqueous layer was back extracted with dichloromethane 
(3x20 ml). The combined organic layers were dried (MgSO4) and evaporated to 
dryness under reduced pressure. The residue was then dissolved in dichloromethane 
(50 ml). Pyrrole (3.2 ml, 46.12 mmol) followed by dichloroacetic acid (2.5 ml, 30.30 
mmol) was added. After 15 min, the products were poured into saturated aqueous 
sodium hydrogen carbonate (30 ml). The organic layer was separated and further 
washed with saturated aqueous sodium hydrogen carbonate (30 ml). The aqueous 
layers were back extracted with dichloromethane (4x30 ml). The dried (MgSO4) 
combined organic layers were evaporated to dryness under reduced pressure. The 
residue was triturated with ethyl acetate (20 ml). The precipitate obtained was 
collected by filtration and washed with ethyl acetate (3 ml) to give the title compound 
as colourless crystals (1.74 g, 82.1 %). 
5H[(CD3)2SO]: 2.09 (3 H, d, J 0.7), 2.12 (3 H, s), 2.18-2.29 (1 H, m), 2.34-2.40 (1 H, 
m), 2.74 (2 H, t, J 6.5), 3.61-3.72 (2 H, m), 4.06 (1 H, m), 5.22 (1 H, t), 5.28 (1 H, t, 
ex, J 5.2), 6.13-6.16 (1 H, m), 7.18-7.20 (2 H, m), 7.26-7.32 (1 H, m), 7.43-7.48 (2 
H, m), 8.19 (1 H, d, J 0.9). 
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Sc[(CD3)2SO]: 12.08 (CH3), 27.69 (CH2), 29.51 (CH3), 37.40 (CH-), 37.77 (CHZ), 
61.12 (CH2), 74.68 (CH), 85.20 (CH), 85.72 (CH), 103.32 (C), 122.01 (CH), 125.75 












Triethylammonium 5'-O-dimethoxytrityl-4-O-phenylthymidine 3'-H-phosphonate 
(1.890 g, 2.40 mmol) and 3'-O-levulinyl-4-O-phenylthymidine (0.833 g, 2.00 mmol) 
were co-evaporated with anhydrous pyridine (2x8 ml) and then re-dissolved in dry 
pyridine (30 ml). After the mixture had been cooled to -40°C (IMS-dry ice bath), a 
solution of bis(2-chlorophenyl) phosphorochloridate (1.15 ml, 5.0 mmol) in dry 
dichloromethane (1.15 ml) was added dropwise to the stirred solution during a period 
of 5 min. The mixture was kept at the same temperature for 15 min and 4-[(2- 
cyanoethyl)sulphanyl]morpholine-3,5-dione (1.20 g, 6.00 mmol) was added. After 15 
min, pyridine-water (2 ml, 1: 1 v/v) was added and the resulting mixture was stirred at 
the same temperature for a further 5 min. The reaction mixture was then poured into 
triethylammonium phosphate buffer (0.5 M, pH 7.00,100 ml) and extracted with 
dichloromethane (2x50 ml). The combined organic layers were further washed with 
saturated aqueous sodium hydrogen carbonate (3x50 ml). The dichloromethane layer 
was dried (MgSO4) and concentrated under reduced pressure. The residue was then 
co-evaporated with toluene (2x15 ml) and redissolved in dry dichloromethane (30 
ml). To the cooled [-50°C (IMS-dry ice bath)], stirred solution, a solution of 
hydrogen chloride in dioxane (5.0 ml, 4 M) was added during 1 min. After 10 min, a 
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mixture of methanol and pyridine (4 ml, 1: 1 v/v) was added and the resulting mixture 
was maintained at the same temperature for a further 5 min. The reactants were then 
partitioned between dichloromethane (50 ml) and saturated aqueous sodium hydrogen 
carbonate (40 ml). The layers were separated and the organic layer was further 
washed with saturated aqueous sodium hydrogen carbonate (2x20 ml). The aqueous 
layers were back-extracted with dichloromethane (2x20 ml). The combined 
dichloromethane layers were dried (MgSO4) and evaporated under reduced pressure. 
The residue was then purified by short column chromatography on silica gel. 
Evaporation of the appropriate fractions, which were eluted with dichloromethane- 
methanol (96: 4 v/v) gave the title compound as a colourless glass (1.620 g, 93.0%). 
5p[(CD3)2SO1: 27.80,27.86. 
SH[(CD3)2SO]: 2.09-2.12 (9 H, m), 2.29-2.43 (3 H, m), 2.50-2.53 (3 H, m), 2.60 (1 
H, m), 2.74 (2 H, m), 2.96 (2 H, m), 3.11-3.21 (2 H, m), 3.63-3.71 (2 H, m), 4.22 (1 
H, m), 4.28 (1 H, s), 4.35 (2 H, m), 5.12 (1 H, s), 5.23 (1 H, m), 5.32 (1 H, m, ex), 
6.15 (2 H, m), 7.16-7.19 (4 H, m), 7.27-7.32 (2 H, m), 7.41-7.46 (4 H, m), 8.01 (1 H, 
d, J 5.5), 8.15 (1 H, d, J 4.7). 
Rt (programme III): 12.22 min. 
DMTr-Cp(s)Tp(s)T-Lev (396) 
HO-Tp(s)T-Lev (4.330 g, 5.00 mmol) and triethylammonium 5'-O-dimethoxytrityl-4- 
N-benzoyl-2'-deoxycytidine 3'-H-phosphonate (4.790 g, 6.00 mmol) were co- 
evaporated with dry pyridine (2x15 ml). The residue was then taken up with 
anhydrous pyridine (75 ml) and cooled to -40°C (IMS-dry ice bath). A solution of 
bis(2-chlorophenyl) phosphorochloridate (2.88 ml, 12.50 mmol) in dichloromethane 
(2.88 ml) was added over a period of 5 min. Aftcr 15 min, 4-[(2- 
cyanoethyl)sulphanyl]morpholine-3,5-dione (3.00 g, 15.00 mmol) was added. The 
reaction mixture was kept at the same temperature for 15 min, and then quenched 
with pyridine-water (5 ml, 1: 1 v/v). After 5 min, it was partitioned between 
triethylammonium phosphate buffer (0.5 M, pH 7.00,200 ml) and dichloromethane 
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(150 ml). The layers were separated and the aqueous layer was back extracted with 
dichloromethane (150 ml). The combined organic layers were then washed with 
saturated aqueous sodium hydrogen carbonate (3x100 ml). The dried (MgSO4) 
combined organic layers were concentrated under reduced pressure. The residue was 
then purified by chromatography on silica gel. Evaporation of the appropriate 
fractions, which were eluted with dichloromethane-methanol (96: 4 v/v) gave the title 
compound as a colourless foam (7.75 g, 95%). 
5p[(CD3)2SO]: 27.97,28.02,28.07,28.16,28.32,28.34. 
Rt (Programme III): 17.57,17.82 min. 
DMTr-Cp(s)Tp(s)T-OH (397) 
To a cooled (ice-water bath), solution of DMTr-Cp(s)Tp(s)T-Lev (4.89 g, 3.00 mmol) 
in pyridine (30.0 ml), a mixture of pyridine (60.0 ml), acetic acid (15.0 ml), hydrazine 
hydrate (0.93 ml, 30.0 mmol) and water (3.0 ml) was added. The reactants were 
stirred at the same temperature for 10 min. Then 2,4-pentanedione (4.4 ml) was 
added. The products were stirred for 15 min and then partitioned between water (200 
ml) and dichloromethane (200 ml) with care. The two layers were separated and the 
organic layer was further washed with saturated aqueous sodium hydrogen carbonate 
(3x 100 ml), dried (MgSO4) and evaporated to dryness under reduced pressure. The 
residue was then dissolved in dichloromethane (10 ml) and added dropwise to diethyl 
ether (300 ml) with stirring. After 30 min, the title compound was collected by 
filtration as a colourless solid (4.40 g, 95.6%). 
8p[(CD3)2SO]: 27.99,28.04,28.10,28.18,28.33,28.35. 
Rt (programme": 16.66,16.96 min. 
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HO-Cp(s)Tp(s)T-Lev (395) 
HO-Tp(s)T-Lev (2.600 g, 3.00 mmol) and triethylammonium 5'-O-dimethoxytrityl-4- 
N-benzoyl-2'-deoxycytidine 3'-H-phosphonate (2.870 g, 3.60 mmol) were co- 
evaporated with dry pyridine (2x10 ml). The residue was redissolved in anhydrous 
pyridine (45 ml) and cooled to -40°C (IMS-dry ice bath). A solution of bis(2- 
chlorophenyl) phosphorochloridate (1.73 ml, 7.50 mmol) in dichloromethane (1.73 
ml) was added to the reactants during a period of 5 min. After 15 min, 4-[(2- 
cyanoethyl)sulphanyl]morpholine-3,5-dione (1.800 g, 9.00 mmol) was added. The 
reaction mixture was stirred at the same temperature for 15 min, and then quenched 
with pyridine-water (3 ml, 1: 1 v/v). After 5 min, it was partitioned between 
triethylammonium phosphate buffer (0.5 M, pH 7.00,200 ml) and dichloromethane 
(2x 100 ml). The two layers were separated and the organic layer was further washed 
with saturated aqueous sodium hydrogen carbonate (3x80 ml). The dried (MgSO4) 
organic layer was concentrated under reduced pressure. The residue was co- 
evaporated with toluene (2x20 ml) and dissolved in dichloromethane (40 ml). After 
this solution had been cooled to -50°C (IMS-dry ice bath), a solution of hydrogen 
chloride in dioxane (4 M, 7.5 ml) was added during 1 min. After 10 min, pyridine- 
methanol (4 ml, 1: 1 v/v) was added and the reaction mixture was maintained at the 
same temperature for 5 min. Then it was poured into saturated aqueous sodium 
hydrogen carbonate (100 ml). The layers were separated and the organic layer further 
washed with saturated aqueous sodium hydrogen carbonate (3x 100 ml). The dried 
(MgSO4) organic layer was concentrated under reduced pressure. The residue was 
then purified by short column chromatography on silica gel. Evaporation of the 
appropriate fractions, which were eluted with dichloromethane-methanol (95: 5 v/v) 
gave the title compound as a colourless foam (3.68 g, 92.3%). 
5p[(CD3)2SO]: 27.91,27.96,28.15,28.33. 
Rt (Programme III): 12.63 min. 
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DMTr-Cp(s)Tp(s)Tp(H) (398) 
Ammonium 4-methylphenyl H-phosphonate (1.630 g, 8.61 mmol) was co-evaporated 
with methanol (15 ml) and triethylamine (2.40 ml, 17.2 mmol) under reduced 
pressure. DMTr-Cp(s)Tp(s)T-OH (4.400 g, 2.87 mmol) was added to the residue and 
co-evaporated with dry pyridine (2x10 ml). The residue was then redissolved in 
anhydrous pyridine (50 ml) and cooled to -40°C (IMS-dry ice bath). Pivaloyl 
chloride (1.06 ml, 8.61 mmol) was added over a period of 5 min and the mixture was 
maintained at the same temperature for 1 h. Water (20 ml) was added and the 
reactants were allowed to warm up to room temperature over a period of I h. They 
were then partitioned between triethylammonium phosphate buffer (0.5 M, pH 7.00, 
200 m]) and dichloromethane (200 ml). The layers were separated, and the organic 
layer was further washed with the same buffer (3x 100 ml). The dichloromethane 
layer was dried (MgSO4) and evaporated under reduced pressure. Toluene (100 ml) 
was added to the residue and the mixture was purified by short column 
chromatography on silica gel. Evaporation of the appropriate fractions, which were 
eluted with dichloromethane-methanol (80: 20 v/v) gave a colourless glass. This 
material was dissolved in dichloromethane (45 ml) and washed with 
triethylammonium phosphate buffer (0.5 M, pH 7.00,35 ml). The layers were 
separated and the dried (MgSO4) organic layer was concentrated under reduced 
pressure to give the title compound as a colourless froth (4.50 g, 92.4%). 
SP[(CD3)2S0]: 
-0.16 (1 P), 27.95,28.02,28.04,28.08,28.25,28.30 (2 P). 
Rt (Programme III): 10.50,10.62 min. 
DMTr-Cp(s)Tp(s)Tp(s)Cp(s)Tp(s)T-Lev (3105) 
DMTr-Cp(s)Tp(s)Tp(H) (3.000 g, 1.77 mmol) and HO-Cp(s)Tp(s)T-Lev (1.960 g, 
1.47 mmol) were co-evaporated with dry pyridine (2x5 ml) and the residue was taken 
up with dry pyridine (20 ml). After the solution had been cooled to -40°C (WS--dry 
ice), a solution of bis(2-chlorophenyl) phosphorochloridate in dichloromethane (2.1 
ml, 1: 1 v/v, 4.41 mmol) was added over a period of 5 min. After 15 min, 4-[(2- 
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cyanoethyl)sulphanyl]morpholine-3,5-dione (0.880 g, 4.41 mmol) was added and the 
reactants were maintained at the same temperature for another 15 min. Pyridine- 
water (2 ml, 1: 1 v/v) was added and the resulting reaction mixture was stirred at the 
same temperature for 5 min. The reactants were then partitioned between saturated 
aqueous sodium hydrogen carbonate (100 ml) and dichloromethane (100 ml). The 
two layers were separated and the organic layer was further washed with saturated 
aqueous sodium hydrogen carbonate (3x50 ml). The dried (MgSO4) organic layer was 
concentrated under reduced pressure. The residue was purified by short column 
chromatography on silica gel. The appropriate fractions, which were eluted with 
methanol-dichloromethane (5: 95-6: 94 v/v) were combined and evaporated to give 
the title compound as a colourless glass (4.00 g, 90.8%). 
5p[(CD3)2S0]: 27.96,28.06,28.15,28.31,28.37. 
Rt (Programme 111): 20.51,20.95 min. 
DMTr-Cp(s)Tp(s)Tp(s)Cp(s)Tp(s)T-OH (3106) 
To a solution of DMTr-Cp(s)Tp(s)Tp(s)Cp(s)Tp(s)T-Lev (3.890 g, 1.30 mmol) in 
pyridine (13 ml) cooled to 0°C (ice-water bath), a mixture of pyridine (26 ml), acetic 
acid (6.5 ml), water (1 ml) and hydrazine hydrate (0.42 ml, 13 mmol) was added. 
After 15 min, 2,4-pentanedione (1.9 ml) was added and the reaction mixture was 
stirred for a further 20 min. Then it was partitioned between dichloromethane (100 
ml) and saturated aqueous sodium hydrogen carbonate (100 ml) with care. The layers 
were separated and the organic layer was further washed with saturated aqueous 
sodium hydrogen carbonate (3x100 ml), dried (MgSO4) and concentrated under 
reduced pressure to dryness. The residue was dissolved in dichloromethane (5 ml) 
and added dropwise to diethyl ether (150 ml) with stirring. The title compound was 
collected as a solid (3.76 g, 92.0%) by filtration. 
5p[(CD3)2SO]: 27.952,28.050,28.126,28.305. 
Rt (Programme 111): 19.34,19.70 min. 
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DMTr-Cp(s)Tp(s) Tp(s)Cp(s)Tp(s)Tp(H) (3107) 
Ammonium 4-methylphenyl H-phosphonate (0.670 g, 3.52 mmol) was co-evaporated 
with methanol (5 ml) and triethylamine (7 ml) under reduced pressure. DMTr- 
Cp(s)Tp(s)Tp(s)Cp(s)Tp(s)T-OH (3.400 g, 1.17 mmol) was added to the residue and 
co-evaporated with dry pyridine (2x5 ml). The residue was then taken up with 
pyridine (15 ml) and cooled to -35°C (lMS-dry ice bath). Pivaloyl chloride (0.43 ml, 
3.52 mmol) was added to the cooled solution over a period of 5 min. After 1 h, water 
(5 ml) was added and the mixture was allowed to warm up to room temperature over 
a period of I h. Then the reactants were partitioned between dichloromethane (100 
ml) and triethylammonium phosphate buffer (0.5 M, pH 7.00,100 ml). The layers 
were separated and the organic layer was further washed with triethylammonium 
phosphate buffer (0.5 M, pH 7.00,3x 100 ml). To the dried (MgSO4) solution, toluene 
(100 ml) was added and the resulting mixture was purified by short column 
chromatography on silica gel. Evaporation of the appropriate fractions, which were 
eluted with methanol-dichloromethane (20: 80 v/v), gave an off-white glass. It was 
then dissolved in dichloromethane (50 ml) and washed with triethylammonium 
phosphate buffer (0.5 M, pH 7.00,15 ml) and dried (MgSO4). Solvent was removed 
under reduced pressure to give the title compound as a colourless froth (3.250 g, 
90.8%). 
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DMTr-Cp(H) (4.601 g, 5.76 mmol) and HO-G-Lev (2.786 g, 4.80 mmol) were co- 
evaporated with dry pyridine (2x5 ml) and the residue redissolved in anhydrous 
pyridine (60 ml). After this solution had been cooled to -50°C (IMS-dry ice bath), a 
solution of bis(2-chlorophenyl) phosphorochloridate in dichloromethane (6.86 ml, 1: 1 
v/v, 14.4 mmol) was added over a period of 5 min. The reactants were stirred for 15 
min followed by addition of 4-[(2-cyanoethyl)sulphanyl]morpholine-3,5-dione (1.920 
g, 9.6 mmol). After 15 min, pyridine-water (3 ml, 1: 1 v/v) was added and the 
resulting mixture was maintained at the same temperature for 5 min. The clear 
solution was then partitioned between dichloromethane (250 ml) and saturated 
aqueous sodium hydrogen carbonate (250 ml). The organic layer was separated, dried 
(MgSO4) and concentrated under reduced pressure. The residue was co-evaporated 
with toluene (3x50 ml) and dissolved in dichloromethane (150 ml). After this solution 
had been cooled to -50°C (IMS-dry ice bath), a solution of hydrogen chloride in 
dioxane (12.0 ml, 4 M) was added during I min. The reactants were kept at the same 
temperature for 15 min, and pyridine-methanol (10 ml, 1: 1 v/v) was added. After 5 
min, the products were poured into saturated aqueous sodium hydrogen carbonate 
(200 ml). The layers were separated and the organic layer was washed with saturated 
aqueous sodium hydrogen carbonate (2x100 ml). The dried (MgSO4) organic layer 
was concentrated under reduced pressure and the residue was purified by short 
column chromatography on silica gel. Evaporation of the appropriate fractions, which 
were eluted with dichloromethane-methanol (97: 3 v/v) gave the title compound as a 
colourless froth (4.995 g, 92.8%). 
5p[(CD3)2SO]: 27.23,27.40,27.49. 
Rt (programme HI): 12.84 min. 
HO-Gp(s)Cp(s)G-Lev (389) 
Triethylammonium 2'-deoxy-6-O-(2,5-dichlorophenyl)-5'-O-(4,4'-dimethoxytrityl)- 
2-N-isobutyrylguanosine 3'-H-phosphonate (2.895 g, 3.05 mmol) and HO-Cp(s)G- 
Lev (2.650 g, 2.54 mmol) were co-evaporated with dry pyridine (2x5 ml) and the 
residue was redissolved in anhydrous pyridine (30 ml). The solution was cooled to 
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-40°C (IMS-dry ice bath) followed by addition of a solution of bis(2-chlorophenyl) 
phosphorochloridate in dichloromethane (3.63 ml, 1: 1 v/v, 7.62 mmol) over a period 
of 5 min. After 15 min, 4-[(2-cyanoethyl)sulphanyl]morpholine-3,5-dione (1.520 g, 
7.62 mmol) was added and stirring was continued for 15 min at the same temperature. 
Then pyridine-water (2 ml, 1: 1 v/v) was added and the reaction mixture was stirred 
for 5 min. The resulting clear solution was partitioned between dichloromethane (120 
ml) and saturated aqueous sodium hydrogen carbonate (120 ml). The organic layer 
was separated, dried (MgSO4) and concentrated under reduced pressure. The residue 
was co-evaporated with toluene (3x30 ml) and dissolved in dichloromethane (60 ml). 
After this solution had been cooled to -50°C (IMS-dry ice bath), a solution of 
hydrogen chloride in dioxane (6.35 ml, 4 Al) was added during 1 min. After the 
reaction mixture had been stirred at the same temperature for 15 min, pyridine- 
methanol (2 ml, 1: 1 v/v) was added. After 5 min, the products were poured into 
saturated aqueous sodium hydrogen carbonate (100 ml). The two layers were 
separated and the organic layer was further washed with saturated aqueous sodium 
hydrogen carbonate (2x100 ml). The dried (MgSO4) organic layer was evaporated 
under reduced pressure. The residue was purified by short column chromatography 
on silica gel. The appropriate fractions, which were eluted with dichloromethane - 
methanol (97: 3 v/v), were concentrated under reduced pressure to give the title 
compound as a colourless glass (4.207 g, 91.0%). 
5p[(CD3)2SO]: 27.70,27.77,27.84,27.98. 
Rt (programme 111): 12.43 min. 
HO-Cp(s)Tp(s)Tp(s)Gp(s)Cp(s)G-Lev (3108) 
DMTr-Cp(s)Tp(s)Tp(H) (2.600 g, 1.53 mmol) and HO-Gp(s)Cp(s)G-Lev (2.110 g, 
1.280 mmol) were co-evaporated with dry pyridine (2x2 ml). The residue was 
redissolved in anhydrous pyridine (15 ml) and cooled to -40°C (IMS-dry ice bath). A 
solution of bis(2-chlorophenyl) phosphorochloridate in dichloromethane (1.83 ml, 1: 1 
v/v, 3.840 mmol) was then added over a period of 5 min. After 15 min, 4-[(2- 
cyanoethyl)sulphanyl]morpholine-3,5-dione (0.770 g, 3.84 mmol) was added. The 
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resulting mixture was maintained at the same temperature for 15 min, followed by 
addition of pyridine-water (2 ml, 1: 1 v/v). The reactants were stirred for 5 min and 
then partitioned between dichloromethane (100 ml) and saturated aqueous sodium 
hydrogen carbonate (100 ml). The layers were separated and the organic layer was 
dried (MgSO4) and concentrated under reduced pressure. The residue was co- 
evaporated with toluene (3x30 ml) and then dissolved in dichloromethane (30 ml). 
After this solution had been cooled to -50°C (IMS-dry ice bath), a solution of 
hydrogen chloride in dioxane (3.2 ml, 4 M) was added over I min. The resulting 
solution was maintained at the same temperature for a period of 15 min and then 
pyridine-methanol (3 ml, 1: 1 v/v) was added. The reactants were. stirred for 5 min 
and then poured into saturated aqueous sodium hydrogen carbonate (80 ml). The 
layers were separated and the organic layer was washed with saturated aqueous 
sodium hydrogen carbonate (2x50 ml). The dried (MgSO4) organic layer was 
concentrated under reduced pressure. The residue was then purified by short column 
chromatography on silica gel. Evaporation of the appropriate fractions, which were 
eluted with dichloromethane-methanol (95: 5 v/v) gave the title compound as a 
colourless glass (3.420 g, 88.5%). 
5p[(CD3)2SO]: 27.11,27.15,27.23,27.29,27.33,27.38,27.50,27.61,27.69. 
Rt (Programme II): 16.15. 
HO-Cp(s)Tp(s)Tp(s)Cp(s)Tp(s)Tp(s)Cp(s) Tp(s)Tp(s)Gp(s)Cp(s)G-Lev (HO-12-Lev) 
(3109) 
DMTr-Cp(s)Tp(s)Tp(s)Cp(s)Tp(s)Tp(H) (2.290 g, 0.749 mmol) and HO-Cp(s)Tp(s) 
Tp(s)Gp(s)Cp(s)G-Lev (1.880 g, 0.624 mmol) were co-evaporated with dry pyridine 
(2x2 ml) and the residue was redissolved in anhydrous pyridine (20 ml). After this 
solution had been cooled to -40°C (IMS-dry ice bath), a solution of bis(2- 
chlorophenyl) phosphorochloridate in dichloromethane (1.10 ml, 1: 1 v/v, 2.25 mmol) 
was added over a period of 5 min. The resulting solution was stirred at the same 
temperature for 15 min and then 4-[(2-cyanoethyl)sulphanyl]morpholine-3,5-dione 
(0.450 g, 2.25 mmol) was added. After the reactants had been maintained at the same 
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temperature for 15 min, pyridine-water (2 ml, 1: 1 v/v) was added. After 5 min, the 
reaction mixture was partitioned between dichloromethane (100 ml) and saturated 
aqueous sodium hydrogen carbonate (100 ml). The layers were separated and the 
organic layer was dried (MgSO4) and concentrated under reduced pressure. The 
residue was co-evaporated with toluene (3x40 ml) and dissolved in dichloromethane 
(50 ml). After it had been cooled to -50°C (IMS-dry ice bath), a solution of hydrogen 
chloride in dioxane (4 M, 1.60 ml) was added during I min. The resulting solution 
was maintained at the same temperature for a further period of 15 min before pyridine 
-methanol (2 ml, 1: 1 v/v) was added. After 5 min, the products were poured into 
saturated aqueous sodium hydrogen carbonate (80 ml). The layers were separated and 
the dichloromethane layer was further washed with saturated aqueous sodium 
hydrogen carbonate (2x50 ml). The dried (MgSO4) organic layer was concentrated 
under reduced pressure and the residue was purified by short column chromatography 
on silica gel. The appropriate fractions, which were eluted with dichloromethane- 
methanol (93: 7 v/v) were concentrated under reduced pressure to give the title 
compound as a colourless froth (2.990 g, 83.5%). 
SP[(CD3)2SO]: 27.79,27.92,27.99,28.06,28.13,28.33. 
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5'-O-Dimethoxytrityl-4-N-benzoyl-2'-deoxycytidine 3'-H-phosphonate (2.160 g, 
2.70 mmol) and 3'-O-levulinyl-4-O-phenylthymidine (0.938 g, 2.25 mmol) were co- 
evaporated with anhydrous pyridine (2x5 ml). The residue was redissolved in dry 
pyridine (30 ml) and cooled down to -40°C (IMS-dry ice bath). A solution of bis(2- 
chlorophenyl) phosphorochloridate in dichloromethane (3.20 ml, 1: 1 v/v, 6.75 mmol) 
was added over a period of 5 min, followed after 15 min by addition of 4-[(2- 
cyanoethyl)sulphanyl]morpholine-3,5-dione (1.350 g, 6.75 mmol). After 15 min, 
pyridine-water (2 ml, 1: 1 v/v) was added. The reaction mixture was maintained at the 
same temperature for 5 min and then partitioned between dichloromethane (100 ml) 
and saturated aqueous sodium hydrogen carbonate (100 ml). The layers were 
separated and the organic layer was washed with saturated aqueous sodium hydrogen 
carbonate (3x50 ml). The dried (MgSO4) organic layer was concentrated under 
reduced pressure. The residue was co-evaporated with toluene (2x 10 ml), dissolved in 
dichloromethane (30 ml) and cooled to -50°C (IMS-dry ice bath). A solution of 
hydrogen chloride in dioxane (4 M, 5.63 ml) was added. After a period of 15 min, 
pyridine-methanol (3 ml, 1: 1 v/v) was added. The reactants were stirred at the same 
temperature for 5 more min and then partitioned between saturated aqueous sodium 
hydrogen carbonate (100 ml) and dichloromethane (100 ml). The layers were 
separated and the organic layer was further washed with saturated aqueous sodium 
hydrogen carbonate (3x50 ml). The dried (MgSO4) dichloromethane layer was 
evaporated under reduced pressure. The residue was purified by short column 
chromatography on silica gel. Evaporation of the appropriate fractions, which were 
eluted with dichloromethane-methanol (97: 3 v/v) gave the title compound as a 
colourless froth (1.860 g, 94.0%). 
8H[(CD3)2SO]: 2.08 (6 H, m), 2.30 (3 H, m), 2.70 (3 H, m), 2.95 (2 H, m), 3.15 (2 H, 
m), 3.64 (2 H, br), 4.25 (2 H, m), 4.40 (2 H, m), 5.15 (1 H, m), 5.25 (2 H, m, 
including 1 ex H), 6.2 (2 H, m), 7.15 (2 H, d, J 8.2), 7.25-7.55 (7 H, m), 7.61 (1 H, t, 
J 7.38), 7.97 (3 H, m), 8.32 (1 H, br), 11.28 (1 H, s, ex). 
SP[(CD3)2SOJ: 27.10,27.17. 
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DMTr-Gp(s)Cp(s)T-Lev (399) 
DMTr-Gp(H) (2.300 g, 2.400 mmol) and HO-Cp(s)T-Lev (1.760 g, 2.0 mmol) were 
co-evaporated with dry pyridine (2x2 ml) and the residue was redissolved in pyridine 
(25 ml). After this solution had been cooled to -40°C (IMS-dry ice bath), a solution 
of bis(2-chlorophenyl) phosphorochloridate in dichloromethane (2.85 ml, 1: 1 v/v, 
6.00 mmol) was added over a period of 5 min. The resulting solution was maintained 
at the same temperature for 15 min and then 4-[(2-cyanoethyl)sulphanyl]morpholine- 
3,5-dione (1.200 g, 6.00 mol) was added. After 15 min, pyridine-water (2 ml, 1: 1 v/v) 
was added and the reactants were stirred at the same temperature for 5 min and then 
partitioned between dichloromethane (100 ml) and saturated aqueous sodium 
hydrogen carbonate (100 ml). The layers were separated and the organic layer was 
washed with saturated aqueous sodium hydrogen carbonate (2x50 ml). The dried 
(MgSO4) organic layer was concentrated under reduced pressure. The residue was 
purified by chromatography on silica gel. Evaporation of the appropriate fractions, 
which were eluted with dichloromethane-methanol (96: 4 v/v) gave the title 
compound as a colourless froth (3.440 g, 96.0%). 
5p[(CD3)2SO]: 27.73,28.20,28.31. 
Rt (Programme III): 19.08,19.41 min. 
DMTr-Gp(s)Cp(s)T-OH (3100) 
To a cooled (ice-water bath) solution of DMTr-Gp(s)Cp(s)T-Lev (2.790 g, 1.55 
mmol) in pyridine (16 ml), a mixture of pyridine (32 ml), acetic acid (8 ml), water 
(1.5 ml) and hydrazine hydrate (0.50 ml, 15.5 mmol) was added. After 15 min, 2,4- 
pentanedione (2.3 ml) was added and the resulting mixture was allowed to warm up 
to room temperature over a period of 15 min. The products were then poured into 
saturated aqueous sodium hydrogen carbonate (100 ml) with care and extracted with 
dichloromethane (150 ml). The layers were separated and the organic layer was 
washed with saturated aqueous sodium hydrogen carbonate (3x 100 ml). The dried 
(MgSO4) organic layer was evaporated under reduced pressure. The residue was 
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dissolved in dichloromethane (4 ml) and added dropwise to diethyl ether (150 ml) 
with stirring. The precipitate obtained was then collected by filtration and dried in 
vacuo to give the title compound as a colourless solid (2.420 g, 92.6%). 
5p[(CD3)2SO]: 28.32,28.18,27.76,27.70. 
Rt (Programme HI): 18.09 min. 
DMTr-Gp(s)Cp(s)Tp(H) (3101) 
Ammonium 4-methylphenyl H-phosphonate (0.720 g, 3.80 mmol), methanol (5 nil) 
and triethylamine (1.06 ml, 7.60 mmol) were co-evaporated under reduced pressure. 
DMTr-Gp(s)Cp(s)T-OH (2.150 g, 1.26 mmol) was added to the residue and the 
mixture was co-evaporated with dry pyridine (2x5 ml). The residue was re-dissolved 
in anhydrous pyridine (15 ml) and cooled to -30°C (IMS-dry ice bath). Pivaloyl 
chloride (0.47 ml, 3.80 mmol) was added during 5 min. The resulting reaction 
mixture was then maintained at the same temperature for I h. Water (5 ml) was added 
and the reactants were allowed to warm up to room temperature over a period of I h. 
The clear solution was then partitioned between dichloromethane (100 ml) and 
triethylammonium phosphate buffer (0.5 M, pH 7.00,80 ml). The layers were 
separated and the organic layer was washed with triethylammonium phosphate buffer 
(0.5 M, pH 7.00,3x80 ml). The dried (MgSO4) organic layer was mixed with toluene 
(50 ml) and the resulting mixture was purified by short column chromatography on 
silica gel. The appropriate fractions, which were eluted with dichloromethane- 
methanol (80: 20 v/v) were concentrated under reduced pressure and the residue was 
redissolved in dichloromethane (50 ml) and washed with triethylammonium 
phosphate buffer (0.5 M, pH 7.00,15 ml). The layers were separated, and the dried 
(MgSO4) organic layer was concentrated under reduced pressure to give DMTr- 
Gp(s)Cp(s)Tp(H) as a colourless froth (2.100 g, 89.5%). 
6p[(CD3)2SO]: 1.45 (1 P, JP_H 578.9), 27.52,27.57,27.67,27.92,28.09 (2 P). 
Rt (Programme III): 10.43 min. 
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HO-Gp(s)Cp(s)Tp(s)Cp(s)Tp(s)Tp(s)Cp(s)Tp(s)Tp(s)Cp(s)Tp(s)Tp(s)Gp(s)Cp(s)G- 
Lev (HO-15-Lev, 3110) 
DMTr-Gp(s)Cp(s)Tp(H) (0.932 g, 0.501 mmol) and HO-Cp(s)Tp(s)Tp(s)Cp(s) 
Tp(s)Tp(s)Cp(s)Tp(s)Tp(s)Gp(s)Cp(s)G-Lev (HO-12-Lev, 2.300 g, 0.400 mmol) were 
co-evaporated with dry pyridine (2x3 ml) and the residue was redissolved in 
anhydrous pyridine (15 ml). After this solution had been cooled to -40'C (rMS-dry 
ice bath), a solution of bis(2-chlorophenyl) phosphorochloridate in dichloromethane 
(0.57 ml, 1: 1 v/v, 1.20 mmol) was added over a period of 5 min. After 15 min, 4-[(2- 
cyanoethyl) su lph any] I morph ol ine-3,5-dione (0.240 g, 1.20 mmol) was added and the 
resulting mixture was stirred at the same temperature for a further period of 15 min. 
Pyridine-water (2 ml, 1: 1 v/v) was then added. After 5 min, the products were 
partitioned between dichloromethane (80 ml) and saturated aqueous sodium hydrogen 
carbonate (80 ml). The layers were separated and the dried (MgS04) organic layer 
was concentrated under reduced pressure. The residue was co-evaporated with 
toluene (3x3O ml) and then dissolved in dichloromethane (40 ml). After this solution 
had been cooled to -50'C (M4S-dry ice bath), a solution of hydrogen chloride in 
dioxane (4 M, 1.0 ml) was added during I min. The reactants were kept at the same 
temperature for a period of 20 min followed by addition of pyridine-methanol (2 ml, 
1: 1 v/v). After 5 min, the reaction mixture was poured into saturated aqueous sodium 
hydrogen carbonate (60 ml). The organic layer was separated and further washed with 
saturated aqueous sodium hydrogen carbonate (2x5O ml). The dried (MgS04) organic 
layer was concentrated under reduced pressure and the residue was purified by short 
column chromatography on silica gel. Evaporation of the appropriate fractions, which 
were eluted with dichloromethane-methanol (92: 8 v/v) gave the title compound as a 
colourless froth (2.570 g, 88.5%). 
5p[(CD3)2SOI: 27.79,27.89,28.05,28.36. 
DMTr-Tp(s)Tp(s)T-Lev (3102) 
Triethylammonium 5'-O-dimethoxytrityl-4-0-phenylthymidine Y-H-phosphonate 
(1.318 g, 1.680 mmol) and HO-Tp(s)T-Lev (1.210 g, 1.33 mmol) were co-evaporated 
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with dry pyridine (2x3 ml) and the residue was redissolved in anhydrous pyridine (20 
ml) and cooled to -40°C (MS-dry ice bath). A solution of bis(2-chlorophenyl) 
phosphorochloridate in dichloromethane (1.98 ml, 1: 1 v/v, 4.20 mmol) was added 
over a period of 5 min. After 15 min, 4-[(2-cyanoethyl)sulphanyl]morpholine-3,5- 
dione (0.840 g, 4.20 mmol) was added and the reactants were kept at the same 
temperature for 15 min. Pyridine-water (2 ml, 1: 1 v/v) was added and after 5 min, the 
reaction mixture was partitioned between dichloromethane (100 ml) and saturated 
aqueous sodium hydrogen carbonate (100 ml). The layers were separated. The 
organic layer was further washed with saturated aqueous sodium hydrogen carbonate 
(2x100 ml), dried (MgSO4) and concentrated under reduced pressure. The residue 
was then purified by short column chromatography on silica gel. Evaporation of the 
appropriate fractions, which were eluted with dichloromethane-methanol (97: 3 v/v) 
gave the title compound as a colourless glass (1.971 g, 91.6 %). 
8p[(CD3)2SO]: 27.99,28.03,28.12,28.30. 
DMTr-Tp(s)Tp(s)T-OH (3103) 
DMTr-Tp(s)Tp(s)T-Lev (1.520 g, 1.00 mmol) was dissolved in pyridine (5 ml) and 
cooled to 0°C (ice-water bath). A solution of hydrazine monohydrate (0.90 ml, 18.55 
mmol), acetic acid (9.2 ml, 0.161 mol) and water (2 ml) in pyridine (8.5 ml) was 
added to the cooled solution. After 10 min, 2,4-pentanedione (5 ml, 48.69 mmol) was 
added and the resulting mixture was allowed to warm up to room temperature over a 
period of 15 min. The reactants were then poured into saturated aqueous sodium 
hydrogen carbonate (90 ml) with care and extracted with dichloromethane (2x60 ml). 
The combined organic layers were further washed with saturated aqueous sodium 
hydrogen carbonate (2x 100 ml); the aqueous layers were back extracted with 
dichloromethane (2x50 ml). The combined organic layers were dried (MgSO4) and 
concentrated under reduced pressure. The residue was dissolved in dichloromethane 
(5 ml) and added dropwise to diethyl ether (200 ml) with stirring. After 30 min, the 
precipitates were collected by filtration and washed with diethyl ether (30 ml) to give 
the title compound as a colourless solid (2.679 g, 95.1 %). 
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8p[(CD3)2SO]: 27.99,28.04,28.12,28.28. 
DMTr-Tp(s)Tp(s)Tp(H) (3104) 
Ammonium 4-methylphenyl H-phosphonate (0.520 g, 2.76 mmol), methanol (3 ml) 
and triethylamine (0.77 ml, 5.52 mmol) were co-evaporated and to the residue was 
added DMTr-Tp(s)Tp(s)T-OH (1.403 g, 0.920 mmol). The mixture was then co- 
evaporated with dry pyridine (2x5 ml). The residue was redissolved in anhydrous 
pyridine (10 ml) and cooled to -30°C (IMS-dry ice bath). Pivaloyl chloride (0.34 ml, 
2.76 mmol) was added over a period of 5 min. The resulting mixture was stirred for 1 
h at the same temperature followed by addition of water (4 ml). The reactants were 
allowed to warm up to room temperature over a period of 1h and then partitioned 
between dichloromethane (70 ml) and triethylammonium phosphate buffer (0.5 M, 
pH 7.00,50 ml). The organic layer was separated and further washed with 
triethylammonium phosphate buffer (0.5 M, pH 7.00,2x50 ml). The dried (MgSO4) 
organic layer was mixed with toluene and the mixture was purified by short column 
chromatography on silica gel. The appropriate fractions, which were eluted with 
dichloromethane-methanol (80: 20 v/v) were evaporated under reduced pressure to 
give a colourless froth. This material was dissolved in dichloromethane (20 ml) and 
washed with triethylammonium phosphate buffer (0.5 M, pH 7.00,20 ml). The 
dichloromethane layer was separated, dried (MgSO4) and concentrated under reduced 
pressure to give the title compound as a colourless glass (1.406 g, 90.7%). 
5p[(CD3)2SO]: 1.52 (1 P), 27.97,28.03,28.06,28.13 (2 P). 
HO-Tp(s)Tp(s)Tp(s)Gp(s)Cp(s)Tp(s)Cp(s)Tp(s)Tp(s)Cp(s)Tp(s)Tp(s)Cp(s)Tp(s) 
Tp(s)Gp(s)Cp(s)G-Lev (HO-18-Lev, 3111) 
DMTr-Tp(s)Tp(s)Tp(H) (0.561 g, 0.33 mmol) and HO-Gp(s)Cp(s)Tp(s)Cp(s)Tp(s) 
Tp(s)Cp(s)Tp(s)Tp(s)Cp(s)Tp(s)Tp(s)Gp(s)Cp(s)G-Lev (HO-15-Lev, 1.860 g, 0.256 
mmol) were co-evaporated with dry pyridine (2x2 ml) and the residue redissolved in 
anhydrous pyridine (10 ml). After this solution had been cooled to -40°C (IMS-dry 
ice bath), a solution of bis(2-chlorophenyl) phosphorochloridate in dichloromethane 
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(0.37 ml, 1: 1 v/v, 0.768 mmol) was added over a period of 4 min. After 15 min, 4-[(2- 
cyanoethyl)sulphanyl]morpholine-3,5-dione (0.154 g, 0.768 mmol) was added and 
the resulting mixture was maintained at the same temperature for 15 min. Water- 
pyridine (1 ml, 1: 1 v/v) was then added. After 5 min, the products were partitioned 
between dichloromethane (60 ml) and saturated aqueous sodium hydrogen carbonate 
(60 ml). The organic layer was separated, dried (MgSO4) and concentrated under 
reduced pressure. The residue was co-evaporated with toluene (3x20 ml) and 
dissolved in dichloromethane (30 ml). After this solution had been cooled to -50°C 
(IMS-dry ice bath), a solution of hydrogen chloride in dioxane (4 M, 0.64 ml) was 
added during 1 min and the reactants maintained at the same temperature for 15 min. 
Then pyridine-methanol (2 ml, 1: 1 v/v) was added and the resulting solution was 
stirred for 5 more min. Then it was poured into saturated aqueous sodium hydrogen 
carbonate (50 ml). The organic layer was separated and further washed with saturated 
aqueous sodium hydrogen carbonate (2x50 ml), dried (MgSO4) and concentrated 
under reduced pressure. The residue was then purified by short column 
chromatography on silica gel. The appropriate fractions, which were eluted with 
dichloromethane-methanol (92: 8 v/v), were evaporated under reduced pressure to 




2-N-isobutyrylguanosine 3'-H-phosphonate (3.651 g, 3.844 mmol) and HO-Cp(s)G- 
Lev (3.340 g, 3.203 mmol) were co-evaporated with dry pyridine (2x5 ml) and the 
residue was redissolved in anhydrous pyridine (40 ml). After this solution had been 
cooled to -40°C (IMS-dry ice bath), a solution of bis(2-chlorophenyl) 
phosphoroch lori date in dichloromethane (4.47 ml, 1: 1 v/v, 9.609 mmol) was added 
over a period of 5 min. After 15 min, 4-[(2-cyanoethyl)sulphanyl]morpholine-3,5- 
dione (1.924 g, 9.609 mmol) was added and the resulting mixture was stirred for 15 
min. Pyridine-water (3 ml, 1: 1 v/v) was added and the reactants were kept for 5 more 
min. Then the products were partitioned between dichloromethane (180 ml) and 
203 
Chapter 7 Experimental 
saturated aqueous sodium hydrogen carbonate (180 ml). The layers were separated 
and the organic layer was further washed with saturated aqueous sodium hydrogen 
carbonate (2x150 ml). The dried (MgSO4) organic layer was concentrated under 
reduced pressure. The residue was purified by short column chromatography on silica 
gel. The appropriate fractions, which were eluted with dichloromethane-methanol 
(97: 3 v/v) were evaporated under reduced pressure to give the title compound as a 
colourless froth (5.916 g, 94.3%). 
SP[(CD3)2SO]: 2.82 (1 P), 28.08,28.19,28.38,28.45. 
DMTr-Gp(s)Cp(s)G-OH (391) 
DMTr-Gp(s)Cp(s)G-Lev (2.300 g, 1.20 mmol) was dissolved in pyridine (6 ml) and 
cooled to 0°C (ice-water bath). To this solution was added a mixture of pyridine (10 
ml), acetic acid (6 ml), hydrazine hydrate (0.62 ml, 12.0 mmol) and water (1.3 ml). 
After 15 min, 2,4-pentanedione (4.3 ml) was added and the resulting solution was 
allowed to warm up to room temperature over a period of 15 min. The products were 
then partitioned between dichloromethane (100 ml) and saturated aqueous sodium 
hydrogen carbonate (100 ml). The aqueous layer was back extracted with 
dichloromethane (50 ml). The combined organic layers were further washed with 
saturated aqueous sodium hydrogen carbonate (3x100 ml). The aqueous layers were 
back extracted with dichloromethane (50 ml). The combined organic layers were 
dried (MgSO4) and concentrated under reduced pressure to dryness. The residue was 
dissolved in dichloromethane (5 ml) and added dropwise to diethyl ether (220 ml) 
with stirring. After 30 min, the precipitate were collected by filtration and dried in 
vacuo to give the title compound as a colourless solid (2.121 g, 95.0%). 
8p[(CD3)2S0]: 27.68,27.74,27.86,27.88. 
DMTr-Gp(s)Cp(s)Gp(H) (392) 
Ammonium 4-methylphenyl H-phosphonate (0.482 g, 2.55 mmol), methanol (3 ml) 
and triethylamine (0.71 ml, 5.1 mmol) were co-evaporated and to the residue was 
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added DMTr-Gp(s)Cp(s)G-OH (1.581 g, 0.850 mmol). The mixture was co- 
evaporated with dry pyridine (2x5 ml). The residue was redissolved in anhydrous 
pyridine (15 ml) and cooled to -30°C (IMS-dry ice bath). Pivaloyl chloride (0.31 ml, 
2.55 mmol) was added over 5 min. The resulting mixture was then stirred at the same 
temperature for 1 h. Water (5 ml) was added and the reactants were allowed to warm 
up to room temperature over a period of I h. Then the clear solution was partitioned 
between dichloromethane (90 ml) and triethylammonium phosphate buffer (0.5 M, 
pH 7.00,80 ml). The organic layer was separated and further washed with 
triethylammonium phosphate buffer (0.5 M, pH 7.00,2x80 ml). The dried (MgSO4) 
organic layer was mixed with toluene (50 ml) and the mixture was purified by short 
column chromatography on silica gel. The appropriate fractions, which were eluted 
with dichloromethane-methanol (80: 20 v/v) were evaporated under reduced pressure 
to give a colourless froth. This material was dissolved in dichloromethane (30 ml) 
and washed with triethylammonium phosphate buffer (0.5 M, pH 7.00,25 ml). The 
organic layer was separated, dried (MgSO4) and concentrated under reduced pressure 
to yield the title compound as a colourless glass (1.543 g, 89.6%). 
SP[(CD3)2SO]: 2.82 (1 P, JP_H 507.7), 28.08,28.19,28.38,28.45 (2 P). 
HO-Gp(s)Cp(s)Gp(s)Tp(s)Tp(s)Tp(s)Gp(s)Cp(s)Tp(s)Cp(s)Tp(s)Tp(s)Cp(s)Tp(s) 
Tp(s)Cp(s)Tp(s)Tp(s)Gp(s)Cp(s)G-Lev (HO-21-Lev, 3112) 
DMTr-Gp(s)Cp(s)Gp(H) (0.273 g, 0.135 mmol) and HO-Tj)(s)Tp(s)Tp(s)Gp(s)Cp(s) 
Tp(s)Cp(s)Tp(s)Tp(s)Cp(s)Tp(s)Tp(s)Cp(s)Tp(s)Tp(s)Gp(s)Cp(s)G-Lev (HO-18-Lev, 
0.861 g, 0.100 mmol) were co-evaporated with dry pyridine (2 nal) and the residue 
was redissolved in anhydrous pyridine (10 ml). After this solution had been cooled to 
-40'C (IMS-dry ice bath), a solution of bis(2-chlorophenyl) phosphorochloridate in 
dichloromethane (0.19 ml, 1: 1 v/v, 0.400 mmol) was added during 3 min. The 
reactants were then kept at the same temperature for 15 min, and then 4-1(2- 
cyanoethyl) su lphanyl I morphol ine-3,5 -d i one (0.060 g, 0.300 mmol) was added. After 
15 min, pyridine-water (I ml) was added and the reaction mixture was maintained at 
the same temperature for a further 5 min. The clear solution was partitioned between 
dichloromethane (50 ml) and saturated aqueous sodium hydrogen carbonate (50 ml). 
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The organic layer was separated, dried (MgSO4) and concentrated under reduced 
pressure. The residue was co-evaporated with toluene (3x20 ml) and dissolved in 
dichloromethane (30 ml). After this solution had been cooled to -50°C (IMS-dry ice 
bath), a solution of hydrogen chloride in dioxane (4 M, 0.30 ml) was added. After 15 
min, pyridine-methanol (2 ml, 1: 1 v/v) was added and the reactants were maintained 
at the same temperature. After 5 min, the products were poured into saturated 
aqueous sodium hydrogen carbonate (40 ml). The organic layer was separated and 
further washed with saturated aqueous sodium hydrogen carbonate (2x30 ml). The 
dried (MgSO4) organic layer was concentrated under reduced pressure and the residue 
was purified by short column chromatography on silica gel. Evaporation of the 
appropriate fractions, which were eluted with dichloromethane-methanol (92: 8 v/v) 
gave the title compound as a colourless froth (0.878 g, 85.2%). 
6p[(CD3)2S0}: 27.10,27.37,27.61,27.66. 
7.5 Experimental for Chapter 4 
N-[(2-Cyanoethyl)sulphanyl]succinimide (420a) 
420a 
N-Bromosuccinimide (17.8 g, 0.1 mol) and di-(2-cyanoethyl) disulphide (17.2 g, 97.2 
mmol) were heated, under reflux, in dry dichloroethane (30 ml) under argon for 2 h. 
After the reaction mixture had been cooled down to room temperature, n-hexane (300 
ml) was added and the mixture was stirred for 10 min. The upper layer was decanted, 
and the oily residue was triturated with ethyl acetate (20 ml) for 10 min. The solid 
obtained was collected by filtration and washed with diethyl ether (70 nil) to give the 
title compound as an off-white solid (12.4 g, 67.3%). (Found, in material 
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recrystallised from absolute ethanol: C, 45.8; H, 4.4; N, 15.2. C7H8N202S requires: C, 
45.64; H, 4.38; N, 15.21 %), mp 110-112°C. 
6H[(CD3)2SO]: 2.71 (4 H, s), 2.75 (2 H, t, J 6.9), 3.02 (2 H, t, J 6.9). 
Sc[(CD3)2SO]: 17.9 (CH2), 28.7 (CH2), 32.8 (CHZ), 119.2 (C), 177.9 (C). 
HO-Cp(s)G-Lev (386) 
Triethyl ammonium 5'-O-dimethoxytrityl-4-N-benzoyl-2'-deoxycytidine 3'-H- 
phosphonate (1.917 g, 2.40 mmol) and 2'-deoxy-6-0-(2,5-dichlorophcnyl)-2-N- 
isobutyryl-3'-O-Ievulinylguanosine (1.161 g, 2.0 mmol) were co-evaporated with dry 
pyridine (2 ml) and the residue was redissolved in dry pyridine (10 ml) at room 
temperature. To the solution was added dropwise, over a period of 5 min, a solution 
of N-[(2-cyanoethyl)sulphanyllsuccinimide (0.921 g, 5.00 mmol) and diphenyl 
phosphoroch I ori date (1.04 ml, 5.02 mmol) in dry pyridine (12 ml). After 15 min, 
water (2 ml) was added. The reaction mixture was stirred for a further 5 min and then 
partitioned between dichloromethane (100 ml) and saturated aqueous sodium 
hydrogen carbonate (100 ml). The organic layer was separated and further washed 
with saturated aqueous so(hum hydrogen carbonate (2x6O ml). The dried (MgSO4) 
organic layer was concentrated under reduced pressure. The residue was co- 
evaporated with toluene (2x4O ml) and dissolved in dichloromethane (50 ml). After 
this solution had been cooled to O'C (ice-water bath), pyrrole (1.65 ml, 23.78 mmol) 
was added followed by addition of a solution of dichloroacetic acid (1.65 ml, 20.00 
mmol) in dichloromethane (20 ml). After 10 min, the reaction mixture was poured 
into saturated aqueous sodium hydrogen carbonate (100 ml). The organic layer was 
separated and further washed with saturated aqueous sodium hydrogen carbonate 
(100 ml). The dried (MgS04) organic layer was concentrated under reduced pressure. 
The residue was fractionated by short column chromatography on silica gel: 
evaporation of the appropriate fractions, which were eluted with dichloromcthane- 
methanol (97: 3 v/v) gave HO-Cp(s)G-Lev as a colourless glass (1.968 g, 94.4%). 
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5H[(CD3)2SO): 0.95 (6 H, m), 2.14 (3 H, s), 2.27-2.33 (1 H, m), 3.59-3.62 (2 H, m), 
4.19-4.22 (1 H, m), 4.33-4.37 (1 H, m), 4.43-4.48 (2 H, m), 5.06-5.09 (1 H, m), 
5.22-5.25 (1 H, m, ex), 5.52 (1 H, m), 6.17 (1 H, m), 6.46 (1 H, m), 7.38-7.53 (4 H, 
m), 7.60-7.72 (3 H, m), 8.01 (2 H, t), 8.30-8.36 (1 H, m), 8.56 (1 11, d, J 2.8), 10.35 
(1 H, s, ex), 11.26 (1 H, s, ex). 
8p[(CD3)2SOJ: 27.21,27.48. 
Rf (System A): 0.21. 
HO-Gp(s)Cp(s)G-Lev (389) 
Triethylammonium 2'-deoxy-6-0-(2,5-dichlorophenyl)-5'-O-(4,4'-diniethoxytrityl)- 
2-N-isobutYrylguanosine Y-H-phosphonate (2.660 g, 2.80 mmol) and HO-Cp(s)G- 
Lev (2.085 g, 2.00 mmol) were co-evaporated with dry pyridine (2 ml). The residue 
was taken up with dry pyridine (10 ml). To the solution was added dropwise, over a 
period of 5 min, a solution of diphenyl phosphorochloridate (1.04 ml, 5.02 mmol) and 
N-[(2-cyanoethyl)sulphanyl]succinimide (0.921 g, 5.00 mmol) in pyridine (30 ml) at 
room temperature. After 20 min, water (2 ml) was added and the reaction mixture 
was allowed to stir for a further 5 min. The products were then poured into saturated 
aqueous sodium hydrogen carbonate (100 ml), and extracted with dichloromethane 
(100 ml). The organic layer was separated and further washed with saturated aqueous 
sodium hydrogen carbonate (2x6O ml). The dried (MgS04) organic layer was 
concentrated under reduced pressure. The residue was co-evaporated with toluene 
QX50 ml) and then redissolved in dichloromethane (50 nil). After the solution had 
been cooled to O'C (ice-water bath), pyrrole (1.65 ml, 23.78 mmol) was added, 
followed by the addition of a solution of dichloroacetic acid (1.65 ml, 20.00 mmol) in 
dichloromethane (20 ml). The reaction mixture was allowed to stir at the same 
temperature for a further 15 min and then poured into saturated aqueous sodium 
hydrogen carbonate (100 ml). The organic layer was separated and further washed 
with saturated aqueous sodium hydrogen carbonate (100 ml). The dried (MgS04) 
organic layer was concentrated under reduced pressure. The residue was purified by 
short column chromatography on silica gel. Evaporation of the appropriate fractions, 
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which were eluted with dichloromethane-methanol (97: 3 v/v) gave the title 
compound as a colourless foam (3.153 g, 95.2%). 
SP[(CD3)2SO]: 27.70,27.77,27.83,27.96. 
Rf (System A): 0.18. 
HO-Tp(s)T-Lev (387) 
Triethyl ammonium 5'-O-dimethoxytrityl-4-0-phenylthymidine Y-H-phosplionate 
(2.829 g, 3.6 mmol) and 3'-O-Ievulinyl-4-0-phenylthymidine (1.249 g, 3.0 niniol) 
were co-evaporated with anhydrous pyridine (2 nil) and the residue was redissolved 
in dry pyridine (15 ml). To this solution was added, dropwise over a period of 5 min, 
a solution of N-[(2-cyanoethyl)sulphanyl]succinimide (1.382 g, 7.50 niniol) and 
diphenyl phosphorochloridate (1.55 ml, 7.48 mmol) in dry pyridine (18 ml) at room 
temperature. After 15 min, water (2 ml) was added and the resulting mixture %vas 
stirred for a further 5 min. The products were poured into saturated aqueous sodium 
hydrogen carbonate (150 ml), and extracted with dichloromethane (150 ml). The 
organic layer was separated and further washed with saturated aqueous sodium 
hydrogen carbonate (2x9O ml). The dried (MgS04) organic layer was concentrated 
under reduced pressure. The residue was co-evaporated with toluene (2x6O nil) and 
dissolved in dichloromethane (80 nil). After this solution had been cooled to O"C 
(ice-water bath), pyrrole (2.48 nil, 35.7 mmol) was added followed by addition of a 
solution of dichloroacetic acid (2.48 ml, 30.0 mmol) in dichloromethane (30 nil). 
After 10 min, the reaction mixture was poured into saturated aqueous sodium 
hydrogen carbonate (150 nil). The organic layer was separated and furthcr washed 
with saturated aqueous sodium hydrogen carbonate (150 nil), dried (MgSO. 1) and 
concentrated under reduced pressure. The residue was fractionated by short colunin 
chromatography on silica gel: evaporation of the appropriate fractions, which were 
eluted with dichloromethane-methanol (97: 3 v/v) gave F10-TI)(s)T-Lev as a 
colourless foam (2.404 g, 92.5%). 
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SH[(CD3)2SO): 2.10 (9 H, m), 2.28-2.44 (3 H, m), 2.57-2.62 (1 H, m), 2.73 (2H, Ili), 
2.91-2.97 (2 H, m), 3.10-3.20 (2 H, m), 3.65-3.71 (2 H, m), 4.21-4.33 (2 H, m), 
4.36-4.40 (2 H, m), 5.12 (1 H, br), 5.23-5.29 (1 H, m), 5.30-5.33 (1 H, m, ex), 6.14- 
6.19 (2 H, m), 7.16-7.19 (4 H, m), 7.26-7.31 (2 H, m), 7.40-7.47 (4 H, m), 8.00 (1 H, 
dd, J 0.9 and 5.3), 8.15 (1 H, dd, J 0.9 and 4.7). 
SP[(CD3)2SO]: 27.81,27.86. 
Rf (System A): 0.22. 
DMTr-Cp(s)Tp(s)T-Lev (396) 
Triethylammonium 5'-O-dimethoxytrityl4-N-benzoyl-2'-deoxycytidinc 3'-H- 
phosphonate (3.355 g, 4.20 mmol) and HO-Tp(s)T-Lev (2.598 g, 3.00 mmol) were 
co-evaporated with dry pyridine (2 ml). The residue was then redissolved in 
anhydrous pyridine (15 ml). To the solution was added dropwise, over a period of 5 
min at room temperature, a solution of diphenyl phosphoroch lori date (1.55 ml, 7.48 
mmol) and N-[(2-cyanoethyl)sulphanyllsuccinimide (1.382 g, 7.50 mmol) in pyridine 
(18 ml). After a period of 20 min, water (2 ml) was added and the resulting mixture 
was stirred for 5 min. Then the reaction mixture was partitioned between 
dichloromethane (150 ml) and saturated aqueous sodium hydrogen carbonate (150 
ml). The two layers were separated; the organic layer was further washed with 
saturated aqueous sodium hydrogen carbonate (2xlOO ml). The dried (MgS04) 
organic layer was concentrated under reduced pressure. The residue was then 
fractionated by short column on silica gel. Evaporation of the appropriate fractions, 
which were eluted with dichloromethane-methanol (97: 3 v/v) gave DMTr- 
Cp(s)Tp(s)T-Lev as a colourless foam (4.526 g, 92.5%). 
öp[(CD3)2S0]: 27.97,28.02,28.07,28.16,28.32,28.34. 
Rf (System A): 0.24. 
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DMTr-Cp(s)Tp(s)T-OH (397) 
To a cooled (ice-water bath) solution of DMTr-Cp(s)7p(s)T-Lev (8.153 g, 5.00 
mmol) in pyridine (30 ml) was added a solution of hydrazine monohydrate (2.44 nil, 
50.30 mmol), acetic acid (25.0 nil, 0.437 mol) and water (5 nil) in pyridine (20 nil). 
After 10 min, 2,4-pentanedione (13.2 nil, 0.128 mol) was added. The reaction mixture 
was allowed to warm up to room temperature. After 15 min, it was poured into 
saturated aqueous sodium hydrogen carbonate (200 nil) with care and extracted with 
dichloromethane (2xl3O nil). The combined organic layers were further washed with 
saturated aqueous sodium hydrogen carbonate (2xlOO nil). The aqueous layers were 
back extracted with dichloromethane (2X5O nil). The combined dried (MgSO4) 
organic layers were evaporated to dryness under reduced pressure. The residue was 
dissolved in dichloromethane (10 nil) and added dropwise to diethyl ether (350 nil) 
with stirring. After 30 min, the solid obtained was collected by filtration and washed 
with diethyl ether (30 nil) to give the title compound as a colourless solid (7.387 g, 
96.4%). 
5p[(CD3)2S0]: 27.98,28.03,28.09,28.16,28.31. 
Rf (System A): 0.17. 
DMTr-Cp(s)Tp(s)Tp(H) (398) 
Ammonium 4-methylphenyl H-phosphonate (2.270 g, 12.00 mmol) and triethylamine 
(4.60 ml, 33.00 mmol) were co-evaporated with anhydrous pyridine (10 nil). DMTr- 
Cp(s)Tp(s)T-OH (6.13 g, 4.0 mmol) was added to the residue and the mixture was co- 
evaporated with dry pyridine (10 ml). The residue was then redissolved in pyridine 
(50 ml) and cooled to -20'C (IMS-dry ice bath). Pivaloyl chloride (1.48 fill, 12.02 
mmol) was added to the cooled solution over a period of 5 min. After I h, water (10 
ml) was added and the reactants were allowed to warm up to room temperature over a 
period of I h. The resulting clear solution was then partitioned between 
dichloromethane (150 mi) and saturated aqueous sodium hydrogen carbonate (90 nil). 
The organic layer was separated and the aqueous layer was back extracted with 
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dichloromethane (2x30 ml). The combined organic layers were washed with 
triethylammonium phosphate buffer (2x100 ml, 0.5 M, pH 7.0), dried (MgSO4) and 
concentrated to a volume of ca. 30 ml under reduced pressure. Toluene (40 ml) was 
added and the mixture was then purified by short column chromatography on silica 
gel. Evaporation of the appropriate fractions, which were eluted with 
dichloromethane-methanol (80: 20 v/v), gave a colourless foam. This material was 
then dissolved in dichloromethane (100 ml) and washed with triethylammonium 
phosphate buffer (50 ml, 0.5 M, pH 7.0). The dichloromethane layer was separated, 
dried (MgSO4) and concentrated under reduced pressure to give the title compound as 
a colourless glass (6.240 g, 91.9%). 
5p[(CD3)2S0]: 1.21 (1 P, JH_p 586.280), 27.91,27.94,27.99,28.03,28.05,28.14 (2 
P). 
HO-Cp(s)Tp(s)Tp(s)Gp(s)Cp(s)G-Lev (HO-6-Lev, 3108) 
DMTr-Cp(s)Tp(s)Tp(H) (4.076 g, 2.40 mmol) and HO-Gp(s)Cp(s)G-LCv (3.312 g, 
2.00 mmol) were co-evaporated with dry pyridine (2 ml). The residue was then 
redissolved in dry pyridine (20 ml) and cooled to O'C (ice-water bath). To this 
solution was added, over a period of 30 sec a solution of pivaloyl chloride (0.62 ml, 
5.03 mmol) in dichloromethane (0.62 ml). After 15 min, well powdered N-[(2- 
cyanoethyl)sulphanyl]succinimide (0.921 g, 5.00 mmol) was added. The reaction 
mixture was then allowed to warm up to room temperature over a period of 25 min 
and then partitioned between dichloromethane (100 ml) and saturated aqueous 
sodium hydrogen carbonate (100 ml). Triethylammonium phosphate buffer (10 ml, 
0.5 M, pH 7.0) was added if emulsion persisted. The organic layer was separated and 
further washed with triethyl ammonium phosphate buffer (100 ml, 0.5 A pH 7.0). 
The dried (MgS04) organic layer was concentrated under reduced pressure. Tile 
residue was co-evaporated with toluene (3x5O ml) and taken up with dichloromethane 
(60 ml) and cooled to O'C (ice-water bath). Pyrrole (1.66 ml, 23.93 mmol), followed 
by the a solution of dichloroacetic acid (3.32 ml, 40.24 mmol) in dichloromethane (20 
ml) was added. After 15 min, the reaction mixture was washed with saturated 
aqueous sodium hydrogen carbonate (2XIOO ml). The organic layer was separated, 
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dried (MgSO4) and concentrated under reduced pressure. The residue was 
fractionated by short column chromatography on silica gel. Evaporation of the 
appropriate fractions, which were eluted with dichloromethane-methanol (94: 6 v/v) 
gave the title compound as a colourless glass (5.820 g, 96.4%). 
SH[(CD3)2SO]: ratio of anomeric protons: (C+T)/G=2.04 (required: 2.00). 
6p[(CD3)2S0]: 27.80,27.84,27.92,27.98,28.02,28.08,28.12,28.19,28.30,28.38. 
Rf (System B): 0.50. 
HO-Cp(s)Tp(s)Tp(s)Cp(s)Tp(s)Tp(s)Gp(s)Cp(s)G-Lev (HO-9-Lev, 458) 
DMTr-Cp(s)Tp(s)Tp(H) (2.123 g, 1.25 mmol) and HO-Cp(s)Tp(s)Tp(s)Gp(s)Cp(s)G- 
Lev (3.018 g, 1.0 mmol) were co-evaporated with dry pyridine (2 ml) and the residue 
was redissolved in pyridine (I I ml) and cooled to O'C (ice-water bath). To this 
cooled solution was added, over a period of 30 see pivaloyl chloride (0.31 ml, 2.52 
mmol). After 15 min, well powdered N-[(2-cyanoethyl)sulphanyl]succinimide (0.461 
g, 2.50 mmol) was added. The resulting reactants were then allowed to warrn up to 
room temperature over 20 min and then partitioned between dichloromethane (80 ml) 
and saturated aqueous sodium hydrogen carbonate (80 mi). The two layers were 
separated and the aqueous layer was back extracted with dichloromethane (2x2O ml). 
The combined organic layers were washed with triethyl ammonium phosphate buffer 
(50 ml, 0.5 M, pH 7.0), dried (MgS04) and evaporated under reduced pressure. The 
residue was co-evaporated with toluene (4x4O ml). 
Another coupling was carried out on a 1.993 mmol scale based on the 5'-OH 
compound. 
The combined materials from the above couplings were then dissolved in 
dichloromethane (120 ml) and cooled to 0°C (ice-water bath). Pyrrole (2.45 ml, 
35.31 mmol) followed by dichloroacetic acid (4.98 ml, 60.37 mmol) was added. After 
45 min, the reaction solution was poured into saturated aqueous sodium hydrogen 
carbonate (150 ml) with care. The two layers were separated and the aqueous layer 
213 
Chapter 7 Experimental 
was back extracted with dichioromethane (2x30 ml). The combined organic layers 
were further washed with triethylammonium phosphate buffer (80 ml, 0.5 M, pH 7.0), 
dried (MgSO4) and evaporated under reduced pressure. The residue was then 
fractionated by short column chromatography on silica gel: evaporation of 
appropriate fractions, which were eluted with dichloromethane-methanol (96: 4 v/v) 
gave the title compound as a colourless glass (12.533 g, 95.6%). 
SH[(CD3)2SO]: aromatic protons: 50 H (required: 53 H), ratio of anomeric protons: 
(C+T): G = 3.63 (required 3.50), T: G (calculation based on the methyl groups of T 
and isobutyryl protecting group on G) = 1.98 (required 2.00). 
SP[(CD3)2SO]: 27.81,27.87,27.92,27.99,28.06,28.13,28.20,28.27,28.33. 
Rf (System B): 0.51. 
HO-Cp(s)Tp(s)Tp(s)Cp(s)Tp(s)Tp(s)Cp(s) Tp(s)Tp(s)Gp(s)Cp(s)G-Lev (HO-12-Lev, 
3109) 
DMTr-Cp(s)Tp(s)Tp(H) (3-374 g, 1.987 mmol) and HO-Cp(s)Tp(s)Tp(s)Cp(s)Tp(s) 
TP(s)Gp(s)Cp(s)G-I, ev (6-691 g, 1.528 mmol) were co-evaporated with dry pyridine 
(2 ml) and the residue was dissolved in pyridine (22 ml). The resulting solution was 
then cooled to OOC (ice-water bath). To this solution was added pivaloyl chloride 
(0.53 ml, 4.30 mmol) over 30 sec. The reactants were stirred at the same temperature 
for 15 min. Well-powdered N-[(2-cyanoethyl)sulphanyllsuccinimide (0.788 g, 4.28 
mmol) was added. The reaction mixture was allowed to warm up to room temperature 
over a period of 20 min and then partitioned between dichloromethane (100 ml) and 
saturated aqueous sodium hydrogen carbonate (100 ml). The two layers were 
separated and the aqueous layer was back extracted with dichloromethane (2x3O nil). 
The combined organic layers were further washed with triethylammoniurn phosphate 
buffer (80 ml, 0.5 M, pH 7.0), dried (MgS04) and concentrated tinder reduced 
pressure. The residue was then co-evaporated with toluene (4x5O ml). 
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A second coupling was carried out on a 1.300 mmol scale based on the 5'-OEl 
compound at the same stoichiometry. 
The combined materials obtained from the above couplings were dissolvcd in 
dichloromethane (130 ml) and cooled to O'C (ice-water bath). To the cooled solution 
was added pyrrole (2.74 ml, 39.49 mmol) follow by dichloroacetic acid (5.48 In], 
66.43 mmol). After 45 min, the reactants were poured into saturated aqueous sodium 
hydrogen carbonate (150 ml) with care. The two layers were separated and the 
aqueous layer was back extracted with dichloromethane (2X30 ml). The combined 
organic layers were then washed with triethylammonium phosphate buffer (80 nil, 0.5 
M, pH 7.0), dried (MgS04) and evaporated under reduced pressure. The residue was 
then fractionated by short column chromatography on silica gel: evaporation of the 
appropriate fraction, which were eluted with dichloromethane-methanol (94: 6 v/v) 
gave the title compound as a colourless glass (14.772 g, 9 1.0%). 
5H[(CD3)2SOI: aromatic protons: 70 H (required: 72 H); ratio of anomeric protons: 
(C+T): G = 5.18 (required: 5.00); T: G (calculation based on the methyl groups of T 
and isobutyryl protecting group on G) = 2.87 (required: 3.00). 
6p[(CD3)2S0]: 27.80,27.92,27.99,28.06,28.13,28.33. 
Rf (System B): 0.50. 
HO-Cp(s)T-Lev (388) 
Triethyl ammonium 5'-O-dimethoxytrityl-4-N-benzoyl-2'-deoxycytidine 3'-H- 
phosphonate (3.835 g, 4.80 mmol) and 3'-O-Ievulinyl-4-0-phenylthymidine (1.666 g, 
4.00 mmol) were co-evaporated with anhydrous pyridine (3 nil) and the residue was 
taken up with dry pyridine (20 nil). To this solution was added dropwise, over a 
period of 5 min, a solution of N-[(2-cyanoethyl)sulphanyllsuccininlide (1.843 g, 10.0 
mmol) and diphenyl phosphorochloridate (2.07 nil, 10.0 mmol) in dry pyridinc (24 
nil). After 15 min, water (3 ml) was added and the resulting mixture was stirred for 5 
min. Then it was partitioned between saturated aqueous sodium hydrogen carbonate 
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(200 ml) and dichloromethane (200 ml). The organic layer was separated and further 
washed with saturated aqueous sodium hydrogen carbonate (2xlOO ml). The organic 
layer was dried (MgS04) and concentrated under reduced pressure. The residue was 
co-evaporated with toluene (2x6O nil) and dissolved in dichloromethane (110 nil). 
After this solution had been cooled to O'C (ice-water bath), pyrrole (3.31 ml, 47.71 
mmol) was added followed by addition of a solution of dichloroacetic acid (3.31 nil, 
40.12 mmol) in dichloromethane (40 ml). After 10 min, the reaction mixture was 
poured into saturated aqueous sodium hydrogen carbonate (200 nil). The organic 
layer was separated and further washed with saturated aqueous sodium hydrogen 
carbonate (200 nil), dried (MgS04) and concentrated under reduced pressure. The 
residue was then fractionated by short column chromatography on silica gel: 
evaporation of the appropriate fractions, which were eluted with dichloromethane- 
methanol (97: 3 v/v) gave HO-Cp(s)T-Lev as a colourless foam (3.4 10 g, 97.0%). 
SH[(CD3)2SO]: 2.10 (6 H, m), 2.40 (3 H, m), 2.75 (2 H, m), 2.95 (2 H, m), 3.66 (2 1-I, 
br), 4.30 (2 H, br), 4.45 (2 H, m), 5.15 (1 H, br), 5.30 (2 H, m, including 1 ex H), 6.20 
(2 H, m), 7.18 (2 H, m), 7.27 (1 H, m), 7.35-7.55 (5 H, m), 7.63 (1 H, m), 8.01 (3 H, 
m), 8.35 (1 H, m), 11.28 (1 H, s, ex). 
6p[(CD3)2SO]: 27.81,27.88. 
Rf (System A): 0.22. 
DMTr-Gp(s)Cp(s)T-Lev (399) 
Triethyl ammonium 2'-deoxy-6-0-(2,5-dichlorophenyl)-5'-O-(4,4'-dimethoxytrityl)- 
2-N-isobutyrylguanosine 3'-H-phosphonate (3.041 g, 3.20 mmol) and HO-Cp(s)7'- 
Lev (2.010 g, 2.29 mmol) were co-evaporatcd with dry pyridine (2 nil). The residue 
was then redissolved in anhydrous pyridine (11.5 nil). To this solution was added 
dropwise, over a period of 5 min, a solution of diphenyl phosphoroch I ori date (1.19 
nil, 5.74 mmol) and N-[(2-cyanoethyl)sulphanyl]succinimide (1.054 g, 5.72 mmol) in 
pyridine (14 ml) at room temperature. After 20 min, water (2 nil) was added. After 5 
min, the products were partitioned between dichloromethane (150 nil) and saturated 
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aqueous sodium hydrogen carbonate (120 ml). The organic layer was separated and 
further washed with saturated aqueous sodium hydrogen carbonate (2x100 ml). The 
dried (MgSO4) organic layer was concentrated under reduced pressure. The residue 
was fractionated by short column chromatography on silica gel. Evaporation of the 
appropriate fractions, which were eluted with dichloromethane-methanol (97: 3 v/v) 
gave DMTr-Gp(s)Cp(s)T-Lev as a colourless glass (3.829 g, 93.2%). 
SP[(CD3)2SO]: 27.68,27.72,28.15,28.28. 
Rj (System A): 0.25. 
DMTr-Gp(s)Cp(s)T-OH (3100) 
DMTr-Gp(s)Cp(s)T-Lev (6-681 g, 3.72 mmol) was dissolved in pyridine (22 ml)and 
cooled to O'C (ice-water bath). To the solution was added a mixture of hydrazine 
monohydrate (1.82 ml, 37.52 mmol), acetic acid (18.6 ml, 0.325 niol) and water (3.7 
ml) in pyridine (15 ml). After 10 min, 2,4-pentanedione (9.8 ml, 95.44 mmol) was 
added. The resulting mixture was allowed to warm up to room temperature over a 
period of 15 min. Then it was poured into saturated aqueous sodium hydrogen 
carbonate (160 ml) with care and extracted with dichloromethane (2xlOO ml). The 
combined organic layers were further washed with saturated aqueous sodium 
hydrogen carbonate (2x8O ml); the aqueous layers were back extracted with 
dichloromethane (2X5O ml). The combined organic layers were dried (MgSO4) and 
evaporated to dryness under reduced pressure. The residue was dissolved in 
dichloromethane (7 ml) and added dropwise to diethyl ether (280 ml) with stirring. 
After 30 min, the precipitate obtained was collected by filtration and washed with 
diethyl ether (30 ml) to give the title compound as a colourless solid (6.017 g, 95.1 %). 
8p[(CD3)2S0]: 27.70,27.76,28.18,28.32. 
Rf (System A): 0.20. 
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DMTr-Gp(s)Cp(s)Tp(H) (3101) 
Ammonium 4-methylphenyl H-phosphonate (1.870 g, 9.885 mmol) and triethylamine 
(3.8 nil, 27.26 mmol) were co-evaporated with dry pyridine (20 nil). DMTr- 
Gp(s)Cp(s)T-OH (5.600 g, 3.295 mmol) was added to the residue and co-evaporated 
with pyridine (2xlO nil). The residue was then redissolved in pyridine (40 ml) and 
cooled to -20'C (IMS-dry ice bath). To the cooled solution was added, over a period 
of 5 min, pivaloyl chloride (1.22 nil, 9.905 mmol). The reactants were stirred at the 
same temperature for I h. Water (10 ml) was then added and the resulting mixture 
was allowed to warm up to room temperature and stirred for I h. The clear solution 
was then poured into saturated aqueous sodium hydrogen carbonate (50 Tril) and 
extracted with dichloromethane (3x6O nil). The combined organic layers were then 
washed with triethylammonium phosphate buffer (2x5O nil, 0.5 M, pH 7.0). The 
aqueous layers were extracted with dichloromethane (2X30 nil). The combined 
organic layers were dried (MgS04) and concentrated to one sixth of the original 
volume. Toluene (50 nil) was added. The mixture was then purified by short colunin 
chromatography on silica gel. Evaporation of the appropriate fractions, which were 
eluted with dichloromethane-methanol (80: 20 v/v), gave a colourless foam. This 
material was then dissolved in dichloromethane (100 nil) and washed with 
triethyl ammonium phosphate buffer (50 nil, 0.5 M, pH 7.0). The dichloromethane 
layer was separated, dried (MgS04) and concentrated under reduced pressure to give 
the title compound as a colourless glass (5.695 g, 92.8%). 
SP[(CD3)2SO]: 1.59 (1 P, 1Jp_H 584.822), 27.54,27.59,27.65,27.70,27.76,27.84 
27.91,27.90,28.02,28.08. 
HO -Gp (s) Cp (s) Tp (s) Cp (s) Tp (s) Tp (s) Cp (s) Tp (s) Tp (s) Cp (s) Tp (s) Tp (s) Gp (s) Cp (s) G- 
Lev (HO-15-Lev, 3110) 
DMTr-Gp(s)Cp(s)Tp(H) (3.770 g, 2.02 mmol) and HO-Cp(s)Tp(s)Tp(s) 
Cp(s)Tp(s)Tp(s)Cp(s)Tp(s)Tp(s)Gp(s)Cp(s)G-Lev (HO-12-Lev, 8.610 g, 1.50 mmol) 
were co-evaporated with dry pyridine (2x5 ml). The residue was then redissolved in 
pyridine (30 ml) and cooled to 0°C (ice-water bath). Pivaloyl chloride (0.56 ml, 4.55 
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mmol) was added over 30 sec. After 15 min, N-[(2-cyanoethyl)sulphanyllsuccinimide 
(0.829 g, 4.5 mmol) was added as a well-powdered solid and the resulting reactants 
were allowed to warm up to room temperature over 20 min. Water (I nfl) was added 
and the reaction mixture was stirred at the same temperature for a further 5 min. Tile 
products were partitioned between dichloromethane (100 ml) and saturated aqueous 
sodium hydrogen carbonate (100 ml). The two layers were separated and the aqueous 
layer was back extracted with dichloromethane (20 ml). The combined organic layers 
were further washed with triethyl ammonium phosphate buffer (50 ml, 0.5 M, pH 7.0), 
dried (MgS04) and evaporated under reduced pressure. The residue was then co- 
evaporated with toluene (4x5O ml). 
Another coupling was carried out on a 1.0 mmol scale at the same stoichiometry. 
The combined materials obtained from the above two couplings were then dissolved 
in dichloromethane (100 nil) and cooled to O'C (ice-water bath). To the cooled 
solution were added pyrrole (2.05 nil, 29.55 mmol) and dichloroacetic acid (4.15 nil, 
50.30 mmol). After 50 min, the reactants were poured into saturated aqueous sodium 
hydrogen carbonate (100 nil) with care. The organic layer was separated and (tie 
aqueous layer was back extracted with dichloromethane (30 ml). The combined 
organic layers were further washed with triethylammonium phosphate buffer (50 nil, 
0.5 M, pH 7.0), dried (MgS04) and evaporated under reduced pressure. The residue 
was fractionated by short column chromatography on silica gel: evaporation of the 
appropriate fractions, eluted with dichloromethane-methanol (94: 6 v/v) gave the title 
compound as a colourless glass (16.389 g, 90.2%). 
SH[(CD3)2SO]: aromatic protons: 83.3 H (required: 89 H), ratio of anomeric protons 
(C+T): G = 4.04 (required 4.00), T: G (calculation based on the methyl groups of T 
and isobutyryl protecting group on G) = 2.16 (required 2.33). 
8p[(CD3)2SO]: 27.80,27.89,28.01,28.06,28.13,28.29,28.36,28.38. 
Rf (System B): 0.51. 
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DMTr-Tp(s)Tp(s)T-Lev (3102) 
Tri ethyl ammonium 5'-O-dimethoxytrityl-4-0-phenylthymidine Y-H-phosphonate 
(2.200 g, 2.8 mmol) and HO-Tp(s)T-Lev (1.732 g, 2.0 mmol) were co-evaporated 
with dry pyridine (2 ml) and the residue was redissolved in anhydrous pyridine (10 
ml). To this solution was added, over 5 min, a solution of diplienyl 
ph osphoroch I ori date (1.04 ml, 5.02 mmol) and N- [ (22 - 
cyanoethyl)sulphanyl]succinimide (0.921 g, 5.00 mmol) in pyridine (12 ml) at room 
temperature. After 20 min, water (2 ml) was added. After a further period of 5 min, 
the reactants were partitioned between dichloromethane (100 ml) and saturated 
aqueous sodium hydrogen carbonate (100 ml). The two layers were separated and tile 
organic layer was further washed with saturated aqueous sodium hydrogen carbonate 
(100 ml). The dried (MgS04) organic layer was concentrated under reduced pressure. 
The residue was fractionated with short column chromatography on silica gel: 
evaporation of the appropriate fractions, which were eluted with dichloromethalle- 
methanol (97: 3, v/v) gave the title compound as a colourless glass (3.200 g, 98.9%). 
6p[(CD3)2S0]: 27.99,28.03,28.12,28.30. 
Rf (System A): 0.24. 
DMTr-Tp(s)Tp(s)T-OH (3103) 
DMTr-Tp(s)Tp(s)T-Lev (3.000 g, 1.85 mmol) was dissolved in pyridine (10 nil) and 
cooled to O'C (ice-water bath). A solution of hydrazine monohydrate (0.90 nil, 18.55 
mmol), acetic acid (9.2 ml, 0.161 mol) and water (2 ml) in pyridine (8.5 ml) was 
added to the cooled solution. After 10 min, 2,4-pentanedione (5 ml, 48.69 niniol) was 
added and the resulting mixture was allowed to warm up to room temperature over a 
period of 15 min. The reactants were then poured into saturated aqueous sodiuni 
hydrogen carbonate (90 ml) with care and extracted with dichloromethane (2x6O nil). 
The combined organic layers were further washed with saturated aqueous sodium 
hydrogen carbonate (2XIOO ml). The aqueous layers were back extracted with 
dichloromethane (2X50 ml). The combined organic layers were dried (MgS04) and 
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concentrated under reduced pressure. The residue was dissolved in dichloromethane 
(5 ml) and added dropwise to diethyl ether (200 ml) with stirring. After 30 min, the 
precipitates were collected by filtration and washed with diethyl ether (30 ml) to give 
the title compound as a colourless solid (2.679 g, 95.1 %). 
öp[(CD3)2S0]: 27.99,28.04,28.12,28.28. 
Rf (System A): 0.17. 
DMTr-Tp(s)Tp(s)Tp(H) (3104) 
Ammonium 4-methylphenyl H-phosphonate (1.986 g, 10.50 mmol) and triethylailline 
(4.0 nil, 28.70 mmol) were co-evaporated with dry pyridine (20 nil). DMTr- 
7p(s)7p(s)T-OH (5.318 g, 3.50 mmol) was added to the residue and co-evaporated 
with pyridine (2x]O nil). The residue was redissolved in anhydrous pyridine (45 till) 
and cooled to -20'C (EMS-dry ice bath). To this cooled solution was then added 
dropwise, over a period of 5 min, pivaloyl chloride (1.3 nil, 10.55 niniol). After the 
reaction mixture had been stirred for Ih at the same temperature, water (15 till) was 
added. The resulting mixture was allowed to warm up to room temperature over a 
period of I h. The clear solution was then poured into saturated aqueous sodium 
hydrogen carbonate (60 nil) and extracted with dichloromethane (2x8O till). The 
combined organic layers were washed with triethylammonium phosphate buffer 
(2x5O nil, 0.5 M, pH 7.0). The aqueous layers were back extracted with 
dichloromethane (2x3O nil). The combined organic layers were dried (MgSO4) and 
concentrated to a volume of ca. 30 nil under reduced pressure. Toluene (50 nil) was 
added and the mixture was subjected to short column chromatography on silica gel: 
evaporation of the appropriate fractions, which were eluted with dichloromethane- 
methanol (80: 20 v/v) gave a colourless glass. This material was then redissolved in 
dichloromethane (100 nil) and washed with triethylammoniurn phosphate buffer (50 
nil, 0.5 M, pH 7.0). The dried (MgS04) organic layer was concentrated tinder reduced 
pressure to give the title compound as a colourless glass (5.496 g, 93.2%). 
8p[(CD3)2SO]: 1.53 (1 P, 1Jp_H 584.644), 28.00 (2 P). 
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HO-Tp(s)Tp(s)Tp(s)Gp(s)Cp(s)Tp(s)Cp(s)Tp(s)Tp(s)Cp(s)Tp(s)Tp(s)Cp(s)Tp(s) 
Tp(s)Gp(s)Cp(s)G-Lev (HO-18-Lev, 3111) 
DMTr-Tp(s)Tp(s)Tp(H) (2.357 g, 1.40 mmol) and HO-Gl)(s)Cl)(s)Tp(s)Cl)(s)Tl)(s) 
Tp(s)Cp(s)Tp(s)Tp(s)Cp(s)Tp(s)Tp(s)Gp(s)Cp(s)G-Lev (HO-15-Lev, 7.570 g, 1.04 
mmol) were co-evaporated with dry pyridine (2 ml). The residue was then redissolved 
in anhydrous pyridine (25 ml) and cooled to 0"C (ice-water bath). To tile cooled 
solution was added pivaloyl chloride (0.40 nil, 3.25 mmol) over 30 sec. After 15 min, 
N-[(2-cyanoethyl)sulphanyl]succinimide (0.589 g, 3.20 mmol) was added and tile 
resulting mixture was allowed to warm up to room temperature over a period of 20 
min. Water (0.5 ml) was then added to the reactants. After 5 min, the reaction mixture 
was partitioned between dichloromethane (80 nil) and saturated aqueous sodium 
hydrogen carbonate (80 ml). The organic layer was separated and tile aqueous layer 
was back extracted with dichloromethane (20 mi). The combined organic layers were 
washed with triethylammonium phosphate buffer (50 nil, 0.5 M, pH 7.0). The organic 
layer was separated and the aqueous layer was back extracted with dichlorometharle 
(20 ml). The combined organic layers were then dried (MgS04) and concentrated 
under reduced pressure. The residue was co-evaporated with toluene (4x5O nil). 
A second coupling was carried out on a 1.152 mmol scale based on the 5'-OH 
compound at the same stoichiometry. 
The combined materials obtained from the above couplings were dissolved in 
dichloromethane (90 ml) and cooled to 0°C (ice-water bath). Pyrrole (1.76 ml, 25.37 
mmol) followed by dichloroacetic acid (3.57 ml, 43.28 mmol) was added. After 70 
min, the reactants were poured into saturated aqueous sodium hydrogen carbonate 
(100 ml) with care. The two layers were separated and the aqueous layer was back 
extracted with dichloromethane (30 ml). The combined organic layers were then 
washed with triethyl ammonium phosphate buffer (50 ml, 0.5 M, pH 7.0). The organic 
layer was separated, dried (MgS04) and concentrated under reduced pressure. Tile 
residue was purified by short column chromatography on silica gel. Tile appropriate 
fractions, which were eluted with dichloromethane-methanol (94: 6 v/v), were 
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concentrated under reduced pressure to give the title compound as a colourless glass 
(16.932 g, 90.0%). 
SH[(CD3)2SO]: Aromatic protons: 100.7 H (required: 107 H), ratio of anomeric 
protons: (C+T): G = 5.10 (required: 5.00), T: G (calculation based on the methyl 
groups of T and isobutyryl protecting group on G) = 3.22 (required: 3.33). 
5p[(CD3)2S0]: 27.80,27.90,27.95,28.05,28.12,28.29,28.35. 
R1 (System B): 0.51. 
DMTr-Gp(s)Cp(s)G-Lev (390) 
Triethylammoniurn 2'-deoxy-6-0-(2,5-dichlorophenyl)-5'-O-(4,4'-dimethoxytrityl)- 
2-N-isobutyrylguanosine Y-H-phosphonate (3.989 g, 4.2 mmol) and HO-Cp(s)G-Lev 
(3.129 g, 3.0 mmol) were co-evaporated with dry pyridine (2 ml) and then 
redissolved in anhydrous pyridine (15 MI). A solution of diphenyl 
phosphorochl ori date (1.55 ml, 7.48 mmol) and N-[(2-cyanoethyl)sulphanyl] 
succinimide (1.382 g, 7.50 mmol) in pyridine (18 ml) was added dropwise, over a 
period of 5 min at room temperature. After the resulting solution had been stirred for 
20 min, water (2 ml) was added. After 5 min, the products were partitioned between 
dichloromethane (150 ml) and saturated aqueous sodium hydrogen carbonate (150 
ml). The organic layer was separated and further washed with saturated aqueous 
sodium hydrogen carbonate (100 ml). The dried (MgS04) organic layer was 
concentrated under reduced pressure. The residue was purified by short colunin 
chromatography on silica gel. Evaporation of the appropriate fractions, which were 
eluted with dichloromethane-methanol (97: 3 v/v) gave the title compound as a 
colourless glass (5.476 g, 93.2%). 
SP[(CD3)2SO]: 27.64,27.67,27.74,27.91. 
Rf (System A): 0.33. 
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DMTr-Gp(s)Cp(s)G-OH (391) 
DMTr-Gp(s)Cp(s)G-Lev (6.855 g, 3.5 mmol) was dissolved in pyridine (20 ml) and 
cooled to O'C (ice-water bath). A solution of hydrazine monohydrate (1.70 ml, 35.04 
mmol), acetic acid (17.4 ml, 0.304 mol) and water (3.5 nil) in pyridine (15 nil) was 
added to the cooled solution. After 10 min, 2,4-pentanedione (9.5 ml, 92.51 mmol) 
was added and the reactants were allowed to warm up to room temperature over 15 
min. The products were then poured into saturated aqueous sodium hydrogen 
carbonate (150 nil) with care and extracted with dichloromethane (2x]00 ml). The 
combined organic layers were further washed with saturated aqueous sodium 
hydrogen carbonate (2XI50 nil). The aqueous layers were back extracted with 
dichloromethane (2x6O ml). The combined dried (MgSO4) organic layers were 
concentrated to dryness under reduced pressure. The residue was then dissolved in 
dichloromethane (7 nil) and added dropwise to diethyl ether (300 ml) with stirring. 
The precipitate obtained was collected by filtration and washed with diethyl ether (50 
ml) to give the title compound as a colourless solid (6.300 g, 96.7%). 
6p[(CD3)2S0]: 27.68,27.74,27.86,27.88. 
Rf (System A): 0.30. 
DMTr-Gp(s)Cp(s)Gp(H) (392) 
Ammonium 4-methylphenyl H-phosphonate (1.677 g, 8.868 mmol) and triethylamine 
(3.4 ml, 24.39 mmol) were co-evaporated with dry pyridine (15 ml). DMTr- 
Gp(s)Cp(s)G-OH (5.500 g, 2.956 mmol) was added to the residue and co-evaporated 
with pyridine (2xlO ml). The residue was redissolved in anhydrous pyridine (40 ml) 
and cooled to -20'C (IMS-dry ice bath). To this cooled solution was then added 
dropwise, over a period of 5 min, pivaloyl chloride (I. I ml, 8.93 mmol). After the 
reaction mixture had been stirred for Ih at the same temperature, water (15 ml) was 
added and the resulting mixture allowed to warm up to room temperature over a 
period of I h. The clear solution was then poured into saturated aqueous sodium 
hydrogen carbonate (60 ml) and extracted with dichloromethane (2x8O ml). The 
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combined organic layers were washed with triethylammonium phosphate buffer 
(2x5O ml, 0.5 M, pH 7.0). The layers were separated and the aqueous layers were 
back extracted with dichloromethane (2x3O ml). The combined organic layers were 
dried (MgS04) and concentrated to ca. one fourth of the original volume under 
reduced pressure. Toluene (50 ml) was added to the residue and the mixture was 
purified by short column chromatography on silica gel: evaporation of the appropriate 
fractions, which were eluted with dichloromethane-methanol (80: 20, v/v) gave a 
colourless glass. This material was redissolved in dichloromethane (100 ml) and 
washed with triethylammonium phosphate buffer (50 ml, 0.5 M, pH 7.0). The dried 
(MgS04) organic layer was concentrated under reduced pressure to give the title 
compound as a colourless glass (5.601 g, 93.5%). 
6p[(CD3)2SO]: 1.55 (1 P. 1JP_H 588.264), 27.51,27.65,27.77 (2 P). 
H0 -Gp (s) Cp (s) Gp (s) Tp (s) Tp (s) Tp (s) Gp (s) Cp (s) Tp (s) Cp (s) Tp (s) Tp (s) Cp (s) Tp (s) 
Tp(s)Cp(s)Tp(s)Tp(s)Gp(s)Cp(s)G-Lev (HO-2I-Lev, 3112) 
DMTr-Gp(s)Cp(s)Gp(H) (2.937 g, 1.45 mmol) and HO-Tp(s)Tp(s)Tp(s)Gp(s)Cp(s) 
Tp(s)Cp(s)Tp(s)Tp(s)cp(s)Tp(s)Tp(s)Cp(s)Tp(s)Tp(s)Gp(s)Cp(s)G-I, ev (HO-18-Lev, 
8.616 g, 1.00 mmol) were co-evaporated with dry pyridine (2x5 ml). The residue was 
then taken up with pyridine (30 ml) and cooled to O'C (ice-water bath). To the cooled 
solution was added, over a period of 30 sec, pivaloyl chloride (0.42 ml, 3.41 mmol). 
The reactants were stirred at the same temperature for 15 min and then N-[(2- 
cyanoethyl)sulphanyl]succinimide (0.626 g, 3.40 mmol) was added. The resulting 
mixture was allowed to warm up to room temperature and stirred for a further 20 min. 
Water (0.5 ml) was added to the reactants. After 5 min, the products were partitioned 
between dichloromethane (80 ml) and saturated aqueous sodium hydrogen carbonate 
(80 ml). The layers were separated and the aqueous layer was back extracted with 
dichloromethane (20 ml). The combined organic layers were washed with 
triethylammonium phosphate buffer (50 ml, 0.5 M, pH 7.0). The two layers were 
separated, and the aqueous layer extracted with dichloromethane (20 ml). The 
combined dried (MgS04) organic layers were concentrated under reduced pressure. 
The residue was co-evaporated with toluene (4x5O ml). 
225 
Chapter 7 Experimental 
A second coupling was carried out on a smaller scale (0.891 mmol of HO-18-Lev) at 
the same stoichiometry. 
The combined materials obtained from the above two batches of coupling were then 
dissolved in dichloromethane (80 ml) and cooled to O'C (ice-water bath). To this 
cooled solution were added pyrrole (1.55 ml, 22.34 mmol) and dichloroacetic acid 
(6.00 ml, 72.73 mmol). After I h, the reactants were poured into saturated aqueous 
sodium hydrogen carbonate (100 ml) with care. The two layers were separated and 
the aqueous layer was back extracted with dichloromethane (30 ml). The combined 
organic layers were washed with triethyl ammonium phosphate buffer (50 ml, 0.5 M, 
pH 7.0). The organic layer was separated and the aqueous layer was back extracted 
with dichloromethane (30 ml). The combined dried (MgS04) organic layers were 
concentrated under reduced pressure. The residue was then purified by short column 
chromatography on silica gel. Evaporation of the appropriate fractions, which were 
eluted with dichloromethane-methanol (93: 7 v/v), gave the title compotind as a 
slightly yellow coloured glass (17.559 g, 90.1%). 
8H[(CD3)2S0]: (ratio of anomeric protons) (T+C): G = 3.12 (required: 3.20), aromatic 
protons (108 H, required: 122 H), T: G (calculation based on the methyl groups of T 
and isobutyryl protecting group on G) = 1.80 (required 2.00). 
5p[(CD3)2SO]: 28.34,28.12,28.05,27.85,27.79,27.70. 
Rf (System B): 0.51. 
HO-Cp(s)Tp(s)Tp(s)Cp(s)Tp(s)Tp(s)Gp(s)Cp(s)G-OH (459) 
Ac-9-Lev (0.200 g, 45.6 ýtmol) was co-evaporated with dry pyridine (2x I ml) and the 
residue dissolved in dry acetonitrile (2.0 ml). To this solution was added 
chlorotrimethylsilane (0.162 ml, 1.276 mmol) and DBU (0.54 ml, 3.65 mmol) at 
room temperature. After 30 min, the reactants were concentrated under reduced 
pressure. The residue was redissolved in acetonitrile (3.6 ml), followed by addition of 
2-nitrobenzaidoxime (0.318 g, 1.915 mmol). After 12 h, the products were 
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concentrated under reduced pressure. The residue was dissolved in methanol (5.0 ml) 
and precipitated with ethyl acetate (120 ml). The solid was collected by centrifugation 
and redissolved in methanol. Ethyl acetate (120 ml) was added and the resulting 
suspension was centrifuged. The solid was dried in vacuo and then incubated with 
aqueous ammonia (33%, d 0.88,3.6 ml) and 2-mercaptoethanol (0.4 ml) at 50'C for 
15 h. After it had been cooled to room temperature, the reaction mixture was 
concentrated under reduced pressure, followed by co-evaporation with ethanol (2x2 
ml). The residue was dissolved in methanol (3 ml) and precipitated with ethyl acetate 
(40 ml). This was repeated two more times and the solid was collected by 
centrifugation. The dried solid residue was dissolved in water Q ml) and passed 
through an Amberlite (IR120, Na+ form) ion exchange column (lxl5 cm). The 
appropriate fractions were concentrated under reduced pressure to a small volume 
(ca. 3 ml). Upon freeze drying, the title compound was obtained as a colourless 
powder (0.220 g, 88.4%). 
5p[D20] 55.90,56.17,56.28,56.33. 
MS (MALDI): 2807.6, required 2807.3. 
HO-Cp(s)Tp(s)Tp(s)Cp(s)Tp(s)Tp(s)Cp(s)Tp(s)Tp(s)Gp(s)Cp(s)G-OH (460) 
Ac-12-Lev (0.360 g, 62.26 gmol) was co-evaporated with dry pyridine (2X2 ml) and 
the residue dissolved in dry acetonitrile (3.6 ml). To this solution was added 
chlorotrimethylsi lane (0.162 ml, 1.276 mmol) and DBU (0.64 ml, 4.280 mmol) at 
room temperature. After 30 min, the reactants were concentrated under reduced 
pressure. The residue was redissolved in acetonitrile (3.6 ml), followed by addition of 
2-nitrobenzaidoxime (0.284 g, 1.709 mmol). After 12 h, the products were 
concentrated under reduced pressure. The residue was dissolved in methanol (5.0 ml) 
and precipitated with ethyl acetate (120 ml). The solid was collected by centrifugation 
and redissolved in methanol. Ethyl acetate (120 ml) was added and the resulting 
suspension was centrifuged. The solid was dried in vacuo and then incubated with 
aqueous ammonia (33%, d 0.88,6.5 ml, 0.111 mol) and 2-mercaptoethanol (0.65 ml, 
9.268 mmol) at 50'C for 15 h. After it had been cooled to room temperature, the 
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reaction mixture was concentrated under reduced pressure. The residue was co- 
evaporated with ethanol (2x5 ml) and then dissolved in methanol (6 ml). Ethyl acetate 
(120 ml) was added and the solid collected by centrifugation. This material was 
redissolved in methanol (6.0 ml, use a sonicator if necessary) and precipitated with 
ethyl acetate (120 ml). The suspension was centrifuged and the precipitate was 
collected by centrifugation. This was repeated one more time and the dried solid 
residue was dissolved in water (5 ml) and passed through an Amberlite (IR120, Na' 
forrn) ion exchange column Qx20 cm). The appropriate fractions were concentrated 
under reduced pressure to a small volume (ca. 5 ml). Upon freeze drying, the title 
compound was obtained as a colourless powder (0.220 g, 88.4%). 
Sp[DZOJ 56.243. 
MS (MALDI): 3753.0, required 3752.4. 
HO-Gp(s)Cp(s)Tp(s)Cp(s)Tp(s)Tp(s)Cp(s)Tp(s)Tp(s)Cp(s)Tp(s)Tp(s)Gp(s)Cp(s) 
G-OH (461) 
Ac-15-Lev (0.200 g, 27.34 Rmol) was co-evaporated with dry pyridine (2x2 mi) and 
the residue dissolved in dry acetonitrile (2 ml). To this solution was added 
chlorotrimethylsilane (68 gl, 0.551 mmol) and DBU (0.36 ml, 2.407 mmol) at room 
temperature. After 30 min, the reactants were concentrated under reduced pressure. 
The residue was redissolved in acetonitrile (2.0 ml), followed by addition of 2- 
nitrobenzaldoxime (0.170 g, 1.026 mmol). After 12 h, the products were concentrated 
under reduced pressure and the residue was incubated with aqueous ammonia (33%, d 
0.88,3.6 ml, 61.39 mmol) and 2-mercaptoethanol (0.4 mi, 5.703 mmol) at 50'C for 
15 h. After it had been cooled to room temperature, the reaction mixture was 
concentrated under reduced pressure. The residue was co-evaporated with ethanol 
(2x5 ml) and then dissolved in methanol (2 ml). Ethyl acetate (40 ml) was added and 
the solid collected by centrifugation. This material was redissolved in methanol (4.0 
ml, use a sonicator if necessary) and precipitated with ethyl acetate (40 ml). Tile 
suspension was centrifuged and the precipitate was collected by centrifugation. This 
was repeated one more time and the dried solid residue was dissolved in water (3 mi) 
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and passed through an Amberlite (IR 120, Na' form) ion exchange column (I x 15 cm). 
The appropriate fractions were concentrated under reduced pressure to a small 
volume (ca. 3 ml). Upon freeze drying, the title compound was obtained as a 
colourless powder (0.110 g, 85%). 
6p[D20] 56.38. 
MS (MALDI): 4721.7, required 4722.4. 
HO-Tp(s)Tp(s)Tp(s)Gp(s)Cp(s)Tp(s)Cp(s)Tp(s)Tp(s)Cp(s)Tp(s)Tp(s)Cp(s)Tp(s) 
Tp(s)Gp(s)Cp(s)G-OH (462) 
Ac-18-1, ev (0.100 g, 11.6 ýtmol) was co-evaporated with dry pyridine (2x2 ml) and 
the residue dissolved in dry acetonitrile (2 ml). To this solution was added 
chlorotrimethylsi lane (68 gl, 0.551 mmol) and DBU (0.294 ml, 1.972 mmol) at room 
temperature. After 30 min, the reactants were concentrated under reduced pressure. 
The residue was redissolved in acetonitrile (3.0 ml), followed by addition of 2- 
nitrobenzaldoxime (0.167 g, 1.009 mmol). After 12 h, the products were concentrated 
under reduced pressure and the residue was incubated with aqueous ammonia (33%, d 
0.88,2.5 ml) and 2-mercaptoethanol (0.25 ml) at 50'C for 15 h. After it had been 
cooled to room temperature, the reaction mixture was concentrated tinder reduced 
pressure. The residue was co-evaporated with ethanol (2X I ml) and then dissolved in 
methanol (2 ml). Ethyl acetate (40 ml) was added and the solid collected by 
centrifugation. This material was redissolved in methanol (3.0 ml, use a sonicator if 
necessary) and precipitated with ethyl acetate (40 ml). The suspension was 
centrifuged and the precipitate was collected by centrifugation. This was repeated one 
more time and the dried solid residue was dissolved in water (3 ml) and passed 
through an Amberlite (IR120, Na' form) ion exchange column (lxl5 cm). The 
appropriate fractions were concentrated under reduced pressure to a small volume 
(ca. 3 ml). Upon freeze drying, the title compound was obtained as a colourless 
powder (50 mg, 75.7%). 
öp[D20] 56.243. 
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MS (MALDI): 5683.7, required 5682.5. 
HO-Gp(s)Cp(s)Gp(s)Tp(s)Tp(s)Tp(s)Gp(s)Cp(s)Tp(s)Cp(s)Tp(s)Tp(s)Cp(s)Tp(s) 
Tp(s)Cp(s)Tp(s)Tp(s)Gp(s)Cp(s)G-OH (220) 
Ac-21-Lev (0.700 g, 67.65 [Lmol) was co-evaporated with dry pyridine (2x5 ml). The 
residue was dissolved in freshly distilled anhydrous acetonitrile (10 ml). To this 
solution was added chlorotrimethyl si lane (0.18 ml, 1.42 mmol) followed by addition 
of DBU (1.26 ml, 8.42 mmol) at room temperature. After 30 min, the reactants were 
evaporated under reduced pressure and the residue was redissolved in dry acetonitrile 
(10 ml). 2-Nitrobenzaldoxime (0.581 g, 3.50 mmol) was added and the resulting 
solution was stirred overnight at room temperature. The reaction mixture was 
concentrated under reduced pressure and the residue was dissolved in methanol (7.0 
ml). Ethyl acetate (200 ml) was added and the resulting suspension was centrifuged. 
The solid obtained was then incubated with aqueous ammonia solution (33%, d 0.88, 
12.0 ml, 0.205 mol) and 2-mercaptoethanol (1.20 ml, 17.11 mmol) at 50'C for 15 h. 
After the reaction mixture had been cooled, it was evaporated under reduced pressure 
and the residue was co-evaporated with ethanol (2x5 ml). Then it was dissolved in 
methanol (7 ml) and precipitated with ethyl acetate (200 ml). The solid obtained was 
collected by centrifugation followed by washing with ethyl acetate (2x2OO ml). After 
this material had been dried in vacuo, it was dissolved in water (10 ml) and passed 
through an Amberlite (IR120, Ne form) ion exchange column QX30 cm). The 
appropriate fractions were concentrated under reduced pre ssure to a small volume 
(ca. 10 ml) and freeze dried to give an off-white powder (450 mg, 93.4%). 
8p[D2O] 56.243. 
MS (MALDI): 6677.9, required 6677.6. 
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Ac-Cp(s)G-Lev (50 mg, 46.1 gmol) was dissolved in dichloromethane (1.0 ml) 
followed by addition of DBU (68.9 g], 0.461 mmol) at room temperature. After 30 
min, a solution of trifluoroacetic acid in dichloromethane (10% w/v, 0.415 mmol, 
0.473 ml) was added. After 5 min, the products were precipitated with diethyl ether 
(30 ml). The solid was collected by centrifugation and redissolved in 
dichloromethane (1.5 ml) and precipitated with diethyl ether (30 mi). This was 
repeated two more times and the residue was taken up with dichloromethane (0.8 ml) 
followed by addition of NN-dimethylaniline (17.5 [d, 0.138 mmol) and 
bromoacetonitrile (9.6 gl, 0.138 mmol). The resulting solution was stirred at room 
temperature for 12 h and then concentrated under reduced pressure. The residue was 
purified by chromatography on silica gel. The appropriate fractions, which were 
eluted with dichloromethane - methanol (97: 3 v/v) were combined and concentrated 
under reduced pressure to give a colourless froth (45 mg). This material was 
dissolved in acetonitrile (0.5 ml) followed by addition of 2-NBO (69.8 mg, 0.420 
mmol) and TMG (47.4 ýtl, 0.378 mmol). After 15 h, the products were concentrated 
under reduced pressure and the residue was incubated in aqueous ammonia solution 
(1.0 ml, 33%, d 0.88) at 55'C for 15 h. The products were cooled and concentrated 
under reduced pressure followed by azeotroping with ethanol (2xI ml). The residue 
was taken up with methanol (1.0 ml) and precipitated with ethyl acetate (30 ml). The 
resulting solid was collected by centrifugation. This was repeated two more times and 
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the residue was dried in vacuo. The solid residue was then dissolved in water (3 ml) 
and passed through an Amberlite (IR120, Naý fon-n) ion exchange column (I. OxIO 
cm). The appropriate fractions were concentrated under reduced pressure to give the 
title compound as a colourless solid (28 mg). 
6p[D20] 0.232. 
SH[DZO] 1.55 (1 H, m), 2.20 (1 H, m), 2.40 (1 H, m), 2.70 (1 H, m), 3.52 (2 H, m), 
3.93 (3 H, m), 4.07 (1 H, t, J 2.9), 4.5 (1 H, m), 5.81 (1 H, d, J 7.5), 5.95 (1 H, dd, J 
5.9 and 8.0), 6.09 (1 H, t, J 6.8), 7.46 (1 H, d, J 7.6), 7.90 (1 H, s). 













Ac-Gp(s)A-Lev (60 mg, ca. 49 gmol, A is a mixture of N-benzoyl and N-acetyl-N- 
benzoyl-2'-deoxyadenosine) was dissolved in dichloromethane (1.0 ml) followed by 
addition of DBU (74.2 gl, 0.496 mmol) at room temperature. After 30 min, a solution 
of trifluoroacetic acid in dichloromethane (10% w/v, 0.508 ml, 0.446 mmol) was 
added. After 5 min, the products were precipitated with diethyl ether (30 ml) and the 
solid was collected by centrifugation. The solid collected was redissolved in 
dichloromethane (1.5 ml) and precipitated with diethyl ether (30 ml). After this had 
been repeated two more times, the residual solid was dissolved in dichloromethane 
(0.5 ml). NN-Dimethylaniline (18.9 g], 0.149 mmol), followed by bromoacetonitrile 
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(10.4 gl, 0.149 mmol) was added. The reaction mixture was stirred at room 
temperature overnight and the solvents were removed under reduced pressure. The 
residue was purified by chromatography on silica gel. The appropriate fractions, 
which were eluted with dichloromethane-methanol (97: 3 v/v) were combined and 
evaporated under reduced pressure to give a colourless froth (47 mg). This material 
was then dissolved in dry acetonitrile (0.5 ml) followed by addition of 2-NBO (71.4 
mg, 0.430 mmol, 5 eq. /function) and TMG (43.2 jil, 0.344 mmol, 4 eq. /function). 
After 12 h, the reaction mixture was concentrated under reduced pressure and the 
residue was incubated in aqueous ammonia (1.0 ml, 33%, d 0.88) at 55'C for 15 h. 
After the reaction mixture had been cooled, it was concentrated under reduced 
pressure followed by azeotroping with ethanol (2x2 mi). The residue was dissolved in 
methanol (1.0 ml) and precipitated with ethyl acetate (30 ml). The solid obtained was 
collected by centrifugation. This was repeated two more times and the colourless 
solid obtained was dried in vacuo. This material was dissolved in water (3 ml) and 
passed through an Amberlite (IR120, Na' form) ion exchange column (1.5xIO cm). 
The nucleotide-containing fractions were pooled and concentrated under reduced 
pressure to a volume of ca. 2 ml. Upon freeze drying, a colourless powder was 
obtained (20 mg) which was identified as fully unblocked phosphate diester. 
SP[D2O] 0.147. 
SH[H20]: 1.82-2.02 (1 H, m), 2.18-2.24 (1 H, m), 2.44-2.50 (1 H, m), 2.70-2.77 (1 
H, m), 3.58 (2 H, d, J 3.5), 4.00-4.06 (3 H, m), 4.15 (1 H, d, J 3.0), 5.74 (1 H, dd, J 
5.8 and 9.8), 6.22 (1 H, t, J 7.8), 7.60 (1 H, s), 7.83 (1 H, s), 8.22 (1 H, s). 
Rt (programme I) 3.28 min. 
HO-GpCpG-OH (529) 
Ac-Gp(s)Cp(s)G-Lev (80 mg, 47.12 gmol) was dissolved in dichloromethane (1.0 ml) 
followed by addition of DBU (0.141 ml, 0.942 mmol) at room temperature. After 30 
min, a solution of trifluoroacetic acid in dichloromethane (10% w/v, 0.848 mmol, 
0.967 ml) was added. After 5 min, the products were precipitated with diethyl ether 
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(30 ml). The solid was collected by centrifugation and redissolved in 
dichloromethane (1.5 ml) and precipitated with diethyl ether (30 ml). This was 
repeated two more times and the residue was taken up with dichloromethane (1.0 ml) 
followed by addition of NN-dimethylaniline (35.9 gl, 0.283 nimol) and 
bromoacetonitrile (19.7 gl, 0.283 mmol). The resulting solution was stirred at room 
temperature for 12 h and then concentrated under reduced pressure. The residue was 
purified by chromatography. The appropriate fractions, which were eluted with 
dichloromethane-methanol (97: 3 v/v) were combined and concentrated under 
reduced pressure to give a colourless froth (40 mg). This material was dissolved in 
acetonitrile (0.5 ml) followed by addition of 2-nitrobenzaldoxime (0.159 mg, 0.958 
mmol) and TMG (96.2 gl, 0.767 mmol). After 15 h, the products were concentrated 
under reduced pressure and the residue was incubated in aqueous ammonia solution 
(1.0 ml, 33%, d 0.88) at 55'C for 15 h. The products were cooled and concentrated 
under reduced pressure followed by azeotroping with ethanol (2X2 ml). The residue 
was taken up with methanol (1.0 ml) and precipitated with ethyl acetate (30 ml). The 
resulting solid was collected by centrifugation. This was repeated two more times and 
the residue was dried under reduced pressure. The solid residue was then dissolved in 
water (3 ml) and passed through an Amberlite (IR120, Na' form) ion exchange 
column (I. OxIO cm). The appropriate fractions were concentrated under reduced 
pressure to give the title compound as a colourless solid ( 17 mg). 
[H2O} SP0.20. 
Rt (programme H) 7.04 min. 
HO-ApTpT-OH (526) 
Ac-Ap(s)Tp(s)T-Lev (70 mg, ca. 49 gmol, A is a mixture of N-benzoyl and N- 
benzoyl-N-acetyl-2'-deoxyadenosine) was dissolved in dichloromethane (1.0 ml) 
followed by addition of DBU (0.148 ml, 0.990 mmol) at room temperature. After 30 
min, a solution of trifluoroacetic acid in dichloromethane (10% w/v, 1.016 ml, 0.891 
mmol) was added and stirred for 5 min. The reaction mixture was precipitated with 
diethyl ether (40 ml). The solid was collected by centrifugation and redissolved in 
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dichloromethane (1.5 mi) and precipitated with diethyl ether (30 mi). After this had 
been repeated two more times, the solid residue was dissolved in dichloromethane 
(1.0 mi) followed by addition of NN-dimethylaniline (37.6 gl, 0.297 mmol) and 
bromoacetonitrile (20.7 gl, 0.297 mmol). The reaction mixture was stirred at room 
temperature overnight and the solvents were removed under reduced pressure. The 
residue was purified by chromatography on silica gel. The appropriate fractions, 
which were eluted with dichloromethane-methanol (97: 3 v/v) were combined and 
evaporated under reduced pressure to give a colourless froth (50 mg). The material 
obtained was then dissolved in dry acetonitrile (1.0 mi) followed by addition of 2- 
NBO (0.120 g, 0.720 mmol, 5 eq. /function) and TMG (72.3 gl, 0.576 mmol, 4 
eq. /function). After 15 h, the reaction mixture was concentrated under reduced 
pressure and the residue was incubated in aqueous ammonia (1.0 mi, 33%, d 0.88) at 
55'C for 15 h. After the reaction mixture had been cooled, it was concentrated under 
reduced pressure, followed by azeotroping with ethanol (2x2 mi). The residue was 
dissolved in methanol (1.0 mi) and precipitated with ethyl acetate (30 mi). The solid 
obtained was collected by centrifugation. This was repeated two more times and the 
colourless solid was then dried in vacuo. The material was dissolved in water (3 mi) 
and passed through an Amberlite (IR120, Ne form) ion exchange column (1.5xlO 
cm). The nucleotide-containing fractions were pooled and concentrated under reduced 
pressure to a volume of ca. 2 mi. Upon freeze drying, a colourless powder was 
obtained (30 mg) which was identified as fully unblocked phosphate diester. 
8p[H2O] 0.090,0.0069. 
Rt (programme II): 10.60 min. 
HO-CpTpT-OH (530) 
Ac-Cp(s)Tp(s)T-Lev (45 mg, 32.86 gmol) was dissolved in dichloromcthane (0.5 ml) 
followed by addition of DBU (98.2 jil, 0.657 mmol) at room temperature. After 30 
min, a solution of trifluoroacetic: acid in dichloromethane (10% w/v, 0.674 ml, 0.591 
mmol) was added and stirred for 5 min. The reaction mixture was precipitated with 
diethyl ether (30 ml). The solid was collected by centrifugation and redissolved in 
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dichloromethane (1.0 ml) and precipitated with diethyl ether (30 ml). After this had 
been repeated two more times, the solid residue was dissolved in dichloromethane 
(0.5 ml) followed by addition of NN-dimethylaniline (25.0 RI, 0.197 mmol) and 
bromoacetonitrile (13.7 gi, 0.197 mmol). The reaction mixture was stirred at room 
temperature overnight and the solvents were removed under reduced pressure. The 
residue was purified by chromatography on silica gel. The oligonucleotide-containing 
fractions, which were eluted with dichloromethane-methanol (96: 4 v/v) were 
combined and evaporated under reduced pressure to give a colourless froth (25 mg). 
The material obtained was then dissolved in dry acetonitrile (0.5 ml) followed by 
addition of 2-NBO (0.062 g, 0.373 mmol, 5 eq. /function) and TMG (37.4 gi, 0.298 
mmol, 4 eq. /function). After 15 h, the reaction mixture was concentrated under 
reduced pressure and the residue was then incubated in aqueous ammonia (1.0 ml, 
33%, d 0.88) at 550C for 15 h. After the reaction mixture had been cooled, it was 
concentrated under reduced pressure, followed by azeotroping with ethanol (2x2 ml). 
The residue was dissolved in methanol (1.0 ml) and precipitated with ethyl acetate 
(30 ml). The solid obtained was collected by centrifugation. This was repeated two 
more times and the colourless solid was dried in vactio. The material was then 
dissolved in water (3 ml) and passed through an Amberlite (IR120, Na' form) ion 
exchange column (1.5xIO cm). The nucleotide containing fractions were pooled and 
concentrated under reduced pressure to a volume of ca. 2 ml. Upon freeze drying, a 
colourless powder was obtained (16 mg) which was identified as fully unblocked 
phosphate diester. 
p[HZO] 0.116. 
Rt (programme 1): 3.74 min. 
HO-CpTpTpGpCpG-OH (532) 
Ac-Cp(s)Tp(s)Tp(s)Gp(s)Cp(s)G-Lev (50 mg, 16.34 gmol) was dissolved in 
dichloromethane (1.0 ml) followed by addition of DBU (0.122 ml, 0.817 mmol) at 
room temperature. After 30 min, a solution of trifluoroacetic acid in dichloromethane 
(10% w/v, 0.838 ml, 0.735 mmol) was added. After 5 min, the reaction mixture was 
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precipitated by diethyl ether (30 ml). The solid was collected by centrifugation and 
redissolved in dichloromethane (1.0 ml) and precipitated with diethyl ether (30 ml). 
After this process had been repeated two more times, the solid material was dried and 
redissolved in dichloromethane (1.0 ml) followed by addition of NN-dimethylaniline 
(30.5 gl, 0.241 mmol) and bromoacetonitrile (16.8 gi, 0.241 mmol) at room 
temperature. After 15 h, the solvents were removed under reduced pressure and the 
residue was purified by chromatography. The appropriate fractions, which were 
eluted with dichloromethane-methanol (95: 5 v/v), were combined and concentrated 
under reduced pressure to give a colourless froth (20 mg). This material was 
dissolved in dry acetonitrile (0.5 ml). 2-NBO (50.0 mg, 0.301 mmol) and TMG (30.2 
[t], 0.241 mmol) were added. The reaction mixture was stirred at room temperature 
overnight and then concentrated under reduced pressure. The residue was heated in 
aqueous ammonia (0.6 ml, 33%, d 0.88) at 55'C for 15 h. After the reaction mixture 
had been cooled, it was concentrated under reduced pressure, followed by 
azeotroping with ethanol (2x2 ml). The residue was dissolved in methanol (1.0 ml) 
and precipitated with ethyl acetate (30 ml) and the solid obtained was collected by 
centrifugation. This was repeated two more times and the colourless solid was dried 
in vacuo. The material was then dissolved in water (3 ml) and was passed through an 
Amberlite (IR120, Ne form) ion exchange column (1.5XIO cm). The nucleotide- 
containing fractions were pooled and concentrated under reduced pressure to a 
volume of ca. 2 ml. Upon freeze drying, a colourless powder was obtained (10 mg) 
which was identified as fully unblocked phosphate diester. 
5p[H20] 0.585,0.255, -0.041, -0.120, -0.625. 
Rt (programme II): 9.64 min. 
HO-CpTpTpCpTpTpCpTpTpGpCpG-OH (12-mer, 533) 
Ac-12-Lev (50 mg, 8.648 gmol) was dissolved in dichloromethane (1.0 ml) followed 
by addition of DBU (0.142 ml, 0.951 mmol) at room temperature. After 30 min, a 
solution of trifluoroacetic acid in dichloromethane (10% w/v, 0.976 ml, 0.856 mmol) 
was added and stiffed for 5 min. The reaction mixture was precipitated by diethyl 
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ether (30 ml). The solid was collected by centrifugation and redissolved in 
dichloromethane (1.5 ml) and precipitated with diethyl ether (30 ml). After this 
process had been repeated two more times, the solid material was dried in vacito and 
redissolved in dichloromethane (1.0 ml), followed by addition of NN-dimethylani line 
(60.3 ýtl, 0.476 mmol) and bromoacetonitrile (33.2 gl, 0.476 mmol). The resulting 
solution was stirred at room temperature overnight and concentrated under reduced 
pressure. The residue was purified by chromatography on silica gel. The appropriate 
fractions, which were eluted with dichloromethane-methanol (96: 4 v/v) were 
combined and concentrated under reduced pressure to give a colourless glass (47 mg). 
This material was dissolved in acetonitrile (1.0 ml) followed by addition of 2-NBO 
(0.132 g, 0.793 mmol) and TMG (79.7 gl, 0.635 mmol), and the reaction mixture was 
stirred at room temperature for 15 h. The solvent was removed under reduced 
pressure and the residue was heated in conc. aqueous ammonia (1.5 ml, 33%, d 0.88) 
at 55'C for 15 h. After the reaction mixture had been chilled, it was concentrated 
under reduced pressure, followed by co-evaporation with ethanol (2x2 ml). The 
residue was dissolved in methanol (2.0 ml) and precipitated with ethyl acetate (40 
ml). The solid was collected by centrifugation and this was repeated two more times. 
The solid material obtained was then dried in vacuo. Water (3 ml) was added and the 
solution was run through an Amberlite (IR120, Na"' form) ion exchange column 
(LOXIO cm). The appropriate fractions were concentrated under reduced pressure to 
give the title compound as a colourless solid (19 mg). 
5p[H20] 0.245,0.188,0.104,0.015, -0.096, -0.223. 
Rt (programme 1): 10.40 min. 
HO-GpCpGpTpTpTpGpCpTpCpTpTpCpTpTpCpTpTpGpCpG-OH (21-mer, 
531) 
Ac-21-Lev (70 mg, 6.76 gmol) was dissolved in dichloromethane (1.0 ml) followed 
by addition of DBU (0.202 ml, 1.353 mmol) at room temperature. After 30 min, a 
solution of trifluoroacetic acid in dichloromethane (10% w/v, 1.39 ml, 1.217 mmol) 
was added and stirred for 5 min. Diethyl ether (40 ml) was added. The solid was 
238 
Chapter 7 Experimental 
collected by centrifugation and redissolved in dichloromethane (1.5 ml) and 
precipitated with diethyl ether (30 ml). This was repeated two more times and the 
solid obtained was dried in vacuo. This material was dissolved in dichloromethane 
(1.0 ml) followed by addition of NN-dimethylaniline (103 gl, 0.811 mmol) and 
bromoacetonitrile (56.5 gl, 0.811 mmol) at room temperature. After 15 h, the reaction 
mixture was concentrated under reduced pressure and the residue was purified by 
chromatography on silica gel. The appropriate fractions, which were eluted with 
dichloromethane-methanol (92: 8 v/v) were combined and concentrated under 
reduced pressure to give a colourless froth (37 mg). This material was dissolved in 
acetonitrile (1.0 ml), followed by addition of 2-nitrobenzaldoxime (107 mg, 0.643 
mmol) and TMG (64.5 gl, 0.514 mmol). The reaction mixture was stirred at room 
temperature overnight and then concentrated under reduced pressure. The residue was 
then heated in conc. aqueous ammonia (33%, d 0.88,1.5 ml) at 55'C for 15 h. After it 
had been chilled, the reaction mixture was concentrated under reduced pressure 
followed by azeotroping with ethanol (2x2 ml). The residue was dissolved in 
methanol (3 ml) and precipitated with ethyl acetate (40 ml). The precipitate was 
collected by centrifugation and this was repeated two more times. The solid obtained 
was dried in vacuo and dissolved in water (4 ml). The resulting solution was passed 
through an Amberlite JR120, Naý form) ion exchange column (3x2O cm). The 
appropriate fractions were concentrated under reduced pressure to give the title 
compound as a colourless solid (20 mg). 
8p[H201 1.323,0.233,0.201,0.172,0.106,0.088,0.002, -0.114, -0.244, -0.486. 
Rt (programme I): 3.12 min. 
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4,4ý-Dimethoxybenzophenone (8 g, 0.033 mol) was heated, under reflux, in thionyl 
chloride (37 ml) and DMF (0.2 ml) for 4 h. The excess of thionyl chloride was 
removed under reduced pressure. The residue was co-evaporated with dry toluene 
(2XIO ml) and further dried with an oil pump. The resulting off-white solid was 
dissolved in anhydrous THF (80 ml) and added dropwise to cooled (ice-water bath), 
stirred methanolic sodium methoxide (27%, 35 ml) over a period of 30 min. The 
reactants were allowed to warm up to room temperature and stirring was continued 
for a further I h. The products were then evaporated to dryness under reduced 
pressure. The residue was dissolved in dichloromethane (100 ml) and washed with 
saturated aqueous sodium hydrogen carbonate QXIOO ml). The dried (MgSO4) 
organic layer was concentrated under reduced pressure to give the title compound as a 
yellow solid (7.85 g, 82%), mp 104-106'C (ethanol). 
8H[CDC131: 3.09 (6 H, s), 3.77 (6 H, s), 6.82 (4 H, d), 7.38 (4 H, d). 
8c[CDC131: 49.18 (CHA 55.24 (CHA 102.78 (C), 113.29 (CH), 128.17 (CH), 135.05 
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Xanthone (19.62 g, 0.1 mol) in thionyl chloride (40 ml) was heated under refl ux for 4 
h. The excess of thiony] chloride was removed by distillation under atmospheric 
pressure and then evaporation under reduced pressure (water pump). The residue was 
co-evaporated with dry toluene (240 ml) and was then further dried at 60'C with an 
oil pump for Ih to give the title compound as a light yellow solid (25.50 g, ca. 






To a methanolic solution of sodium methoxide (25%, 76.3 ml, 2.83 mol) cooled to 
O'C, a solution of 9,9-dichloroxanthene (25.5 g, 0.1 mol) in tetrahydrofuran (100 ml) 
was added dropwise during a period of 30 min under nitrogen. After the addition was 
complete, the reaction mixture was allowed to warm up to room temperature and 
stirred for a further I h. The products were then concentrated to dryness under 
reduced pressure. The residue was dissolved in dichloromethane (150 ml) and washed 
with saturated aqueous sodium hydrogen carbonate (3xlOO ml). The dried organic 
layer (MgS04) was concentrated under reduced pressure to give the title compound 
(Found, in material recrystallized from ethanol-triethylamine: C, 74.19; H, 5.64%. 
C15HI403 requires: C, 74.36; H, 5.82) as a pale yellow solid (22.9 g, 94.5%), mp 59- 
61 'C. 
51, [CDC13): 2.94 (6 H, s), 7.23 (4 H, m), 7.42 (2 H, m), 7.74 (2 H, m). 
5c[CDC131: 51.81 (CH3)i 96-60 (C), 116.51 (CH), 118.77 (C), 123.38 (CH), 127.36 
(CH), 130.20 (CH), 153.23 (C). 
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Oxaloyl chloride (12.5 g, 8.6 ml, 0.098 mol), followed by well-powdered aluminium 
chloride (5 g, 37.5 rnmol) was added to a cooled (ice - water bath), stirred solution of 
di-p-tolyl ether (5 g, 0.0252 mol) in carbon disulphide (37 ml). After 2 h, more 
aluminium chloride (4.0 g, 30.0 mmol) was added and the reactants were allowed to 
warm up to room temperature. After 16 h, the products were added slowly to cooled 
(ice-water bath), stirred hydrochloric acid (ca. 3.2 M, 120 ml). After 30 min, the 
organic layer was separated and the aqueous layer was back-extracted with 
dichloromethane (5x5O ml). The combined organic layers were dried (MgS04) and 
concentrated under reduced pressure. The residue was stirred with saturated aqueous 
sodium hydrogen carbonate (100 ml) at 60'C for 20 min. The precipitated solid was 
collected by filtration and recrystallized from ethanol to give the title compound as 
colourless needles (5.1 g, 90%), mp 139-141'C. 
8, i[CDC131: 2.46 (6 H, s), 7.37 (2 H, d, J 8.6), 7.51 (2 H, dd, J 2.2 and 8.5), 8.11 (2 
H, d, J 1.3). 
5c[CDC131: 20.84 (CHA 117.71 (CH), 121.38 (C), 125.96 (CH), 133.43 (C), 135.89 
(CH), 154.37 (C), 177.32 (C). 
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2,7-Dimethylxanthone (5 g, 0.022 mol) was heated, under reflux, in thionyl chloride 
(25 ml) and DMF (ca. 0.2 ml) for 4 h. the products were evaporated to dryness under 
reduced pressure and the residue was co-evaporated with dry toluene (2x 15 ml) to 
give the title compound as a pink solid (6.1 g, ca. 100%). No attempt has been made 







A solution of 2,7-dimethyl-9,9-dichloroxanthene (6.1 g, 0.022 mol) in anhydrous 
THF (50 ml) was added dropwise to a cooled (ice - water bath), stirred solution of 
sodium methoxide in methanol (27%, 25 ml, ca. 0.11 mol) over a period of 30 min. 
The reactants were then allowed to warm up to room temperature and, after a further 
period of I h, the products were concentrated to dryness tinder reduced pressure. The 
residue was dissolved in dichloromethane (100 ml) and washed with saturated 
aqueous sodium hydrogen carbonate (3xlOO ml). The aqueous layer was back 
extracted with dichloromethane (2xlOO ml). The combined organic layers were dried 
NOW and evaporated under reduced pressure to give the title compound (Found, 
in material recrystallized from ethanol-triethylamine: C, 75.54; H, 6.66%. C17HI803 
requires: C, 75.53; H, 6.71 %) as a yellow solid (5.5 g, 91 %), mp 81-82.5'C. 
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5H[CDC131: 2.40 (6 H, s), 2.92 (6 H, s), 7.08 (2 H, d, J 8.3) 7.20 (2 H, d, J 8.3), 7.50 
(2 H, s). 
8C[CDC131: 153.23 (C), 132.64 (C), 131.09 (CH), 126.98 (CH), 118.16 (C), 116.21 
(CH), 96.94 (C), 51.84 (CHA 20.91 (CH3)- 










Uridine (0.3 g, 1.23 mmol) and dimethoxydi-(p-anisyl)methane (0.459 g, 1.59 mmol) 
were co-evaporated with dry acetonitrile (2xlO ml). The residue was then suspended 
in dry acetonitrile (20 ml) followed by addition of (±)-10-camphorsulphonic acid (20 
mg). After the reactants had been stirred at room temperature for 2 h, triethylamine 
(0.5 ml) was added. The products were then concentrated under reduced pressure. 
The residue was partitioned between dichloromethane (20 ml) and saturated aqueous 
sodium hydrogen carbonate (2x2O ml). The layers were separated and the dried 
(MgS04) organic layer was evaporated under reduced pressure. The residue was 
purified by chromatography on silica gel. The appropriate fractions, which were 
eluted with dichloromethane-methanol (9: 1 v/v) were combined and concentrated 
under reduced pressure to give the title compound (Found, in material recrystallized 
from dichloromethane: C, 61.1; H, 5.2; N, 5.65. C24H24N208-0.2 H20 requires C, 
61.06; H, 5.2 1; N, 5.93%; mp I 12-1140C) as a colourless solid (0.415 g, 95%). 
8H[(CD3)2SOI: 3.55-3.61 (2 H, m), 3.75 (3 H, s), 3.76 (3 H, s), 4.26 (1 H, m), 4.69 (1 
H, dd, J 3.2 and 6.6), 4.90 (1 H, dd, J 2.6 and 6.6), 5.11 (1 H, t, ex, J 5.4), 5.62 (1 H, 
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d, J 2.6), 6.00 (1 H, d, J 2.6), 6.88-6.96 (4 H, m), 7.29-7.37 (4 H, m), 7.81 (1 H, d, J 
8.1), 11.40 (1 H, s, ex). 
5c[(CD3)2SOI: 55.12 (CH3), 61.35 (CHA 81.58 (CH), 84.14 (CH), 86.27 (CH), 91.38 
(CH), 101.72 (CH), 113.34 (CH), 113.62 (CH), 127.34 (CH), 127.62 (CH), 133.34 
(C), 142.30 (C), 150.33 (C), 159.14 (C), 159.28 (C), 163.17 (C). 
Rf (System B): 0.53. 
2', 3'-O-(Xanthen-9-ylidene)uridine (616a) 
H 
616a 
Uridine (0.3 g, 1.23 mmol) and 9,9-dimethoxyxanthene (0.44 g, 1.84 mmol) were co- 
evaporated with acetonitrile (2xlO nil) and then suspended in acetonitrile (20 nil) 
followed by addition of (±)-10-camphorsulphonic acid (20 mg). After the reaction 
mixture had been stirred for 2h under argon, triethylamine (0.5 nil) was added. The 
products were concentrated under reduced pressure and the residue was partitioned 
between dichloromethane (20 nil) and saturated aqueous sodium hydrogen carbonate 
(2X20 nil). The layers were separated and the dried (MgS04) organic layer was 
concentrated under reduced pressure. The residue was purified by chromatography on 
silica gel. The appropriate fractions, which were eluted with dichloromethane- 
methanol (98: 2 v/v) were combined and concentrated under reduced pressure to give 
the title compound (Found, in material recrystallized from dichloromethane: C, 61.3; 
H, 4.2; N, 6.4. C22HI8N207-0.5 H20 requires: C, 61.25; H, 4.44; N, 6.50%; mp 152- 
153'Q as a colourless solid (0.46 g, 88%). 
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5H[(CD3)2SOI: 3.68 (2 H, m), 4.40 (1 H, m), 5.22 (2 H, m), 5.48 (1 H, dd, J 2.5 and 
6.4), 5.70 (1 H, d, J 8.0), 6.14 (1 H, d, J 2.5), 7.35 (4 H, m), 7.55 (1 H, dd, J 1.2 and 
7.8), 7.75 (1 H, dd, J 1.2 and 2.5), 7.92 (2 H, m), 11.48 (1 H, br, s). 
8c[(CD3)2SOI: 61.38 (CH2), 82.54 (CH), 85.44 (CH), 86.39 (CH), 91.36 (CH), 
101.73 (CH), 105.12 (C), 116.55 (CH), 116.83 (CH), 121.09 (C), 122.68 (C), 123.66 
(CH), 123.89 (CH), 125.52 (CH), 126.43 (CH), 130.43 (CH), 130.97 (CH), 142.06 
(CH), 150.28 (C), 150.48 (C), 151.71 (C), 163.30 (C). 
Rf (System B): 0.54. 
2', 3'-O-(2,7-Dimethylxanthen-9-ylidene)uridine (616b) 
616b 
Uridine (300 mg, 1.23 mmol) and 2,7-dimethyl-9,9-dimethoxyxanthene (0.54 g, 2.0 
mmol) were co-evaporated with dry acetonitrile (2XIO ml). The residue was 
suspended in dry acetonitrile (15 ml) followed by addition of (±)-10- 
camphorsulphonic acid (20 mg). After 4 h, triethylamine (0.5 ml) was added. The 
products were then concentrated under reduced pressure. The residue was partitioned 
between dichloromethane (30 ml) and saturated aqueous sodium hydrogen carbonate 
(2X20 ml). The layers were separated. The dried (MgS04) organic layer was 
evaporated under reduced pressure. The residue was then fractionated by 
chromatography on silica gel. The appropriate fractions, which were eluted with 
dichloromethane-methanol (98: 2 v/v) were combined and concentrated under 
reduced pressure to give the title compound (Found, in material recrystallized from 
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dichloromethane: C, 63.9; H, 4.8; N, 6.1. C24H22N207 requires: C, 64.00; H, 4.92; N, 
6.22%) as a colourless solid (0.39 g, 70%), mp 153-155'C. 
8H[(CD3)2SOI: 2.39 (3 H, s), 2.40 (3 H, s), 3.63-3.70 (2 H, m), 4.36 (1 H, m), 5.14 (1 
H, dd, J 2.8 and 6.3), 5.22 (1 H, t, ex, J 5.3), 5.45 (1 H, dd, J 2.9 and 6.3), 5.69 (1 H, 
dd, J 1.9 an d 8.0), 6.15 (1 H, d, J 2.7), 7.20-7.29 (2 H, m), 7.3 1-7.3 6 (2 H, m), 7.4 9 
(I H, s), 7.69 (1 H, s), 7.90 (2 H, d, J 8.0), 11.47 (1 H, br, s). 
5c[(CD3)2SOI: 20.52 (CH3), 61.32 (CH2), 82.28 (CH), 85-26 (CH), 86.05 (CH), 
90.96 (CH), 10 1.74 (CH), 105.38 (C), 116.26 (CH), 116.54 (CH), 120.67 (C), 122.28 
(C), 125.21 (CH), 126.10 (CH), 130.97 (CH), 131.54 (CH), 132.57 (C), 132.69 (C), 
141.83 (CH), 148.43 (C), 149.88 (C), 150.52 (C), 163.24 (C). 






Glycerol (0.74 ml, 10 mmol) and 9,9-dimethoxyxanthene (1.21 g, 5 mmol) were co- 
evaporated with dry acetonitrile (10 ml). The residue was then taken up with dry 
acetonitrile (20 ml). (±)-IO-Camphorsulphonic acid (10 mg) was added and the 
mixture was allowed to stir under argon at room temperature. After 4 h, triethylamine 
(0.1 ml) was added and the resulting reaction mixture was concentrated under 
reduced pressure. The residue was partitioned between dichloromethane (20 ml) and 
saturated sodium hydrogen carbonate (2XIO ml). The dried (MgS04) organic layer 
was concentrated and the residue was purified by chromatography on silica gel: the 
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appropriate fractions, which were eluted with dichloromethane-methanol (99: 1 v/v) 
were combined and evaporated under reduced pressure to give the title conlj)ound 
(Found, in material recrystallized from ethyl acetate-petroleum spirit (bp 40-60'C): 
C, 70.8; H, 5.2. C16HI404 requires: C, 7 1.10; H, 5.22%) as a colourless solid (I. I g, 
81.4%). mp 108-109.5'C; Rf (system B) 0.52; Xmax (EtOH)/nm. 288 (F- 3680). 
5H[(CD3)2SO]: 3.67-3.80 (2 H, m), 4.05 (1 H, t, J 7.9), 4.38 (1 H, dd, J 6.3 and 7.9), 
4.58-4.65 (1 H, m), 5.14 (1 H, t, ex, J 5.6), 7.26-7.33 (4 H, m), 7.46-7.51 (2 H, ni), 
7.72 (1 H, dd, J 1.3 and 7.8), 7.89 (1 H, dd, J 1.3 and 7.8). 
8c[(CD3)2SOI: 61.07 (CH2), 67.37 (CH2), 78.48 (CH), 100.24 (C), 116.17 (CH), 
116.44 (CH), 123.22 (C), 123.48 (CH), 123.84 (C), 126.46 (CH), 127.02 (CH), 
130.05 (CH), 130.22 (CH), 150.65 (C), 151.15 (C). 
(±)-1,2-0-(2,7-Dimethylxanthen-9-ylidene)glyceroI (630b) 
630b 
2,7-Dimethyl-9,9-dimethoxyxanthene (0.81 g, 3 mmol) and glycerol (0.369 g, 4 
mmol) were co-evaporated with dry acetonitrile (2xIO ml) and the residue was 
redissolved in anhydrous acetonitrile (20 ml). Then (±)-10-camphorsulphonic acid 
(10 mg) was added and the mixture was allowed to stir under argon at room 
temperature. After 4 h, triethylamine (0.1 ml) was added. The reaction mixture was 
concentrated under reduced pressure. The residue was dissolved in dichloromethane 
(20 ml) and washed with saturated sodium hydrogen carbonate (2xlO ml). The dried 
(MgS04) dichloromethane layer was concentrated under reduced pressure. The 
residue was purified by chromatography on silica gel. The appropriate fractions, 
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which were eluted with dichloromethane - methanol (99: 1 v/v) gave the title 
compound (Found, in material recrystallized from ethyl acetate - petroleum spirit (bp 
40-60'C): C, 71.6; H, 6.2. C18H1804-0.2 H20 requires: C, 71.60; H, 6.14%) as a 
colourless solid (0.60 g, 67%), mp 137-138'C, Rf (system B) 0.60. Xmax (EtOH)/nm 
297 (P- 39 10). 
5H[(CD3)2SOI: 2.34 (3 H, s), 2.36 (3 H, s), 3.67-3.78 (2 H, m), 4.03 (1 H, t, J 7.9), 
4.39 (1 H, dd, J 6.3 and 7.8), 4.58-4.62 (1 H, m), 5.11 (1 H, t, ex, J 5.6), 7.15 (2 H, 
dd, J 5.3 and 8.4), 7.24 (2 H, dd, J 1.9 and 8.3), 7.47 (1 H, d, J 1.4), 7.63 (1 H, d, j 
1.6). 
5c[(CD3)2SOI: 20.46 (CHA 20.50 (CHA 61.06 (CH2), 67.47 (CH2), 78.27 (CH), 
100.46 (C), 115.84 (CH), 116.09 (CH), 122.72 (C), 123.37 (C), 126.18 (CH), 126.72 
(CH), 130.58 (CH), 130.76 (CH), 132.13 (C), 132.23 (C), 148.69 (C), 149.21 (C). 




D-Mannitol (1.82 g, 10 mmol) was azeotroped with dry pyridine (20 1111) and tile 
residue was suspended in dry pyridine (30 ml) and cooled to O'C (ice-water bath). 
9,9-Dichloroxanthene (6.32 g, 50 mmol) was added and after 10 min the reaction 
mixture was allowed to warm up to room temperature. After I h, the products were 
poured into saturated aqueous sodium hydrogen carbonate (150 ml). After the 
resulting mixture had been stirred at room temperature for I h, the precipitate was 
collected by filtration and washed with water (340 ml). The air-dried solid was 
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suspended in ethyl acetate (25 ml) with stirring for 10 min and petroleum spirit (bp 
40-60'C, 25 ml) was added. After I h, the mixture was filtered and the residue was 
washed with ethyl acetate-petroleum spirit (1: 1 v/v, 40 ml) to give the title compolind 
as an off-white solid (4.55 g, 84.5%) (Found in material recrystallized from ethyl 
acetate: C, 7 1.0; H, 4.8. C32H2608 requires C, 70.89; H, 4.9 1 %) mp 222.5-224'C. 
5H[(CD3)2SOI: 3.83 (2 H, t, J 7.7), 4.13 (2 H, m), 4.31 (2 H, dd, J 6.2,8.3), 4.62 (2 H, 
dd, J 6.9 and 13.9), 5.25 (2 H, d, ex, J 7.7), 6.81 (2 H, m), 7.22 (6 H, m), 7.34 (2 H, 
7.41 (2 H, m), 7.64 (4 H, dd, J 1.3 and 7.8). 
5c[(CD3)2SOI: 68.60 (CH2), 70.91 (CH), 77.24 (CH), 100.46 (C), 116.56 (CH), 
116.79 (CH), 123.40 (C), 123.73 (CH), 123.80 (CH), 124.02 (C), 126.79 (CH), 
127.04 (CH), 130.43 (CH), 130.51 (CH), 150.97 (C), 151.52 (C). 




Lead (IV) acetate (9.05 g, 20.4 mmol) was added in one portion to a stirred, cooled 
(ice-water bath) mixture of 1,2: 5,6-di-O-(xanthen-9-ylidene)-D-mannitoI (3.15 g, 
5.83 mmol), sodium hydrogen carbonate (1.96 g, 23.3 mmol) and ethyl acetate (115 
ml). After I h, the products were filtered through a bed of Celite (20 g) and the 
residue was washed with ethyl acetate (30 ml). The combined filtrate and washings 
were added dropwise over a period of 15 min to a stirred solution of sodium 
borohydride (1.75 g, 47.3 mmol) in ethanol (115 ml) at O'C. After a further period of 
I h, sodium hydroxide pellets (0.8 g) and then 1.0 M aqueous sodium hydroxide (50 
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ml) were added with continued stirring. The products were filtered and the layers 
were separated. The aqueous layer was extracted with dichloromethane (3X20 ml) and 
the combined organic layers were concentrated to dryness. When petroleum spirit 
(bp 40-60'C, 100 ml) was added to a solution of the residue in dichloromethane (20 
ml), the title compound (Found, in material recrystallized from ethyl acetate- 
petroleum spirit (bp 40-60'Q: C, 70.85; H, 5.1. C16HI404 requires: C, 71.10; H, 
5.22%, ) was obtained as a colourless solid, mp 105-107'C. Rf (System 13): 0.59, 
[()C] 20 +15.7 (c 1.5, ethanol). D 
8H[(CD3)2SOI: 3.66-3.78 (2 H, m), 4.03 (1 H, t, J 7.9), 4.37 (1 H, dd, J 6.3 and 7.9), 
4.58-4.64 (1 H, m), 5.11 (1 H, t, ex, J 5.6), 7.25-7.32 (4 H, m), 7.46-7.51 (2 H, m), 
7.70 (1 H, dd, J 1.3 and 7.8), 7.87 (1 H, dd, J 1.3 and 7.8). 
5c[(CD3)2SOI: 60.95 (CH2), 67.26 (CH2), 78.36 (CH), 100.09 (C), 116.05 (CH), 
116.32 (CH), 123.09 (C), 123.37 (CH), 123.72 (C), 126.34 (CH), 126.89 (CH), 
129.94 (CH), 130.11 (CH), 150.51 (C), 151.02 (C). 
()ý- (-)-1,2-0 -(Xanthen-9 -yl idene) glycerol (634a) 
HO 
634a 
A solution of L-ascorbic acid (2.67 g, 15.2 mmol) and 9,9-dimethoxyxanthene (4.5 g, 
18.6 mmol) in acetonitrile (20 ml) was evaporated under reduced pressure. The 
residue was suspended in dry acetonitrile (40 ml) and (±)-10-camphorsulphonic acid 
(50 mg, 0.22 mmol) was added. The reactants were heated, under reflux, in an 
atmosphere of nitrogen for 3 h. The resulting mixture was evaporated to half volume 
and lithium carbonate (2.29 g, 31 mmol) was added. The resulting mixture was 
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evaporated to dryness under reduced pressure and the residue was dissolved in water 
(70 ml). Aqueous hydrogen peroxide (25%, 5.5 ml, 48 mmol) was added dropwise 
over 5 min to the stirred, cooled (ice-water bath) solution. After a further period of 10 
minutes, the reactants were allowed to warm up to room temperature. After 16 h, tile 
products were filtered and the filtrate was concentrated to dryness under reduced 
pressure. After it had been co-evaporated with absolute ethanol (220 ml), the residue 
was extracted with boiling ethanol (270 ml). The extract was concentrated to dryness 
under reduced pressure. The residue was dissolved in ethyl acetate (60 ml) and 
sodium hydrogen carbonate (2.56 g, 30.5 mmol) was added. Lead (IV) acetate (6.8 g, 
15.2 mmol) was then added in two portions to the cooled (ice-water bath), stirred 
mixture. After 30 min, the reactants were allowed to warm up to room temperature. 
After a further period of 3 h, the products were cooled (ice-water bath) and filtered 
through a bed of Celite. The residue was washed with ice-cold ethyl acetate (40 mi). 
The combined filtrate and washings were added dropwise to a cooled (ice-water 
bath), stirred suspension of sodium borohydride (0.756 g, 20 mmol) in absolute 
ethanol (80 ml). The reactants were then allowed to warm up to room temperature. 
After a further period of 3 h, aqueous sodium hydroxide (1.0 M, 40 ml) was added to 
the products and stirring was continued for an additional 30 min. The layers were 
separated and the aqueous layer was extracted with dichloromethane (4x6O ml). The 
combined organic layers were concentrated under reduced pressure and the residue 
was partitioned between dichloromethane (50 ml) and water (50 ml). The aqueous 
layer was extracted with dichloromethane (2x3O ml). The combined organic layers 
were dried (MgS04) and evaporated under reduced pressure. The residue was 
fractionated by short column chromatography on silica gel. The appropriate fractions, 
which were eluted with dichloromethane, were combined and evaporated under 
reduced pressure to give the title compound as a colourless solid (1.7 g, 41.5% overall 
yield) (Found, in material recrystallized from ethyl acetate-petroleum spirit (bp 40- 
60'Q: C, 70.7; H, 5.3. C16HI404'0-1 H20 requires C, 70.63; H, 5.26%), mp, 105- 
106'C, Rf 0.52 (system B), [(X] 20 -15.3 (c 1.5, ethanol). The 1H and 13 C NMR spectra D 
of this compound were identical to the corresponding spectra of the racemic material. 
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1,2: 5,6-Di-O-(2,7-dimethylxanthen-9-ylidene)-D-mannitoI (631b) 
631b 
A suspension of D-mannitol (0.364 g, 2.0 mmol) in dry pyridine (2x5 ml) was 
evaporated under reduced pressure. The residue was suspended in dry pyridine (10 
ml) and cooled (ice-water bath). 9,9-Dichloro-2,7-dimethylxanthene (1.34 g, ca. 4.8 
mmol) was added. After 10 min, the reactants were allowed to warm up to room 
temperature with continued stirring. After a further period of 2 h, methanol (I ml) 
was added and the products were concentrated under reduced pressure. The residue 
was partitioned between dichloromethane (50 ml) and saturated aqueous sodium 
hydrogen carbonate (50 ml). The dried (MgS04) organic layer was evaporated under 
reduced pressure. The residue was purified by short column chromatography on silica 
gel. The appropriate fractions, which were eluted with dichloromethane-methanol 
(99: 1 v/v) were combined and evaporated under reduced pressure to give the title 
compound as a colourless froth (0.97 g, 81 %) (Found: M', 594.223 1,12 C361 H34 160,, 
requires nilz 594.2254), Rf (system B) 0.59. 
8H[(CD3)2SOI: 2.00 (6 H, s), 2.38 (6 H, s), 3.94 (2 H, d, J 7.7), 4.19 (2 H, t, J 7.8), 
4.42 (2 H, m), 4.73 (2 H, m), 5.38 (2 H, s, ex, J 7.7), 7.11-7.19 (6 H, m), 7.27 (2 H, 
m), 7.49 (4 H, d, J 6.9). 
8c[(CD3)2SOI: 19-99 (CHA 20.44 (CHA 68.16 (CH2), 70.61 (CH), 76.93 (CH), 
100.51 (C), 115.80 (CH), 116.07 (CH), 122.52 (CH), 123.21 (C), 126.19 (CH), 
126.43 (CH), 130.57 (CH), 130.64 (CH), 132.13 (C), 148.66 (C), 149.13 (C). 
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(Cl r(+)-1,2-0-(2,7-Dimethylxanthen-9-ylidene)glyceroI (632b) 
632b 
Water (1.5 ml), sodium hydrogen carbonate (0.05 g, 0.6 mmol) and sodium 
metaperiodate (0.236 g, 1.1 mmol) were added to a stirred solution of 1,2: 5,6-di-0- 
(2,7-dimethylxanthen-9-ylidene)-D-mannitoI (0.330 g, 0.55 mmol) in THIF (5 ml) at 
room temperature. After 3 h, the products were concentrated under reduced pressure 
and the residue was partitioned between dichloromethane (15 ml) and saturated 
aqueous sodium hydrogen carbonate (15 ml). The aqueous layer was separated and 
back-extracted with dichloromethane (2x5 ml). The combined organic layers were 
dried (MgS04) and added dropwise over a period of 30 min to a suspension of 
sodium borohydride (0.083 g, 2.2 mmol) in ethanol (5 ml). After 30 min, acetone (I 
ml) was added. After a further period of 10 min, the products were evaporated under 
reduced pressure. The residue was partitioned between dichloromethane (15 ml) and 
saturated aqueous sodium hydrogen carbonate (15 ml). The layers were separated and 
the aqueous layer was back-extracted with dichloromethane (2x5 ml). The combined 
organic layers were dried (MgS04) and concentrated under reduced pressure. The 
residue was fractionated by short column chromatography on silica gel. The 
appropriate fractions, which were eluted with dichloromethane-methanol (99: 1 v/v) 
were combined and evaporated under reduced pressure to give the title compound as a 
colourless glass (0.230 g, 69% which later solidified (found, in material 
recrystallized from ethyl acetate-petroleum spirit (bp 40-60'C): C, 72.2; H, 6.0. 
C18HI804 requires: C, 72.47; H, 6.08% mp 143-144'C; Rf (system B) 0.60; 
[(X] 20+18.2 (c 1.5, ethanol). The 1H and 13 C NMR spectra were identical to the D 
corresponding spectra obtained from the racemic material. 
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(*(-) -1,2-0 -(2,7-Di methylxan then -9-ylidene)glycerol (634b) 
634b 
L-Ascorbic acid (1.48 g, 8.3 mmol) was heated, under reflux, with 9,9-dimethoxy- 
2,7-dimethylxanthene (2.7 g, 10.0 mmol) in the presence of (±)-10-camphorsulphonic 
acid (20 mg, 0.09 mmol) in dry acetonitrile (30 ml) for 3h as in the above preparation 
of U; ý(-)-1,2-0-(xanthen-9-ylidene)glycerol. Subsequent reactions with aqueous 
hydrogen peroxide, lead (IFV) acetate in ethyl acetate and sodium borohydride in 
ethanol-ethyl acetate, as in the above preparation of - 1,2-0- (xan then -9- 
ylidene)glycerol and with the same stoichiometry gave, after chromatography, the 
title compound as a colourless solid (0.800 g, 32% overall yield) (Found, in material 
recrystallized from ethyl acetate - petroleum spirit (bp 40-60'C): C, 72.4; H, 6.1. 
C18HI804 requires: C, 72.47; H, 6.08%), mp 143-144'C; Rf (System B) 0.60; 
[CC] 20-18.2 (c 1.5, ethanol). The 1H and 13 C NMR spectra of this compound were D 
identical to the corresponding spectra of the racemic material. 
(±)-l-O-Stearoylglycerol (635) 
0 
HO 0 'lý C17H35 
OH 
635 
To a stirred solution of (±)-1,2-0-(xanthen-9-ylidene)glyceroI (0.811 g, 3.0 mmol) in 
dichloromethane (15 ml), 1-methylimidazole (0.477 ml, 6.0 mmol) was added, 
followed by addition of a solution of stearoyl chloride (1.090 g, 3.6 mmol) in 
dichloromethane (15 ml). After 1.5 h, triethylamine (1.0 ml) and water (0.2 ml) were 
added and the reaction mixture was stirred for 10 min and then poured into saturated 
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aqueous sodium hydrogen carbonate (15 ml). The layers were separated and the 
organic layer was further washed with saturated aqueous sodium hydrogen carbonate 
(15 ml). The dried (MgS04) organic layer was concentrated under reduced pressure. 
The residue was stirred in methanol (15 ml) for 30 min. The mixture was chilled (ice 
-water bath) and filtered to give the putative (±)-l-0-stearoyl-2,3-0-(xanthen-9- 
ylidene)glycerol as a colourless solid (1.432 g, 89.7%). 
This material (0.532 g, ca. 1.0 mmol) was dissolved in a solution of pyrrole in 
dichloromethane (3.4 ml, 1: 9 v/v) followed by addition of a solution of dichloroacetic 
acid in dichloromethane (3.4 ml, 1: 9 v/v). After 15 min, the reaction mixture was 
partitioned between dichloromethane (10 ml) and sodium phosphate buffer (20 ml, 
1.0 M, pH 6.0). The layers were separated and the organic layer was further washed 
with the above phosphate buffer (15 ml). The combined aqueous layers were back- 
extracted with dichloromethane (20 ml). The combined, dried (MgS04) organic 
layers were concentrated under reduced pressure. The residue was taken up with 
diethyl ether (20 ml) followed by addition of a solution of anhydrous iron (111) 
chloride (0.487 g, 3.0 mmol) in diethyl ether (30 ml). After 30 min, the solid formed 
was removed by filtration and washed with diethyl ether (2xl5 ml). The filtrate and 
washings were combined and washed with aqueous sodium phosphate buffer (4x25 
ml, 1.0 M, pH 6.0). The aqueous layers were filtered through a bed of Celite and 
back-extracted with diethyl ether (2xl5 ml). The combined dried (MgS04) ether 
layers were concentrated under reduced pressure to a volume of ca. 50 ml and stirred 
with activated charcoal (0.3 g) for 30 min. The mixture was then filtered through a 
bed of Celite and washed with diethyl ether (2xl5 ml). The filtrate and washings 
were combined and concentrated under reduced pressure to give the title compound 
(0.320 g, 90.4%). (Found, in material recrystallized from hexane: C, 69.5; H, 11.75. 
C21H4204'0.25 H20 requires C, 69.47; H, 11.80%) as a colourless solid, mp 72-73'C. 
5H[CDC]31 0-81 (3 H, t, J 6.8), 1.20 (28 H, m), 1.55 (2 H, m), 2.28 (2 H, t, J 7.6), 3.53 
(I H, dd, J 5.8 and 11.5), 3.63 (1 H, dd, J 3.9,11.5), 3.87 (1 H, m), 4.08 (1 H, dd, J 
6.1 and 11.7), 4.14 (1 H, dd, J 4.7 and 11.7). 
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8H[CDC131 13.88,22.06,24.39,28.43,28.68,28.86,29.00,30.33,31.26,33.41, 
62.56,65.41,69.21,172.85. 
The above experiment was repeated on the same scale and with the same 
stoichiometry, starting from (±)-1,2-0-(2,7-dimethylxanthen-9-ylidene)glyceroI 
(0.895 g, 3.0 mmol) instead of (±)-1,2-0-(xanthen-9-ylidene)glycerol. The 
intermediate putative 1-0-stearoyl-2,3-0-(2,7-dimethylxanthen-9-ylidene)glyceroI 
(1.61 g) was obtained as a colourless solid. This material (0.565 g) was converted into 
(±) -I -0-stearoyl glycerol (0.322 g, 85% overall yield) under precisely the same 
conditions described above. The physical properties (mp, 1H and 13 C NMR spectra) of 








To a stiffed solution of g(-)-1,2-0-(xanthen-9-ylidene)glyceroI (0.811 g, 3.0 mmol) 
in dichloromethane (15 ml), 1-methylimidazole (0.477 ml, 6.0 mmol) was added, 
followed by addition of a solution of stearoyl chloride (1.090 g, 3.6 mmol) in 
dichloromethane (15 ml). After 1.5 h, triethylamine (1.0 ml) and water (0.2 ml) were 
added and the reaction mixture was stirred for 10 min and then poured into saturated 
aqueous sodium hydrogen carbonate (15 ml). The layers were separated and the 
organic layer was further washed with saturated aqueous sodium hydrogen carbonate 
(15 ml). The dried (MgS04) organic layer was concentrated under reduced pressure. 
The residue was stirred in methanol (15 ml) for 30 min. The mixture was chilled (ice 
- water bath) and filtered to give the putative (Sý1-0-stearoyl-2,3-0-(xanthen-9- 
ylidene)glycerol as a colourless solid (1.484 g). 
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This material (0.565 g, ca. 1.0 mmol) was dissolved in a solution of pyrrole in 
dichloromethane (3.4 ml, 1: 9 v/v) followed by addition of a solution of dichloroacetic 
acid in dichloromethane (3.4 ml, 1: 9 v/v). After 15 min, the reaction mixture was 
partitioned between dichloromethane (10 ml) and sodium phosphate buffer (20 ml, 
1.0 M, pH 6.0). The layers were separated and the organic layer was further washed 
with the above phosphate buffer (15 ml). The combined aqueous layers were back- 
extracted with dichloromethane (20 ml). The combined, dried (MgS04) organic 
layers were concentrated under reduced pressure. The residue was taken up with 
diethyl ether (20 ml) followed by addition of a solution of anhydrous iron (HI) 
chloride (0.487 g, 3.0 mmol) in diethyl ether (30 ml). After 30 min, the solid formed 
was removed by filtration and washed with diethyl ether (2xl5 ml). The filtrate and 
washings were combined and washed with aqueous sodium phosphate buffer (4x25 
ml, 1.0 M, pH 6.0). The aqueous layers were filtered through a bed of Celite and 
back-extracted with diethyl ether (2xl5 ml). The combined dried (MgS04) ether 
layers were concentrated under reduced pressure to a volume of ca. 50 ml and stirred 
with activated charcoal (0.3 g) for 30 min. The mixture was then filtered through a 
bed of Celite and washed with diethyl ether (2xl5 ml). The filtrate and washings 
were combined and concentrated under reduced pressure to give the title comj)ound 
(0.325 g, 79% overall yield). (Found, in material recrystallized from hexane: C, 69.9; 
H, 11-9- C2jH4204'0-l H20 requires C, 69.99; H, 11.8%) as a colourless solid, mp 
68.5-69.5'C; [(X] 20 +3.64 (c 4.1; C5H5N). D 
5H[CDC]31 0.81 Q H, t, J 6.8), 1.20 (28 H, m), 1.55 (2 H, m), 2.28 (2 H, t, J 7.6), 3.53 
(I H, dd, J 5.8 and 11 -5), 3.63 (1 H, dd, J 3.9,11.5), 3.87 (1 H, m), 4.08 (1 H, dd, J 
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(4(-)-l-O-Stearoylglycerol (639) 
OH 
Ho 0y C17H35 
0 
639 
To a stirred solution of (Sý(+)-1,2-0-(xanthen-9-ylidene)glyceroI (0.811 g, 3.0 mmol) 
in dichloromethane (15 ml), I-methylimidazole (0.477 ml, 6.0 mmol) was added, 
followed by addition of a solution of stearoyl chloride (1.090 g, 3.6 mmol) in 
dichloromethane (15 ml). After 1.5 h, triethylamine (1.0 ml) and water (0.2 ml) were 
added and the reaction mixture was stirred for 10 min and then poured into saturated 
aqueous sodium hydrogen carbonate (15 ml). The layers were separated and the 
organic layer was further washed with saturated aqueous sodium hydrogen carbonate 
(15 ml). The dried (MgS04) organic layer was concentrated under reduced pressure. 
The residue was stirred in methanol (15 ml) for 30 min. The mixture was chilled (ice 
- water bath) and filtered to give the putative (41-0-stearoyl-2,3-0-(xantheii-9- 
ylidene)glycerol as a colourless solid (1.406 g). 
This material (0.565 g, ca. 1.0 mmol) was dissolved in a solution of pyrrole in 
dichloromethane (3.4 ml, 1: 9 v/v) followed by addition of a solution of dichloroacetic 
acid in dichloromethane (3.4 ml, 1: 9 v/v). After 15 min, the reaction mixture was 
partitioned between dichloromethane (10 ml) and sodium phosphate buffer (20 ml, 
1.0 M, pH 6.0). The layers were separated and the organic layer was further washed 
with the above phosphate buffer (15 ml). The combined aqueous layers were back-- 
extracted with dichloromethane (20 ml). The combined, dried (MgS04) organic 
layers were concentrated under reduced pressure. The residue was taken up with 
diethyl ether (20 ml) followed by addition of a solution of anhydrous iron (111) 
chloride (0.487 g, 3.0 mmol) in diethyl ether (30 ml). After 30 min, the solid formed 
was removed by filtration and washed with diethyl ether (2xl5 ml). The filtrate and 
washings were combined and washed with aqueous sodium phosphate buffer (4x2s 
ml, 1.0 M, pH 6.0). The aqueous layers were filtered through a bed of Celite and 
back-extracted with diethyl ether (2XI5 ml). The combined dried (MgS04) ether 
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layers were concentrated under reduced pressure to a volume of ca. 50 ml and stirred 
with activated charcoal (0.3 g) for 30 min. The mixture was then filtered through a 
bed of Celite and washed with diethyl ether (2xl5 ml). The filtrate and washings 
were combined and concentrated under reduced pressure to give the title compound 
(0.333 g, 77% overall yield). (Found, in material recrystallized from hexane: C, 69.8; 
H, 11 -9- C21H4204-0.2 
H20 requires C, 69.6 1; H, 11.8%) as a colourless solid, mp 69- 
70'C; [(X] 20 -3.68 (c 4.1; C5H5N). D 
5H[CDC]31 0-81 (3 H, t, J 6.8), 1.20 (28 H, m), 1.55 (2 H, m), 2.28 (2 H, t, J 7.6), 3.53 
(I H, dd, J 5.8 and 11.5), 3.63 (1 H, dd, J 3.9,11.5), 3.87 (1 H, m), 4.08 (1 H, dd, J 
6.1 and 11.7), 4.14 (1 H, dd, J 4.7 and 11.7). 




(a) (±)-i-O-Stearoyl-2,3-0-(xanthen-9-ylidene)glyceroI (0.532 g, 1.0 mmol), the 
putative intermediate in one of the above preparations of (±)- I- 0-stearoyl glycerol, 
was dissolved in pyrrole - dichloromethane (1: 9 v/v; 3.4 ml; ca. 4.9 mmol of pyrrole) 
and dichloroacetic acid - dichloromethane (1: 9 v/v; 3.4 ml-, ca. 4.1 mmol of 
dichloroacetic acid) was added to the stirred solution at room temperature. After 15 
min, the products were partitioned between dichloromethane (15 ml) and saturated 
aqueous sodium hydrogen carbonate (15 ml). The layers were separated. The organic 
layer was washed with saturated aqueous sodium hydrogen carbonate (15 mi), dried 
(MgS04) and evaporated under reduced pressure. The residue was fractionated by 
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short column chromatography on silica gel. The appropriate fractions, which were 
eluted with petroleum ether (60-80'C)-ethyl acetate (95: 5 v/v), were combined and 
evaporated under reduced pressure to give the title compound as a colourless solid 
(0.285 g, 92%). (Found in material recrystallized from aqueous methanol: C, 80.3; H, 
5.0; N, 8.9. C21H16N20*0-1 H20 requires: C, 80.28; H, 5.20; N, 8.92%), mp 189- 
190'C; Rf (system Q 0.44. 
8H[(CD3)2SO] 5.37 (2 H, m), 5.86 (2 H, dd, J 2.6 and 5.6), 6.63 (2 H, dd, J 2.6 and 
4.4), 7.04 (4 H, m), 7.14 (2 H, m), 7.28 (2 H, m), 10.35 (2 H, br, s). 
8c[(CD3)2SO] 44.79,106.36,108.82,116.11,118.99,123.33,127.76,128.31,129.70, 
135.65,150.84. 
(b) 9,9-Dimethoxyxanthene (0.484 g, 2.0 mmol) was dissolved in pyrrole- 
dichloromethane (1: 9 v/v; 6.7 ml, ca. 9.7 mmol of pyrrole) and dichloroacetic acid- 
dichloromethane (1: 9 v/v; 6.7 ml; ca. 8.1 mmol of dichloroacetic acid) was added to 
the stirred solution at room temperature. After 20 min, the products were poured into 
saturated aqueous sodium hydrogen carbonate (15 ml). The layers were separated, 
and the organic layer was washed with saturated aqueous sodium hydrogen carbonate 
(15 ml), dried (MgS04) and then evaporated under reduced pressure. The residue was 
fractionated by short column chromatography on silica gel to give a colourless solid 
(0.462 g, 74%), identical in all respects (mp, Rf, 
1H and 13 C NMR spectra) to the 
product obtained above. 
261 
Chapter 7 E. Werimental 
2,7-Dimethyl-9,9-di-(pyrrol-2-yl)xanthene (648) 
648 
(a) (±)-l-O-Stearoyl-2,3-0-(2,7-dimethylxanthen-9-ylidene)glyceroI (0.565 g, 1.0 
mmol), the putative intermediate in one of the above preparations of (±)-l-0- 
stearoyl glycerol, was dissolved in pyrrole-dichloromethane (1: 9 v/v; 3.4 ml; ca. 4.9 
mmol of pyrrole) and dichloroacetic acid-dichloromethane (1: 9 v/v; 3.4 ml; ca. 4.1 
mmol of dichloroacetic acid) was added to the stirred solution at room temperature. 
After 15 min, the products were partitioned between dichloromethane (15 ml) and 
saturated aqueous sodium hydrogen carbonate (15 ml). The layers were separated. 
The organic layer was washed with saturated aqueous sodium hydrogen carbonate (15 
ml), dried (MgS04) and evaporated under reduced pressure. The residue was 
fractionated by short column chromatography on silica gel. The appropriate fractions, 
which were eluted with petroleum ether (60-80'C)-ethyl acetate (95: 5 v/v), were 
combined and evaporated under reduced pressure to give the title compound as a 
colourless solid (0.280 g, 82%). (Found in material recrystallized from aqueous 
methanol: C, 80.86; H, 5.65; N, 8.12. C23H20N20 requires: C, 81.15; H, 5.92; N, 
8.23%), mp 215-216'C; Rf (System Q 0.50. 
6H[(CD3)2SO] 2.19 (6 H, s), 5.36 (2 H, dd, J 2.9 and 4.5), 5.85 (2 H, dd, J 2.6 and 
5.5), 6.63 (2 H, dd, J 2.5 and 4.3), 6.80 (2 H, d, J 1.7), 6.99 (2 H, d, J 8.2), 7.06 (2 H, 
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(b) 9,9-Dimethoxyxanthene (0.540 g, 2.0 mmol) was dissolved in pyrrole- 
dichloromethane (1: 9 v/v; 6.7 ml, ca. 9.7 mmol of pyrrole) and dichloroacetic acid- 
dichloromethane (1: 9 v/v; 6.7 ml; ca. 8.1 mmol of dichloroacetic acid) was added to 
the stirred solution at room temperature. After 20 min, the products were poured into 
saturated aqueous sodium hydrogen carbonate (15 ml). The layers were separated, 
and the organic layer was washed with saturated aqueous sodium hydrogen carbonate 
(15 ml), dried (MgS04) and then evaporated under reduced pressure. The residue was 
fractionated by short column chromatography on silica gel to give a colourless solid 
(0.442 g, 64%), identical in all respects (mp, Rf, 1H and 13 C NMR spectra) to the 
product obtained above. 
Hydrolysis studies of 2', 3'-O-protected uridine derivatives (612,613, and 616a, b) 
in methanol-water- trilluoroacetic acid (7: 2: 1) at 30'C 
A stock solution of an internal standard (3ý--O-benzoylthymidine, 0.050 g) in methanol 
(35 ml), water (10 ml) and trifluoroacetic acid (5 ml) was prepared. Substrates (ca. 
0.001 g) were dissolved in preheated (to 30'Q stock solution (1.0 ml) and the 
resulting solutions were maintained at 30 (-+O. I)'C in a Digi-block heating apparatus. 
After appropriate intervals of time, aliquots (20 ýtl) were removed, quenched with 0.1 
M triethylammonium. acetate buffer (pH 7.0,40 [d) and methanol (40 gl), and 
analysed by HPLC (25 cmx4.6 mm Hypersil ODS 5R column). The HPLC column 
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